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Abstract 
Senile plaques of Alzheimer’s disease (AD) patients are composed primarily of the 
amyloid-β-peptide peptide (Aβ), and within these plaques Cu2+ ions are found 
concentrated and directly bound to Aβ. Cu2+ homeostasis is severely impaired in AD 
patients and recent in vivo studies implicate Cu2+ in the etiology of AD. However the 
role of Cu2+ ions in AD is currently highly disputed due to the low reported affinity 
of Aβ for Cu2+ (nM and µM), and Cu2+ binding to Aβ is thought to result in 
amorphous aggregation rather than fibril formation. These two aspects, along with 
the coordination geometry, stoichiometry and toxicity of the Cu2+-Aβ complex were 
investigated in this thesis. In Chapter 3, circular dichroism and fluorescence 
spectroscopy alongside competitive metal capture show a surprisingly high 
picomolar affinity for both monomeric and fibrillar Aβ. In Chapter 4 electron 
paramagnetic resonance was used to study the structure and stoichiometry of the 
copper-Aβ complex in both monomeric and fibrillar Aβ. Both Aβ forms were able 
to bind a full stoichiometric complement of Cu2+ ions, with identical square planar 
coordination geometry. Importantly Cu2+ ion binding did not disrupt fibril structure. 
In Chapter 5 of this thesis it is shown that, in contrast to the predominant belief in 
the AD field, stoichiometric and sub-stoichiometric amounts of Cu2+ actually 
accelerate the rate of fibril formation. Finally, the toxic effects of Aβ and Cu2+ were 
studied in a PC12 clonal cell line. The presence of Cu2+ ions were found to enhance 
Aβ cell toxicity, and substoichiometric concentrations of Cu2+ were found to be the 
most toxic, suggesting that Cu2+ induced fibril formation and Cu2+ induced toxicity 
may be linked. Therefore this study finds considerable support for an altered 
amyloid hypothesis where Cu2+ dyshomeostasis has a central role in AD. 
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1.1. General Introduction to Alzheimer’s Disease  
Alzheimer’s disease (AD) is a form of senile dementia, and is thought to affect 42 % 
of the UK population, through either having the disease or knowing a close friend or 
family member with the condition (Alzheimer's Research Trust / YouGov 2008). 
Furthermore a new case of dementia occurs in England and Wales every 3.2 minutes 
(Matthews, et al. 2005). AD is currently incurable, which puts a financial and 
emotional strain on those caring for the patient. In people aged 60 or over, dementia 
contributed 11.2 % of all years lived with disability, more than stroke (9.5 %), 
cardiovascular disease (5.0 %) or all cancers (2.4 %) (World Health Organization 
2003). AD is ultimately fatal, characterised by increasing destruction of the neuronal 
tissues in the brain. Symptoms include jealousy, memory lapses, paranoia, loss of 
reasoning powers, incomprehension and stupor.  
 
In Figure 1.1 a time line of some selected developments in AD is outlined. There are 
many important findings that have been omitted, but the key developments 
considered to be relevant to this thesis are shown. The first event is the observation 
in 1906 by Alois Alzheimer of the neurofibrillary tangles and amyloid plaques in the 
brain of a patient who had displayed the symptoms of dementia (Alzheimer 1907). 
Strikingly, isolation of the major protein in the AD plaques, amyloid-beta-peptide 
(Aβ), did not occur until 1984 (Glenner, et al. 1984). Another major event is the 
development of the amyloid cascade hypothesis in 1992 (Hardy, et al. 1992), which 
hypothesises that formation of fibres and plaques by Aβ is the key event in AD 
(discussed in more detail later in this chapter). Since 1985 there have been large 
strides forward in understanding the disease, but a therapeutic that halts or reverses 
progression of the disease remains elusive.  
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1989:Use of ThT fluorescent dye to monitor fibril formation4
1900
1980
2000
2010
1906: Alois Alzheimer establishes that dementia is associated 
with neurofibrillary tangles and amyloid plaques1
1984: Aβ is isolated from amyloid cores2
1986: Amyloid precursor protein (APP) gene identified3
1990: Mutations identified in APP which can cause early onset AD5
1995: Presenilin genes 1 and 2 discovered8
1990
1997: The common core structure of amyloid fibrils is shown by X-ray 
diffraction9
1993: Role for apoE in AD suggested7
1998:Cu2+ shown to aggregate Aβ and concentrated in amyloid plaques10
1999:β-secretase identified as an aspartic protease11
2001:Neprilysin identified as an Aβ protease12
2002: Copper levels increased in AD patients serum13
2003:Cu2+ shown directly bound to Aβ histidine in amyloid plaques14
2004: Drosophilia model for AD developed15
2005: Molecular structure of fibrils varies and is self-propagating16
2006: Aβ*56 suggested as toxic species17
2007: Aβ fibrils contain a steric zipper18
2008: Plaques in mice shown to cause toxicity19
2009: Oxidative stress is essential for Aβ toxicity in drosophilia20
1992:Amyloid cascade hypothesis proposed6
Figure 1.1. A timeline with selected advances from the field of AD relative to Cu2+ ions and 
Aβ. References are as follows: 1Alzheimer 1907, 2Glenner, et al. 1984, 3 St George-Hyslop et al. 1987, Tanzi et al.
1987, 4Naiki et al. 1989, 5Van Broeckhoven et al. 1990, Levy et al. 1990, 6Hardy et al. 1992, 7Strittmatter et al.
1993, 8Sherrington et al. 1995, Levy-Lahad et al. 1995, 9Sunde et al. 1997, 10Atwood et al. 1998, 11Hussain et al.
1999, Vassar et al. 1999, 12Iwata et al. 2001, 13Squitti et al. 2002, 14Dong et al. 2003, 15Iijima et al. 2004 16Makin
et al. 2005, 17Lesne et al. 2006, 18Sawaya et al. 2007, 19Meyer-Luehmann et al. 2008, 20Rival et al. 2009  
 
1.2. Amyloid-beta-Peptide 
The two fundamental characteristics of the AD brain are extracellular amyloid 
plaques and intracellular neurofibrillary tangles. ~ 90 % of the amyloid plaques 
consist of the fibrillar form of Aβ (Masters, et al. 1985). The remaining 10 % is a 
variety of other components including membrane lipids from degenerated axons, 
metal ions, and traces of other components from the interstitium (Atwood, et al. 
2002). In vivo Aβ can be between 39 and 43 residues long, with Aβ(1-40) and Aβ(1-
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42) being the two most biologically important forms. Aβ(1-40) is also more 
common, with Aβ(1-42) only ~10 % as abundant as Aβ(1-40).  
 
The sequence of Aβ(1-43) is shown below: 
          5  10      15            20           25           30      35             40                  
DAEFR  HDSGY  EVHHQ  KLVFF  AEDVG  SNKGA  IIGLM  VGGVV  IAT 
 
The first 15 residues are mainly hydrophilic, and contain His6, His13 and His14 (in 
bold) which are important for Cu2+ chelation. The propensity of the amino acids in 
Aβ(1-43) to form fibrils can be predicted by the TANGO algorithm (Figure 1.2) 
(Fernandez-Escamilla, et al. 2004). It is evident that residues 17-21 (the central 
hydrophobic cluster) and residues 30-42 in the C-terminal tail have a high 
propensity for fibril formation.  
 
Figure 1.2 also shows that Aβ(1-42) has two more amino acids with a propensity to 
form β-fibrils than Aβ(1-40), illustrating why Aβ(1-40) is more soluble and forms 
fibrils slower than Aβ(1-42). Aβ(1-42) is the more amyloidogenic form, and is the 
main form in amyloid plaques (Suzuki, et al. 1994). Consequently, an increase in the 
ratio of Aβ(1-42):Aβ(1-40) is thought to be a key event in AD development. The 
43rd residue of Aβ(1-43) is threonine, which has a low aggregation score, and Aβ(1-
43) is not thought to be a predominant species in vivo, thus it is not considered 
further in this thesis. 
 
1.2.1. Location and Function of Aβ 
Aβ is constitutively anabolised and catabolised in the brain throughout life in all 
humans. It is present in the cerebrospinal fluid (CSF) and plasma in humans with a 
typical concentration of 5 nM (Vigo-Pelfrey, et al. 1993). Aβ is predominately 
generated in the golgi bodies through the amyloidogenic processing of the amyloid 
precursor protein (APP), see Section 1.2.3, then trafficked to the cell membrane 
(Gasparini, et al. 2001). 
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Figure 1.2. TANGO output for the propensity of residues within Aβ to form β-
fibrils. Input parameters were the sequence of Aβ(1-43), pH 7.4, 37 ºC, and an ionic 
strength of 160 mM. The algorithm assumes that in β-fibrils the nucleating regions 
will be fully buried and tend to satisfy their hydrogen-bonding potential. Three 
energy contributions are assessed by the algorithm: a residue-specific cost in 
conformational entropy for fixing that residue in a beta-strand conformation and side 
chain-side chain interactions of residue i with residues at positions i+1 and i+2. 
(Fernandez-Escamilla et al. 2004).
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The normal physiological role of Aβ is not clear. It seems unlikely that Aβ only has 
detrimental functions as Aβ production occurs throughout the cell. Interestingly, the 
application of Aβ to cortical neurons promoted endocytosis of NMDA (N-methyl-D-
aspartic) receptors (Snyder, et al. 2005). These receptors occur at the post-synaptic 
membrane at glutamatergic synapses, and are vulnerable to excitotoxicity in AD. 
Excitoxicity can occur when NMDA receptors are overactivated, such as by a 
pathological excess of the neurotransmitter glutamate. Over-activation results in 
high levels of Ca2+ ions entering the cell which activates a number of enzymes that 
go on to damage cell structures. Thus Aβ’s normal function may be to depress 
synaptic function, protecting against excitotoxicity.  
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Aβ is also part of a range of signalling cascades (Lee, et al. 2002) and able to induce 
pro-inflammatory activities (Paris, et al. 1999). It has also been suggested to have a 
role as a cellular antioxidant or sacrificial quencher of reactive oxygen species 
(Nadal, et al. 2008, Teng, et al. 2005). Very recently Aβ has also been proposed to 
be an anti-microbial peptide, which may normally function in the innate immune 
system protecting against a range of microorganisms. AD brain homogenates had 
significantly higher antimicrobial activity than aged matched non-AD samples 
(Soscia, et al. 2010). 
 
1.2.2. Amyloid Precursor Protein 
Amyloid Precursor Protein (APP) is a transmembrane protein encoded on 
chromosome 21 in humans (Kang, et al. 1987). APP695 is the principal neuronal 
form, two other forms (APP751 and APP770) are more common in other cell types 
(Kang, et al. 1987, Kitaguchi, et al. 1988, Ponte, et al. 1988, Tanzi, et al. 1988). APP 
has a short cytoplasmic region and a large extracellular domain. The Aβ sequence is 
within residues 672 to 711 (Aβ(1-40)) or 713 (Aβ(1-42)) of APP770. This section of 
APP spans the 28 residues of the extracellular domain and the 12-15 residues of the 
transmembrane domains. APP contains two copper binding sites, one within the Aβ 
domain which is covered in more detail in Chapter 4, and a second (the APP copper 
binding domain (CuBD)) between residues 124-189 of APP. The CuBD binds Cu2+ 
with a nanomolar affinity (Hesse, et al. 1994). 
 
Multiple roles for APP have been suggested, broadly falling into three categories: 
 
• acting as a contact receptor in its transmembrane form, with a role in forming 
functional synapses through cell adhesion 
 
• a trophic role in its secreted form after cleavage, promoting cell proliferation 
and motility  
 
• a role in metal ion homeostasis. APP shares structural homology to copper 
chaperones and may function as a Cu+ binding neuronal metallochaperone 
(Bayer 2006) or as a cell surface metalloreductase, as APP is capable of 
reducing Cu2+ to Cu+ (Barnham, et al. 2003). APP knock out mice show an 
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increase in copper levels in the brain (White, et al. 1999) whereas 
overexpression of APP was reported to result in significantly reduced copper 
levels in transgenic mice brains (Maynard, et al. 2002). 
 
1.2.3. APP Trafficking and Processing 
 
Figure 1.3. A diagram of intracellular trafficking of APP. APP molecules 
(black bars) are trafficked through the constitutive secretory pathway where 
they undergo post-translational modifications in the endoplasmic reticulum 
and golgi body,  then are trafficked to the plasma membrane (step 1). APP is 
then internalised (step 2) and trafficked through the endocytic and recycling 
compartments back to the cell membrane (step 3). The non-amyloidogenic
pathway mainly occurs at the cell surface where α-secretases reside. 
Alternatively the amyloidogenic pathway occurs in endocytic organelles where 
β-secretase and γ-secretase are present (Thinakaran et al. 2008). 
 
 
APP trafficking is shown in Figure 1.3. APP matures through the constitutive 
secretory pathway, during which it undergoes N-glycosylation (glycans attached to a 
nitrogen in asparagine or arginine side chains) in the endoplasmic reticulum and O-
glycosylation (glycans attached to the hydroxy oxygen of serine, threonine and 
tyrosine side-chains) in the golgi bodies. Upon exiting the golgi body, APP is 
trafficked to the plasma membrane. Once APP reaches the cell surface, it is 
internalised and either trafficked via the endocytic/recycling pathway back to the 
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cell surface, or degraded in the lysosome (Thinakaran, et al. 2008). APP trafficking 
is likely to vary depending on the cell type, and the intracellular organelles/transport 
vesicles involved in APP trafficking in neurons require further characterisation. 
 
During trafficking APP can undergo one of two processing events. The non-
amyloidogenic pathway, without the production of Aβ, is the sequential processing 
of APP by α and γ-secretases and occurs mainly at the cell surface (Sisodia 1992). 
The amyloidogenic pathway is the cleavage of APP by β-secretase then γ-secretase, 
resulting in Aβ secretion and occurs during trafficking through the endocytic 
organelles (Koo, et al. 1994). 
 
Non-amyloidogenic pathway  
In the non-amyloidogenic pathway APP is cleaved at the cell membrane by α-
secretase (Sisodia 1992). The identity of α-secretase is most likely to be a member 
of the ADAM (a disintegrin and metalloprotease) family, probably ADAM10 and/or 
ADAM17 (Parvathy, et al. 1998). The α-secretase site in APP is between residues 
687 and 688 of APP (Lys16 and Leu17 of the Aβ sequence), 12 amino acids 
upstream from the extracellular side of the membrane (see Figure 1.4).  
 
Figure 1.4. The region of APP primary structure region which includes the 
sequence of amyloid-beta-peptide (Aβ). Residues in Aβ are enlarged and in bold, and 
residues residing in the transmembrane region of the neuronal cell are in italics. 
Secretase cleavage sites are in red for α-secretase, blue for β-secretase and green for γ-
secretase. Major cleavage sites are shown with unbroken arrows, and minor cleavage 
sites are shown with broken arrows (adapted from (Barrow 1999)).
-EVEMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIV-
Cell membrane
1 10 20 30 40
β-secretase α-secretase γ-secretase
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α-secretase cleavage results in the release of an extracellular domain (sAPPα) 
(Parvathy, et al. 1999) and leaves a membrane tethered α-C-terminal fragment 
(CTFα) (Allinson, et al. 2003). sAPPα may be involved in cell differentiation and 
proliferation (Caille, et al. 2004, Kwak, et al. 2006) CTFα is then cleaved within the 
transmembrane domain by γ-secretase to release the soluble 3kDa N-terminal 
fragment p3 extracellularly and APP intracellular domain (AICD) into the 
cytoplasm. AICD may be involved in nuclear signalling via transcriptional 
regulation (Cao, et al. 2001) while p3’s function is yet to be elucidated, but it has 
been shown to be non-toxic to neuronal cells (Minogue, et al. 2009). The non-
amyloidogenic pathway is shown in Figure 1.5a. 
 
γ-secretase is a multimeric membrane-bound protease complex composed of four 
essential subunits: 1) presenilin-1 or –2 (PS1 and PS2) (De Strooper, et al. 1998, 
Thinakaran, et al. 1996, Wolfe, et al. 1999), 2) nicastrin (Yu, et al. 2000), 3) APH-1 
and 4) PEN-2 (Francis, et al. 2002). The presenilin subunits are aspartyl proteases 
which provide the active core of the γ-secretase complex. The γ-secretase complex is 
found in multiple cellular locations including the ER, golgi, endosomes and plasma 
membrane and has a role in both APP processing pathways. 
 
Amyloidogenic pathway  
In the amyloidogenic pathway (Figure 1.5b) APP is cleaved by β-secretase between 
residues 671 and 672 of APP to leave the C-terminal fragment (CTFβ) tethered to 
the membrane and release a soluble N-terminal fragment (sAPPβ). CTFβ is cleaved 
by the γ-secretase complex to release Aβ. Importantly γ-secretase cleaves at multiple 
sites within the transmembrane domain of APP, resulting in Aβ being between 38 to 
43 residues in length. The position of the γ-secretase cleavage site is of key 
importance in determining the ratio of Aβ(1-40) to Aβ(1-42). The γ-secretase is also 
a therapeutic target, discussed further in Section 1.9. 
 
The major β-secretase in neurons is BACE1 (beta-site APP-cleaving enzyme). 
BACE1 is a 501 amino acid, transmembrane aspartyl protease (Hussain, et al. 1999, 
Vassar, et al. 1999) which acts on APP intracellularly during the secretory/endocytic 
steps of APP trafficking (Koo and Squazzo 1994) (see Figure 1.3). BACE1 contains 
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a dileucine motif (LL) which causes BACE1 to be internalised to the endosomes 
where it can co-localise with APP (Pastorino, et al. 2002). Deletion of the β-
secretase gene in mice resulted in only minor behavioural changes and the mice 
remained viable and fertile (Harrison, et al. 2003, Roberds, et al. 2001). Absence of 
BACE1 will prevent production of Aβ (Luo, et al. 2001), making it a highly 
attractive therapeutic target, which is discussed in Section 1.9. 
 
Figure 1.5. Processing of APP. (a) The non-amyloidogenic pathway with 
sequential processing of APP by membrane bound α and γ-secretases, does 
not release Aβ. (b) The amyloidogenic pathway of APP is the β and γ-
secretase cleavage of APP, generating Aβ. Adapted from McDowall 2010.
(a) (b)
 
 
1.2.4. Influences on the APP Processing Pathways in Sporadic AD 
Membrane properties could be key in affecting APP processing. Aβ generation in a 
neuronal cell line was shown to be dependent on lipid rafts (Cordy, et al. 2003). 
Lipid rafts are important in membrane signalling and trafficking and are identified 
by their high levels of sphingolipids, cholesterol and saturated fatty acids. The key 
proteins in the amyloidogenic pathway, APP, BACE and the presenilins, all co-
localise to the rafts, (Riddell, et al. 2001) whereas the likely candidate for the α-
secretase, ADAM10, does not (Kojro, et al. 2001).  
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Decreased intracellular copper levels occur in AD, and this decrease also promotes 
amyloidogenic processing of APP (Cater, et al. 2008). BACE1 binds a single Cu+ 
ion with high affinity, coordinating the ion with cysteine residues from the C-
terminal (Angeletti, et al. 2005). Thus APP processing could be altered through 
disrupted BACE1-Cu+ binding, potentially increasing BACE1 activity or BACE1 
association with APP, resulting in the amyloidogenic pathway being favoured. 
Copper deficiency also leads to decreased activity of the antioxidant protein SOD-1, 
resulting in oxidative stress (Paynter, et al. 1979). Oxidative stress appears to favour 
the amyloidogenic pathway by increasing the expression, protein levels and activity 
of BACE1 and γ-secretase (Tabaton, et al. 2007, Tamagno, et al. 2002).  
 
1.2.5. Aβ Catabolism 
Factors that affect APP processing and Aβ anabolism have been intensely studied, 
however in sporadic AD, Aβ anabolism does not appear to change, yet Aβ(1-42) 
levels accumulate in both normal and AD brains from the age of 40 (Funato, et al. 
1998). Thus attention has focused on changes in Aβ clearance from the brain. Aβ 
has a relatively short half life in the brain, ~2 hrs in young mice. However in mice 
with amyloid deposits Aβ’s half-life is doubled, suggesting deterioration of Aβ 
catabolism could have an important role in AD (Cirrito, et al. 2003).  
 
Neprilysin is a key enzyme in Aβ catabolism, degrading Aβ at or near the synapses, 
and also inside vesicles during axonal transport (Huang, et al. 2006). Importantly 
there is a 20-40 % reduction in neprilysin levels in the brains of aged mice, and 
disruption of the neprilysin gene causes an accumulation of Aβ in the mouse brain 
(Iwata, et al. 2005). Thus a decrease in neprilysin levels may be partly responsible 
for Aβ accumulation and onset of AD.  
 
1.2.6. Genetics of Familial AD 
Familial Alzheimer’s disease (fAD) results in an early onset of AD, usually in 
patients only aged 45-60 years old. FAD only accounts for a small number of total 
AD cases (~5 %). However, it has proved instrumental in understanding the risk 
factors in AD and in giving Aβ a central role in the pathogenesis of AD.  
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A summary of some of the key mutations that cause fAD are shown in Table 1.1. 
Down’s syndrome arises from trisomy of chromosome 21, which is the chromosome 
the APP gene is located on. The extra copy results in an increase in Aβ and the early 
onset of AD. Mutations within APP that lead to fAD are predominantly located at, 
or near, the α, β and γ cleavage sites, resulting in the amyloidogenic processing 
pathway being favoured, and leading to the production of more Aβ. The arctic 
mutation does not affect APP processing but results in much more aggressive 
amyloidosis (Cheng, et al. 2004). Additionally the Flemish, and Arctic mutations of 
APP also make Aβ more resistant to neprilysin degradation (Tsubuki, et al. 2003).  
 
Forms fibrils 
faster
More amyloidogenicAPP E693G (Arctic)
More Aβ(1-42)Alteration of APP 
processing
PS1 and PS2 mutations
More Aβ(1-42)Alteration of site of γ-
secretase cleavage
APP V717I (London)
More Aβ(1-42)Alteration of site of γ-
secretase cleavage
APP I716V (Florida)
More AβInhibition of α-secretase
cleavage
APP A692G (Flemish)
More AβPotentiation of β-secretase
cleavage
APP K670N/ M671L 
(Swedish)
More AβMore APP productionDown’s syndrome (trisomy
of chromosome 21)
Molecular effectBiochemical causeMutation
Table 1.1. Summary of mutations which result in early onset Alzheimer’s disease. 
The site of the mutation in APP770 is followed by the commonly used name for the 
mutation in parentheses. Adapted from (Hardy 1997).
 
 
To date, no cases of familial AD caused by mutations or dysfunction of β-secretase, 
or lack of α-secretase have been found. Instead mutations in presenilin 1 (PS1) and 
presenilin 2 (PS2) genes (part of the γ-secretase complex) account for the majority 
of fAD cases. More than 150 mutations in PS1 and ~ 10 mutations in PS2 have been 
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identified (Tabaton and Tamagno 2007). Mutations of PS shift the preferred site of 
γ-secretase cleavage from residue 40 to 42 of Aβ (Scheuner, et al. 1996, Thinakaran, 
et al. 1996) thus increasing the Aβ(1-42):Aβ(1-40) ratio.  
 
1.2.7. Genetics of Sporadic AD 
Although ageing is still the only known definite risk factor in sporadic AD, there are 
so-called AD “susceptibility” genes which, in conjunction with environmental 
factors, increase susceptibility to AD. Indeed after advanced age, having a parent 
with sporadic AD (especially if it is the mother) is the most significant risk factor for 
developing AD (Mosconi, et al. 2010). 
 
The apolipoprotein E (ApoE) gene on chromosome 19 has been consistently 
implicated in increasing susceptibility to sporadic AD. ApoE is a major 
apolipoprotein and a cholesterol carrier in the brain. In humans, the ApoE gene 
exists as three different polymorphic alleles: ε2, ε3 and ε4. The ε3 allele is the most 
common allele, prevalent in ~ 60 % in the population (Mahley 1988). Interestingly, 
the ε4 allele is only present in ~ 15 % of the general population, but is present in ~ 
40 % in AD patients. The ε4 allele results in a 2.3-3 fold increased risk of AD 
compared to the ε3 allele, whereas the ε2 allele actually decreases the risk of AD 
(Farrer, et al. 1997). The ε4 allele is thought to increase the risk of AD through 
higher plasma cholesterol levels, resulting in enhanced Aβ deposition and formation 
of plaques (Shobab, et al. 2005). However as only ~ 40 % of AD sufferers carry the 
ε4 allele its presence can not be necessary to cause the disease, with multiple other 
genes increasing susceptibility for AD. 
 
Finally there are also environmental factors which are thought to increase the 
likelihood of developing AD, including traumatic brain injury (Roberts, et al. 1994), 
inflammation (Akiyama, et al. 2000) and occupational exposure to pesticides (Baldi, 
et al. 2003) and high blood pressure and high cholesterol (Kivipelto, et al. 2001). 
Alternatively the consumption of unsaturated fatty acids and omega-3 
polyunsaturated fatty acids might help to reduce the risk of AD (Morris, et al. 2003). 
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1.3. The Amyloid Cascade Hypothesis 
Genetic evidence strongly supports Aβ as the causative agent of Alzheimer’s disease 
but the role of Aβ in the progression of AD is still unclear. The best hypothesis for 
the key events in the development of AD is the amyloid cascade hypothesis (Hardy 
and Higgins 1992), shown in Figure 1.6. In this hypothesis genetic and 
environmental factors result in an increase in the ratio of Aβ(1-42):Aβ(1-40) 
resulting in Aβ fibril formation and synaptic injury. Downstream of Aβ deposition 
altered kinase/phosphatase activities occur, resulting in hyperphosphorylation of the 
protein tau. Finally oxidative injury and neuronal dysfunction results in widespread 
cell death and dementia (Hardy 1997). 
 
There are some holes in the amyloid cascade hypothesis. Formation of Aβ plaques is 
a key event in the hypothesis but the number and presence of amyloid deposits do 
not correlate with AD severity, and neurodegeneration sometimes precedes plaque 
formation. Likewise, immunisation of AD patients with Aβ(1-42) was found to clear 
amyloid plaques from the brain but not prevent progression of neurodegeneration 
(Holmes, et al. 2008). However, this can be explained by the “toxic oligomer” 
hypothesis (see Section 1.7) where it is small, diffusible, oligomers of Aβ which 
cause toxicity, not fully formed plaques. A second problem with the hypothesis, 
which is still unexplained, is that APP and Aβ are present and ubiquitous in all 
humans throughout their lives, but amyloid deposits are focal (mainly near synapses 
and the cerebrovascular lamina media) and temporal (mainly occurring in people 
over 65). Thus it is still a mystery as to why fibril formation occurs, and why some 
people develop sporadic Alzheimer’s disease and others do not. One alternative to 
the amyloid cascade hypothesis is that the damage observed in AD brains is caused 
by intracellular neurofibrillary tangles (NFTs) composed of tau, not Aβ. 
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Amyloid cascade hypothesis
Missense mutations in APP, PS1, or PS2 genes (fAD)
Ageing, plus genetic and environmental risk factors (sporadic)
Increased Aβ(1-42) production and accumulation
Aβ(1-42) oligomerisation and deposition as diffuse plaques
Subtle effects of Aβ oligomers on synapses
Microglial and astrocytic activation 
(complement factors, cytokines etc.)
Progressive synaptic and neuritic injury
Altered neuronal ionic homeostasis; oxidative injury
Altered kinase/phosphatase activities          tangles
Widespread neuronal/neuritic dysfunction and cell death with
transmitter deficits
DEMENTIA
Figure 1.6. Amyloid cascade hypothesis (Hardy et al. 1992).
 
 
1.4. Tau 
Tau is a microtubule binding protein whose primary function is to stabilise 
microtubules. Tau is not the focus of this thesis and so will only be mentioned 
briefly. For a more in-depth review please see (Avila 2006) or (Ballatore, et al. 
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2007). The microtubule-binding ability of tau is post-translationally regulated, 
primarily by serine/threonine-directed phosphorylation. This phosphorylation occurs 
under normal, non-disease conditions at a small number of potential phosphate-
acceptor amino acid residues and effectively modulates the binding affinity of tau 
for the microtubules. 
 
However during neurodegeneration nearly all these residues become 
phosphorylated- the “hyperphosphorylation” of tau. This results in an abnormal loss 
of binding of tau to the microtubules and a break-down in the equilibrium between 
free tau and microtubule associated tau. The increased cytosolic concentrations of 
free tau leads to aggregation and fibrillisation resulting in the formation of NFTs, 
composed of paired helical filaments. NFTs can sequester normal tau and become 
physical obstacles to the transport of vesicles and other cargo. Thus tau has both a 
loss of function (no longer stabilising microtubules) and also a toxic gain of function 
(formations of NFTs). Because of the prominent accumulation of NFTs, AD is 
considered a tauopathy, along with a range of other frontotemporal dementias. 
 
1.4.1. Tau vs Aβ 
Initially there was a debate as to whether Aβ or tau was responsible for AD onset 
and progression. “Tauists” point out that neuron loss and neurodegeneration could 
be caused by the NFTs, as the tau-mediated collapse of the microtubules causes 
substantial damage and numerous toxic effects, including loss of signalling and the 
death of the cell. However, mutations in the gene encoding tau cause frontotemporal 
dementia with parkinsonism, and NFTs but no amyloid plaques (Spillantini, et al. 
1998). In contrast, Aβ(1-42) accumulation subsequently induces tau aggregation, 
phosphorylation, neuronal death and dementia, suggesting tau aggregation is 
downstream of Aβ fibril formation (Price, et al. 1999). These findings, in addition to 
the genetic evidence in Section 1.2.6, are strongly in favour of Aβ as the disease- 
causing agent, and the debate is essentially settled, with a win for the “baptists” (β-
amyloid proteins supporters). However it is still not clear how Aβ induces 
neurodegeneration, and it is still possible that a common factor might induce both 
plaques and tangles. 
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1.5. Aβ Structure 
1.5.1. Monomeric Aβ Structure 
The starting population of freshly solubilised Aβ in vitro is a rapidly exchanging 
pool of Aβ monomers and low order oligomers, with transiently different secondary 
structure (Bitan, et al. 2003). The protein backbone undergoes inherent fluctuations, 
searching through possible conformations available to the polypeptide chain 
(Dinner, et al. 2000). There are different possibilities for the conformational changes 
that Aβ undergoes during fibril formation, such as random coil (RC)  α-helix, RC 
 β-strand and α-helix  β strand transitions. Whether fibril formation begins with 
Aβ as predominantly unstructured (random coil) or with α-helical structure in vitro 
depends on experimental conditions. Solution NMR performed in the absence of 
organic solvents such as trifluoroethanol or sodium dodecyl sulfate have shown that 
monomers of both Aβ(1-40) and Aβ(1-42) are devoid of α-helical or β sheet 
structure (Zhang, et al. 2000). However in the presence of ‘membrane-mimics’ such 
as organic solvents, both forms of Aβ are predominantly α-helical (Barrow, et al. 
1992, Soto, et al. 1995). In vivo it is possible that the protein undergoes a number of 
changes in secondary structure during fibril formation. In fact differences in the 
structure of low molecular weight Aβ species in freshly solubilised Aβ have been 
suggested as an explanation for the observed differences in fibril morphology 
(Goldsbury, et al. 2005), described in Section 1.5.3.  
 
1.5.2. Fibrillar Aβ Structure 
The secondary structure of Aβ fibrils, like all amyloid proteins, is composed of β-
sheet. This is due to β-sheets being the most thermodynamically stable secondary 
structure for oligomers (Perczel, et al. 2007). X-ray fibre diffraction patterns can be 
used to detect the structure of fibrils and significantly, they indicate that β-strands 
align perpendicularly to the fibril axis, and this ‘cross-β motif’ is a defining feature 
of all fibres (Serpell 1999, Sunde, et al. 1997). Figure 1.7a shows an X-ray 
diffraction pattern of fibrils.  
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Figure 1.7. X-ray diffraction of fibrils. (a) Characteristic X-ray diffraction pattern 
of fibrils. (b) Diagram of characteristic meridional signals at 4.7-4.8 Å and the 
equatorial signal at 10.7 Å. The diagram in (c) shows the ~4.8 Å signal arises from 
the spacing between hydrogen bonded β-strands within a β-sheet and the equatorial 
signal at 10.7 Å arises from the intersheet spacing. Taken from (Rambaran et al.
2008) and (Serpell 2000).
(a) (b) (c)
~10.7 Å
~4.8 Å
 
 
The diffraction pattern includes a strong meridional signal at 4.8 Å, arising from the 
spacing between hydrogen bonded β-strands within a β-sheet. The equatorial signal 
at 10.7 Å arises from the intersheet spacing, emphasised in Figure 1.7b and c 
(Makin, et al. 2005). The cross-β nature of the fibres is important as it greatly 
restricts the possible individual states of the individual β-strands. 
 
Due to the large size, heterogeneous morphology, and poor solubility of protofibrils 
and amyloid fibrils, it is very difficult to obtain high-resolution structure 
determination of these species. Solid state NMR has proved to be vital in 
understanding the tertiary molecular structures of fibrils. In the Tycko model shown 
in Figure 1.8a (Tycko 2006), the structure of a protofilament is shown. 
Protofilaments are the underlying subunits of fibres, which also have a fibrillar 
morphology and laterally associate to form fibres (Serpell, et al. 2000).  
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Figure 1.8. Structural model for the formation of a protofilament. (a) Two 
peptide molecules, with residues 1-8 not shown due to their lack of structure. 
Residues 10-22 and 30-40 have β-strand conformation and form two separate in-
register parallel β-sheets. Blue arrows show side-chain-side-chain interactions 
and side-chain-backbone interactions (b) Cartoon representation of the four 
layered β-sheet fibril. Each cross-β unit is a double-layered structure, with 
parallel β-sheets formed by residues 12–21 (red arrows) and 30–40 (blue arrows) 
(Tycko 2006).
(a)
(b)
 
 
In Tycko’s model residues 1-8 are disordered, 10-22 and 30-40 have β-strand 
conformations and form two in-register parallel β-sheets, and these two β-strand 
segments are connected by a turn involving residues 23-29. Intersheet contacts occur 
between odd-numbered side chains in the N-terminal β-strand and even numbered 
side chains in the C-terminal β-strand. A salt bridge between Asp23 and Lys28 
stabilises the two β-strands. The amino acid side chains extend perpendicularly to 
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the fibril axis and determine important properties of the fibrils including packing 
distance between sheets and contact surfaces of the protofilaments (Meinhardt, et al. 
2009).  
 
There are some small differences between Tycko’s model in Figure 1.8 and other 
models of Aβ fibrils, for example Antzutkin et al’s study on Aβ(10-35) resulted in a 
model where residues 1-9 are structurally disordered but 10-22 and 30-35 form β-
strands, with residues 23-29 forming a loop between the sheets (Antzutkin, et al. 
2002). However small differences in experimentally derived structures of fibres are 
not surprising in light of findings that the molecular structure of fibrils can be 
affected by the fibril growth conditions (see Section 1.5.3). 
 
Hydrogen/deuterium (H/D) exchange techniques can provide important information 
about structural rearrangements that occur during fibril formation. H/D exchange 
shows the pattern and extent of hydrogen bonding within the fibril and suggests 
which of the backbone amide protons are engaged in H-bonds and the proportion of 
total backbone amides that are engaged. Core portions of β-sheet are more highly 
protected than loop and random coil regions. Kheterpal et al found that all of the 
backbone amide hydrogens of monomeric Aβ undergo rapid H/D exchange, 
indicating the absence of protective structure. In contrast, in Aβ fibrils at least 50 % 
of the backbone residues were resistant to exchange, suggesting a highly protected, 
rigid core structure (Kheterpal, et al. 2000). Additionally H/D exchange has shown 
relatively free exchange within the fibril of the amide protons from residues 1-14 
suggesting that this portion of the peptide is not involved in the hydrogen-bonded 
core. Residues 15-23 and residues 28-35 showed protective structure, consistent 
with the Aβ peptide folding back on itself to form an enclosed structure 
(Whittemore, et al. 2005). This is similar to the structure in Figure 1.8 suggested by 
Tycko, although with slightly different stretches of amino acids proposed to take 
part in the β-strand parts of the fibril and the β-turn. 
 
Overall morphology of the fibrils is commonly visualised using atomic force 
microscopy (AFM) and electron microscopy (EM). Cryo-EM has been particularly 
successful at determining fibril structure at high resolution. Figure 1.9 shows the 
structure of one morphology of an Aβ(1-40) fibre.  
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Figure. 1.9. A 3D reconstruction of an Aβ(1-40) fibril imaged by cryo-
EM. (A) Ice-embedded Aβ(1-40) fibril cropped from a raw electron 
micrograph, displaying the distance of one helical pitch. (B) Projection of the 
3D fibril reconstruction. (C) Side-view surface rendering of the fibril 
reconstruction (Sachse et al 2008).
 
The averaged 3D fibril structure shows a width of 19 nm and a helical pitch (twist) 
of 285 nm. The fibril consists of two protofilaments and a local twofold symmetry 
within each region suggests that pairs of β-sheets are formed from equivalent parts 
of two Aβ(1-40) peptides contained in each protofilament (Sachse, et al. 2008). The 
pairing between the β-sheets occurs via tightly packed interfaces, and this supports 
the possibility of a dry steric zipper within the fibrils. The presence of a dry steric 
zipper was shown by an x-ray microcrystallography study performed on fragments 
of fibril forming peptides (including Aβ). It is formed by two closely interdigitated 
β-sheets, with the side chains intermeshing with close complementarity (Sawaya, et 
al. 2007). The presence of a steric zipper was found to be common to 30 other 
segments from fibril-forming proteins that form amyloid-like fibrils, adding further 
evidence to the idea that amyloid fibrils share a common architecture. 
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Once protofilaments have formed, they can laterally associate to form more mature 
amyloid fibrils. It is not clear how many protofibrils form a fibre. An X-ray fibre 
diffraction study suggested that thin sections of amyloid fibrils formed from 
fragments of Aβ show cross-sections containing five or six protofilaments 
(Kirschner, et al. 1987). However an alternative study using cryo-EM suggests that 
only one or two protofilaments make up a fibre (Schmidt, et al. 2009). It is likely 
that the variation is due to different fibril growth conditions, as discussed in Section 
1.5.3. A summary of the formation of fibrils is shown in Figure 1.10. 
 
Figure 1.10. Aβ fibril assembly. Different structures which form along the 
pathways of fibril formation in Alzheimer’s Disease, beginning with the Aβ
peptide, which oligomerises to form β sheets, then protofilaments, and finally 
fibrils (Serpell 2000).  
 
 
Once formed, the fibrils can then associate further to form the plaques observed in 
AD brains (Figure 1.11a). It is not clear whether there is an underlying structure to 
the plaques, however a promising suggestion is that they form spherulites. These 
micrometre-sized, roughly spherical structures are composed of ordered arrays of 
amyloid fibrils in radial arrangements which characteristically show a typical 
Maltese cross pattern of light extinction under the polarizing microscope (Figure 
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1.11b). Importantly it has been shown that spherulites formed in vitro with Aβ are 
nearly identical to the plaques observed in vivo in AD brain tissue, suggesting that 
spherulites and amyloid plaques may be the same species (Exley, et al. 2010). 
 
(a)
Figure 1.11. Microscopic examination of fibrillar deposits in Alzheimer's disease.
(a) Immunohistochemical detection of amyloid plaques (arrows). (b) Typical Maltese 
cross aspect of plaques stained with Congo red and visualized by polarized microscopy 
(Rostagno et al 2009). 
(b)
 
 
1.5.3. Polymorphism in Aβ Fibrils 
The cross-β and parallel nature of Aβ fibrils is generally agreed on. However a large 
degree of polymorphism in the size and degree of twisting of the fibrils is observed 
by techniques such as transmission electron microscopy and atomic force 
microscopy, not only between different labs and sample preparation techniques but 
even within the same sample pool (Hortschansky, et al. 2005). The different 
structures can also affect the toxicity of the fibrils. Electron microscopy and solid 
state NMR showed that fibrils grown under quiescent conditions had a maximum 
diameter of 9 ± 1 nm, a periodic twist and were toxic to neuronal cell cultures. 
Conversely, fibrils grown under agitated conditions had a diameter of 5 ± 1 nm, no 
twisting and were not toxic to cell cultures (Petkova, et al. 2005). Interestingly the 
parent fibrils, which had been grown under these two different conditions, could 
seed fresh solutions of Aβ. The fresh solutions of Aβ were grown under identical 
conditions, yet the parent morphology was ‘passed on’ to the daughter and 
granddaughter fibrils (Figure 1.12). Solid state NMR shows that the differences are 
at a molecular level, for example β-strand segments in quiescent Aβ(1-40) fibrils 
included residues 10 to 14, 16 to 22, 30 to 32, and 34 to 36, whereas those in 
agitated Aβ(1-40) fibrils include residues 10 to 22, 30 to 32, and 34 to 36. This study 
suggests that, if different fibril growth conditions do lead to fibril conformations 
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with varying toxicities, then this may explain the conflicting reports as to whether 
fibrils are or are not toxic (discussed in Section 1.7). 
 
1.6. Fibril Formation  
Fibril formation is predominantly associated with disease, however it is also 
important in nature. E. coli contains the protein curlin, which forms fibrils to 
colonise inert surfaces and mediates binding to host proteins (Chapman, et al. 2002). 
Furthermore, in humans melanosomes (lysosome-related organelles) contain 
functional amyloid which allows melanin granules to form (Berson, et al. 2003). 
However there are a large number of systems in vivo designed to prevent unwanted 
aggregation and fibril formation from occurring (Meriin, et al. 2005), and the 
majority of amyloids seem to not be ‘selected for’, but are accidental and result in 
disease, including Huntington’s disease, Parkinson’s disease, prion diseases and 
Alzheimer’s disease. 
 
Figure 1.12. TEM images of Aβ(1–40) fibrils formed by different 
incubation conditions. Parent fibrils were prepared by incubation of 
Aβ(1–40) solutions either under quiescent conditions or with gentle 
agitation. Daughter and granddaughter fibrils were grown under identical 
conditions but were seeded with sonicated fragments of parent and daughter 
fibrils, respectively (Petkova et al 2005).
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1.6.1. Fibril Detection 
A range of techniques can detect the formation of fibrils. The presence of amyloid 
fibrils has been defined by scoring 4 points using the scoring system shown in Table 
13 (Nilsson 2004). 
 
Thioflavin T (ThT) is a benzothiazole dye that binds rapidly and with a high 
specificity to amyloid fibrils. The free dye has an excitation maxima at 385 nm and 
an emission maxima at 445 nm. Upon binding a new excitation maximum appears at 
450 nm and enhanced emission occurs at 482 nm (LeVine 1993). This dye is used 
throughout this thesis to monitor fibril formation and is discussed in more detail in 
Chapter 2. 
 
1Gel formation
1Low solubility in denaturant or protease resistance
1Protofibril intermediate or seeded kinetics
2β-sheet secondary structure
2Congo Red binding
2ThT binding
Score for a positive testCharacteristic
Table 1.2. Characteristics of fibril formation (Nilsson 2004)
 
 
Congo Red (CR) is a histologic dye that will bind to amyloid. In normal light the 
amyloid appears red, but between crossed polarizers the colour changes to a 
yellow/green, i.e. the dye exhibits birefringence. The mode of interaction of CR with 
fibrils is not completely understood, although the general consensus is that binding 
is dependent on the presence of cross β-pleated sheets (Klunk, et al. 1989). 
Additionally it has been suggested that binding could occur between two negatively 
charged sulfate groups of CR and two positively charged amino acid residues of two 
separate protofilaments (Frid, et al. 2007). A potential problem with CR is that it has 
recently been shown to disturb the processes of protein misfolding and aggregation 
by stabilising native protein monomers or partially folded intermediates, and 
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decreasing the concentration of toxic oligomers (Frid, et al. 2007). Thus its use 
could itself alter the formation of fibrils. 
 
TEM imaging of the fibres is also an excellent method for determining their 
formation. As described previously, amyloid fibrils viewed by TEM are straight, 
unbranched, ~6-12 nm in width and of indeterminate length ((Makin and Serpell 
2005)). However upon a grid viewed in TEM the fibril sample can contain a 
multitude of morphologies of aggregates, including spherical, amorphous, and sheet 
like/rope-like assemblies of many fibrils wrapped together (Goldsbury, et al. 1997). 
Thus it is not always clear cut which species are fibrils and which are not, or 
likewise what percentage of fibrils is needed to reliably state that a protein sample 
has formed fibrils. 
 
Fourier transform infra-red (FTIR) and circular dichroism (CD) spectroscopy can 
both be used to compare the protein sample before and after fibril formation, an 
increase in β sheet secondary structure is observed upon fibril formation. In FTIR a 
peak near 1645 cm-1 is indicative of random coil, and after fibril formation has 
occurred a peak between 1620 and 1640 cm-1 suggests that β sheet formation has 
occurred. Likewise in CD a transition from a band at 197 nm to a band at 217 nm 
reflects the random coil to β-sheet transition. However β sheet secondary structure is 
not entirely indicative of the presence of amyloids as it can also be displayed by 
other kinds of aggregates.  
 
Seeding also indicates the formation of fibrils. Unseeded Aβ should have a lag phase 
before undergoing fibril formation (for further details please see Chapter 5). To 
determine whether a preparation of Aβ is in the fibrillar form, a seed from a 
potentially fibrillar sample (usually 10 % of the total volume) is added to a fresh 
sample of monomeric Aβ, e.g. 100 µl of seed to 900 µl of monomeric Aβ. The lag 
phase should now be significantly reduced or removed altogether. If however the 
seed is actually only aggregate or monomeric Aβ, the addition will have no effect on 
the lag phase of the monomeric sample.  
 
The final three determinants of fibril formation according to Nilsson’s table are a 
change in solubility, protease resistance and gel formation. When Aβ undergoes a 
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change in structure from random coil to β-strand and subsequently forms β sheet, it 
results in key changes that are measurable in vitro. The first is that the peptide 
becomes highly insoluble, even in denaturant. The second is that the fibrillar form of 
Aβ is no longer vulnerable to protease treatment. Likewise the formation of fibrils 
may result in some protein samples visibly showing an increase in viscosity and gel 
formation. Sometimes precipitates will be observed. This is likely to be dependent 
on the molecular weight of the protein being studied. As Aβ is a relatively short 
peptide, it would have to be present at a high concentration to have this effect.  
 
1.6.2. Protein Misfolding Pathways 
Aβ undergoes a misfolding pathway in AD to form amyloid fibrils. It is generally 
agreed that this pathway is based on a nucleation event followed by elongation. 
Considering that fibrils are much more stable thermodynamically than the 
monomeric form of Aβ, it is surprising that we do not all develop Aβ fibrils and AD 
at a much younger age. Fortunately the overall rate of amyloid formation is stunted 
by the slow generation of nuclei (nucleation phase), which once formed, is followed 
by a much more rapid elongation phase. The slow formation of the nucleus can be 
observed in growth curves of fibril formation, where the characteristic lag phase can 
be removed if a preformed fibril is added to the system. 
 
1.6.3. Identification of the Nucleus 
The nucleating event that triggers fibril formation is still unclear. Four proposed 
nucleating events are described below: 
 
α-helix formation (Soto, et al. 1995) 
Soluble Aβ has been proposed to be in equilibrium between α-helix and β sheet 
secondary structure. The transition to β-sheet may be the nucleating factor, with the 
ability to form fibrils only occurring once β-sheet structure has been obtained. 
Increasing the propensity for α-helical secondary structure results in a reduction in 
fibril formation ability and likewise amino acid substitutions that disfavour α-helical 
formation accelerate formation of fibrils.  
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Folding nucleus formation (Lazo, et al. 2005) 
An intramolecular nucleation event in both Aβ(1-40) and Aβ(1-42) has been 
suggested, where Val24-Lys28 forms a “folding nucleus” by forming a turn. The 
turn brings the central hydrophobic cluster (CHC) of Leu17-Ala21 and the 
hydrophobic C-terminus in contact, allowing hydrophobic side chain interactions to 
form, a pre-requisite of fibril formation. However it has been shown that residues 
14-23 are the minimal fibril forming fragment of Aβ (Tjernberg, et al. 1999), thus 
casting some doubt as to whether residues 24-28 are the nucleating factor in Aβ 
fibril formation. 
 
Micelle formation (Lomakin, et al. 1996) 
The formation of micelles as the nucleus has also been suggested. In this model if a 
critical Aβ(1-40) concentration is reached or exceeded, then nucleation occurs 
through the formation of micelles, with a hydrodynamic radii (Rh) of 7 nm. It is 
assumed that these micelles act as sites of nucleation. At Aβ(1-40) concentrations 
less than the critical protein concentrations, micelles do not form and subsequently, 
nucleation is heterogeneous, with multiple nucleation pathways, possibly through 
seeding on impurities. 
 
Paranuclei formation (Bitan, et al. 2003) 
The formation of paranuclei for Aβ(1-42) has also been observed. Solubilised Aβ(1-
42) can form paranuclei, composed of pentamers and hexamers. Paranuclei are not 
observed for Aβ(1-40) as their formation is mediated by Ile41 and Ala42. Once 
formed, the paranuclei then assemble further to form early protofibrils However 
preventing the formation of the paranuclei did not prevent fibril formation, although 
it did influence the abundance and size of early Aβ oligomers.  
 
Thus in conclusion it is apparent that the identification of the nucleus is still unclear, 
and whether secondary structure changes (formation of a turn or transition to β-
sheet) is the crucial stage, or if formation of a specific species (micelle or 
paranuclei) is more important is still to be established.  
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1.6.4. Elongation 
Once formed, the nucleus can either decay back to the ground state (reduce in size or 
return to being unstructured/α-helical) or advance by a series of elongation steps to 
low molecular weight oligomers which then increase in size to oligomers and fibres. 
A typical fibril formation pathway is shown in Figure 1.13, however elongation of 
fibrils is not necessarily a linear process, as oligomers of Aβ can be depicted as “on-
pathway” precursors to fibre formation, as in Figure 1.13, or alternatively off-
pathway and in competition with fibre formation. Wu et al used conformational 
specific antibodies to identify two different species, fibrillar oligomers (smaller 
aggregates 5- 15 nm diameter) and fibrils (straight 10- 20 nm diameter, 500 – 900 
nm length). Despite being structurally and immunologically related to fibrils, 
fibrillar oligomers would not seed fibrils, only more fibrillar oligomers, suggesting 
they are an off-pathway stage of fibril formation (Wu, et al. 2010). Individual 
species in the fibril formation pathway, and their associated toxicity, is described in 
the next section. 
 
Figure 1.13. Aβ fibril formation. Typical fibril formation pathway, assuming 
that all species formed are on-pathway. Aβ forms a β-strand structure and low 
molecular weight (LMW) oligomers, then further association results in 
oligomers, protofibrils and fibrils, before finally forming plaques.
Unfolded 
monomer LMW species Oligomers
ProtofibrilsFibrilsPlaques
Folding 
event
 
 
1.7. Nature of the Toxic Species 
The mechanism by which Aβ is toxic is hotly debated. Plaques are one of the most 
obvious features of the Alzheimer’s disease brain, and initially were considered the 
toxic species, however there are several pieces of evidence that cast doubt as to their 
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responsibility for the neurodegeneration observed. Firstly, plaque formation is not 
unique to the disease state, and studies have shown that there is not always a link 
between the presence of amyloid plaques and cognitive decline (Yankner, et al. 
2008). Secondly, it is the soluble low molecular weight species of Aβ that seem to 
correlate best with AD severity, including the patient’s age at death (McLean, et al. 
1999). The different species that have been isolated from the fibril formation 
pathway and suggested to be toxic are discussed below.  
 
Dimers 
Dimers are one of the smallest species thought to be toxic. Aβ aliquots were 
removed at a range of time points during fibril formation and the species stabilised 
by photo-induced chemical cross-linking. Of all the low molecular weight species, 
spanning monomers to hexamers, it was dimers that correlated best with inhibition 
of cytochrome c oxidase (COX) in human mitochondria (Crouch, et al. 2005). 
 
Aβ-derived diffusible ligands 
Aβ-derived diffusible ligands (ADDLs) are a group of Aβ oligomers whose 
molecular mass ranges between 17-42 kDa (Lambert, et al. 1998). ADDLs are 
composed of ~4-10 monomers and are toxic to neuron cultures and also able to 
inhibit long term potentiation (Walsh, et al. 2002). Their culpability is also 
strengthened by a study showing that ADDL concentration is ~70 fold higher in AD 
patients than non-sufferers (Gong, et al. 2003). 
 
Aβ*56 
The only species of a definite size that has been isolated so far is Aβ*56, a 56 kDa 
oligomer which was isolated from transgenic mice brains. This soluble oligomer is 
larger than the size range of the ADDLs and had the strongest inverse correlation 
with mouse performance in a Morris water maze test, which assesses spatial 
memory. Even more convincingly, injecting Aβ*56 into the brains of four month old 
rats correspondingly decreased their spatial memory (Lesne, et al. 2006).  
 
Oligomers/Protofibrils 
Oligomers and protofibrils are high molecular weight species that form before 
fibrils. Aβ oligomers are small globular structures that measure ~ 2–5 nm. 
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Oligomers were ~ 40x more toxic to neuronal cells in vitro compared to monomeric 
preparations and ~10x more toxic than fibrils (Dahlgren, et al. 2002). Injection of 
oligomers into rat brains has been shown to disrupt cognitive function including 
inhibiting hippocampal long-term potentiation (LTP) in vivo (Cleary, et al. 2005, 
Walsh, et al. 2002). 
 
Protofibrils are thought to be composed of beaded chains of 5 nm diameter beads 
with a length of greater than 150 nm. They are sometimes described as flexible and 
curved and have been shown to be toxic in a number of studies (Dahlgren, et al. 
2002, Hartley, et al. 1999, Walsh, et al. 1999). However there is a great deal of 
variation in different groups definition of oligomers and protofibrils, and this 
complicates gaining a true understanding of whether these groups constitute a 
discrete toxic species or not. This is discussed further in Section 1.7.1. 
 
Fibrils/Plaques 
Despite the data in favour of oligomers as the toxic species, there remains some 
strong support for mature fibrils and plaques as a toxic species in fibril formation. 
Perhaps the most convincing evidence for plaques being the toxic species comes 
from transgenic mice studies. In vivo multiphoton microscopy showed that plaque 
formation was followed by neurodegeneration, not the other way round, implicating 
fibres rather than toxic oligomers. This study established a direct causal relationship 
between plaques and neurodegeneration, with neuronal morphological changes 
evident in the days after plaque formation (Meyer-Luehmann, et al. 2008). 
Additionally mapping of neuronal cell density showed that neuronal loss only 
occurred in the immediate vicinity of amyloid plaques (Urbanc, et al. 2002). Finally 
monomeric and oligomeric Aβ were both found to have no effect on membrane 
conductance, whereas fibrils caused a large increase in electrical conductivity, 
indicative of a toxic effect on the membrane (Schauerte, et al. 2010). Thus it remains 
to be seen whether plaques can be written off as “the tombstones” of Alzheimer’s 
disease, rather than the toxic agent.  
 
1.7.1. Problems with Studies on the Toxic Form of Aβ 
A major problem with studies that aim to characterise a particular species or group 
that forms during fibril formation is that under experimental conditions (usually 
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conducted at much higher Aβ concentrations than would occur in vivo) Aβ will 
aggregate rapidly. This difficulty in confidently identifying one stable intermediate 
which can be reliably isolated explains why some of the “toxic species” include a 
large range of oligomeric sizes, such as the ADDLs. Thus unless methods are used 
to stabilise each species (though this itself will change the nature of the sample), it is 
probable that aggregation will continue throughout the experiment and thus 
monomers will rapidly dimerise, small oligomers will become large oligomers and 
so on. To highlight one study, Stine et al used atomic force microscopy (AFM) on 
Aβ(1-42) to elucidate conditions for fibril formation and oligomerisation (Stine, et 
al. 2003). Throughout the paper they define the following species: 
 
Unaggregated peptide: 1.1 nm 
Small diameter fibrils: 2 nm 
Globular aggregates: 2 -5 nm 
Oligomers: 2 – 4nm 
Intermediate diameter fibrils: 4- 6 nm 
Amyloid fibrils: 4 nm 
Protofibrils: < 200 nm 
Short fibrils: < 1 µm 
Mature fibrils: > 1 µm 
 
A problem with studies such as these, where size is used as a species determinant, is 
that the Aβ monomeric population does not fold and assemble synchronously, a 
distribution of conformational/assembly states exists before fibril formation is 
completed. Thus an experimental sample that exists as homogenously one species, 
for example protofibrils of a certain diameter is highly unlikely. Attempts at 
specificity have been made, such as Kayed et al who developed an antibody which 
will recognise fibril forming intermediates, however even this antibody will 
recognise both small spherical species and larger elongated species highlighting the 
difficulty in defining clearly and reproducibly an intermediate in fibril forming 
pathways (Kayed, et al. 2003).  
 
The methods used to characterise the sizes of Aβ species are also subject to scrutiny. 
Hepler et al found significant discrepancies in the apparent molecular weight of Aβ 
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species depending on whether gel electrophoresis, atomic force microscopy (AFM) 
or size exclusion chromatography coupled to multiangle laser light scattering 
detection (SEC/MALLS) were used (Hepler, et al. 2006). Thus caution must be used 
when interpreting results and defining species as the toxic agents of AD. 
 
1.8. Mechanism of Aβ Toxicity 
The mechanism of Aβ toxicity, as well as the toxic species, is still unclear. 
Membrane alterations, intracellular interactions and oxidative stress are three major 
areas where Aβ is thought to promote toxicity. 
 
1.8.1. Membrane Alterations 
Within APP, Aβ resides partially in the membrane. Consequently Aβ has a 
predominantly polar N terminus, and largely hydrophobic C terminus. This 
hydrophobic tail has led to the hypothesis that the toxicity is due to Aβ interactions 
with cell membranes (Simakova, et al. 2007). There are several ways this could lead 
to toxicity: 
 
1. Membrane insertion will disrupt the structure and function of the plasma 
membrane (Arispe, et al. 2007, Kremer, et al. 2000).  
 
2. The conductance of lipid bilayers and cell membranes will increase in the 
presence of Aβ oligomers, through Aβ indirectly thinning the membrane, or causing 
localised structural defects (Sokolov, et al. 2006).  
 
3. Aβ forms ion channels, resulting in increased conductance of Ca2+ and other 
cations. This results in cell death via triggering Ca2+ sensitive apoptosis signalling 
pathways (Arispe, et al. 2007).   
 
The formation of ion channels is yet to be convincingly proven. However it is easy 
to imagine the damage that a fibril could cause by forming near or on the cell 
membrane. In fact a study using human islet amyloid polypeptide found that the 
degree of fibril growth at the membrane and membrane damage were closely related, 
suggesting that it is the process of fibril formation, rather than a particular toxic 
species, that distorts and damages cell membranes (Engel, et al. 2008). 
  Chapter 1. Introduction 
52 
1.8.2. Intracellular Interactions  
An emerging role for intracellular Aβ is that it exerts toxicity at very early stages in 
AD dysfunction. Theoretically the intracellular environment should favour fibril 
formation, due to the lower pH of certain intracellular organelles and crowding 
effects. Increases in intraneuronal Aβ deposits in transgenic mice occurred at the 
same time as abnormalities in behaviour and physiology (Billings, et al. 2005), but 
before plaque or tangle formation. Additionally in transgenic mice Aβ(1-42) 
accumulates in presynaptic and especially postsynaptic compartments at the 
synapse. This accumulation was associated with abnormal synapse morphology, and 
also occurred before amyloid plaques formed (Takahashi, et al. 2002). In a very 
recent study in clonal cell lines intracellular intermediates preceded extracellular Aβ 
plaques and cell death, and it was suggested that fibrils grow out of cells, rather than 
associate with them extracellularly. It is not until the cell ultimately dies due to 
intracellular fibril formation that the fibrils (and all intracellular structures) are 
released into the extracellular milieu (Friedrich, et al. 2010). 
 
An intracellular protein, endoplasmic reticulum amyloid-β-peptide binding protein 
(ERAB) has been identified that can mediate the cellular toxicity of Aβ (Yan, et al. 
1997). Expression of ERAB is higher in the brains of AD patients compared to age-
matched controls. ERAB is predominantly localised within neurons in the brain and 
Aβ toxicity was markedly increased in the presence of ERAB as measured by both 
the MTT reduction assay and monitoring induction of apoptosis.  ERAB has since 
been shown to be an L-3-hydroxyacyl-coenzyme A dehydrogenase type II (NADH2) 
(He, et al. 1998). It is also now more commonly referred to as Aβ-binding alcohol 
dehydrogenase (ABAD) and emphasis has shifted to its role in the mitochondria, 
with the discovery that ERAB/ABAD binds to Aβ within mitochondria (Lustbader, 
et al. 2004).  Prevention of ERAB/ABAD binding to Aβ within mitochondria 
resulted in protection from Aβ induced cytochrome C release from mitochondria, a 
marker for cellular stress and apoptosis.  Additionally protection from Aβ-ABAD 
toxicity coincided with a reduction in ROS generation, suggesting that the 
interaction between ABAD/ERAB and Aβ results in mitochondrial dysfunction due 
to the production of ROS and ultimately cell death (Lustbader, et al. 2004).   
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The theory that intracellular changes begin the cascade of neurodegeneration is an 
attractive one. However studies of the Aβ secretory pathway show that most Aβ 
produced is secreted from the cell. Indeed intraneuronal Aβ(1-42) levels actually 
decrease with increasing development of AD (Gouras, et al. 2000). Thus 
extracellular Aβ would have to be re-internalised, and it is debatable whether 
intracellular Aβ would reach concentrations high enough to cause the significant 
toxicity that would be expected from the trauma observed in AD brains.  
 
1.8.3. Oxidative Stress 
Increased levels of oxidative damage are characteristic of AD brains. Oxidative 
stress has also been observed to occur before the formation of amyloid plaques 
(Nunomura, et al. 2006). In early studies, Aβ was suggested to generate ROS 
(reactive oxygen species) spontaneously (Hensley, et al. 1994). However further 
studies using electron paramagnetic resonance spin-trapping, found no evidence of 
spontaneous formation of peptide-derived free radicals during the incubation of 
Aβ(1-40) (Turnbull, et al. 2001), and it now seems highly unlikely that Aβ is 
capable of generating ROS alone.  
 
It was then suggested that Aβ could produce ROS in the presence of transition 
metals through Fenton/Haber-Weiss reactions (Huang, et al. 1999). The ability of 
Cu2+ to undergo Fentons/Haber-Weiss reactions and generate ROS is described in 
Section 1.10.3 of this chapter. Aβ has a methionine at position 35 and in Aβ isolated 
from plaques the methionine is oxidised (Dong, et al. 2003). Potentially, Met35 
could donate electrons for metal ion reduction, and in doing so initiate a redox cycle. 
Additionally it has been suggested that the methionine is central to Aβ toxicity 
(Butterfield, et al. 2002). However redox potentials suggest that Aβ(1-42) itself 
cannot be oxidised by Cu2+ and instead requires other cellular species (Jiang, et al. 
2007). This is supported with results from ROS detection assays where Aβ(1-40) 
and Aβ(1-42), either as monomers or as fibrils could not generate ROS in the 
presence of Cu2+ alone but required physiological reductants such as ascorbate 
(Nadal, et al. 2008). 
 
Alternatively, Aβ has been proposed to have a protective role as an antioxidant. 8-
hydroxyguanosine (8-OHG) is an indicator of oxidative damage. Neurons containing 
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extensive Aβ deposits, contained the lowest levels of 8-OHG (Nunomura, et al. 
1999). This inverse relationship between amyloid deposits and 8-OHG levels 
suggests that Aβ  might actually be produced in response to oxidative stress. 
Additionally hydroxyl radicals generated by Fenton/Haber-Weiss reactions of Cu2+ 
and ascorbate are quenched by Aβ, suggesting Aβ has a role as a sacrifical quencher 
of ROS (Nadal, et al. 2008). An explanation for these two contrasting roles of Aβ, 
pro-oxidant and antioxidant, may be the ability of Aβ not to catalytically generate 
ROS, but instead to chelate Cu2+ in a redox active form, perhaps resulting in an 
accumulation of redox-active Cu2+ at the cell membrane.  
 
In summary the exact toxic mechanism is still unclear, but it is possible the theories 
are closely interconnected. The exact temporal and spatial events that lead to AD 
brain neurodegeneration are likely to be linked to both energetics (production of 
ROS) and mechanics (membrane damage).  
 
1.9. Current Therapeutics 
Studies of familial AD patients who have mutations within the APP or presenilin 
genes show that Aβ(1-42) levels are elevated by as little as 30 % (Scheuner, et al. 
1996) yet this is enough to markedly accelerate Aβ deposition. Thus therapeutics 
that can reduce Aβ(1-42) levels by as little as 30 % might slow AD development 
enough to increase the asymptomatic stage of the disease and consequently decrease 
the number of years that patients live with AD. 
 
Currently four drugs are approved by regulatory agencies such as the U.S. Food and 
Drug Administration (FDA) and the European Medicines Agency (EMEA) to aid 
management of AD. Three of the drugs (Donepezil, Galantamine and Rivastigmine) 
are acetylcholinesterase inhibitors. Acetylcholinesterase inhibitors have been 
developed in response to post-mortem and biopsy studies which found decreases in 
acetylcholine synthesis and release in AD brains (Bowen, et al. 1977, Davies, et al. 
1976). By inhibiting acetylcholinesterase activity, more acetylcholine is available at 
the synapse and subsequently cognitive function is improved.  
 
Memantine, the fourth drug, is an N-methyl-D-aspartic acid receptor (NMDAR) 
antagonist. It was developed because NMDAR-mediated glutamate excitotoxicity is 
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associated with the neuronal death characteristic of AD. Glutamate is the most 
abundant neurotransmitter in the body, and is bound at chemical synapses by the 
NMDAR, on the membranes of post-synaptic neurons. However excitotoxicity can 
occur when receptors for glutamate such as the NMDAR are overactivated. 
Overactivation from excess glutamate allows high levels of calcium ions to enter the 
cell, activating a number of enzymes, which damage cell structures, resulting in cell 
death. The extent of AD symptoms correlates well with the neuronal death caused 
by excess glutamate. Thus using an NMDA receptor antagonist such as Memantine 
should prevent excess glutamate binding and subsequent excitotoxicity.  
 
In the UK the National Institute for Clinical Excellence (NICE) only recommends 
treatment by three of the four drugs. Donepezil, Galantamine and/or Rivastigmine 
are recommended for treatment in moderate Alzheimer's disease only. These drugs 
show small improvements in cognition and/or behaviour (Rogers, et al. 1998). 
Controversially NICE has not recommended the use of Memantine. It was intended 
to be used for patients with moderate to severe AD as it showed reduced clinical 
deterioration in patients with AD (Reisberg, et al. 2003). However NICE ruled that 
its cost outweighed its benefits. Unfortunately all four drugs show modest 
improvement only, and there are no indications that treatment delays or halts 
progression of the disease.  
 
As of 2010, more than 800 clinical trials are in the process of being carried out for 
identification of a possible treatment for AD (http://www.clinicaltrials.gov). Table 
1.3 outlines some of the current research areas that are being developed into 
therapeutics.   
 
Aβ antibodies are also being investigated.  The seminal study in this area used 
transgenic mice which over-express mutant human APP (Val717Phe)(Schenk, et al. 
1999). Synthetic human Aβ(1-42) was used as an immunogen (active 
immunisation). Treatment began before plaque formation was observed. Eight of the 
nine transgenic mice immunised with Aβ(1-42)  developed serum antibody titres 
against Aβ(1-42) of greater than 1:10000. The result of this was that immunisation 
with Aβ(1-42) almost completely prevented Aβ deposition, with seven of the nine 
mice having no detectable Aβ deposits in their brains. Additionally there was a near-
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total reduction in the Aβ burden in the hippocampus.  In contrast, control animals 
that had been immunised with phosphate buffered saline only contained numerous 
Aβ deposits and had a significantly greater Aβ burden (P = 0.0005).  The Aβ(1-42) 
immunised mice lacked all the hallmarks of neurodegeneration characteristic of AD, 
including an absence of dystrophic neurites, and dramatically reduced astrocytosis. 
Presumably immunisation either prevents deposition and/or promotes clearance of 
Aβ in the brain. The same study also observed the effect of immunisation after 
plaque formation had occurred, and found immunisation with Aβ significantly 
slowed the development of existing pathologies in the animals. 
 
Passive immunisation has also been closely studied.  The ability of Aβ binding 
proteins to act as an Aβ “sink” was assessed. The antibody m266 showed a low 
picomolar affinity and thus could bind Aβ in the presence of physiological buffers 
and endogenous Aβ binding proteins. The same transgenic mouse model as used in 
the Schenk study above was used to assess the effects of m266 in vivo.  Unbound Aβ 
plasma levels were reduced from 140 pg/ml in control mice to essentially 
undetectable levels in mice treated with m266, suggesting all plasma Aβ was bound 
to m266. Additionally the amount of Aβ bound to m266 increased over several days 
to ~ 1000 fold above endogenous plasma Aβ levels. This strongly implies that 
circulating m266 facilitates the transfer of Aβ into the plasma from the CNS 
(DeMattos, et al. 2001). The same group produced a follow-up study where they 
determined the effect of m266 on learning and memory. The group administered 
m266 to transgenic mice and found that it formed a complex with Aβ in both the 
plasma and CSF of the mice, and resulted in rapid reversal of memory impairment in 
learning and memory tasks (Dodart, et al. 2002).   
 
However a further study using passive immunization in transgenic mice found that 
although administration of Aβ immunisation significantly reduced amyloid, it also 
induced a two-fold increase in cerebral microhaemorrhages and a significant 
increase in haemorrhage severity over controls. This may results from passive 
immunization compounding the weakening of cerebral blood vessels which occurs 
during amyloid deposition (Pfeifer, et al. 2002). Furthermore a phase II clinical 
study using a serum Aβ antibody (AN1792) was halted when 6 % of the patients 
developed meningoencephalitis (Orgogozo, et al. 2003). 
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A further study was carried out with the antibody An1792, and found that 
immunisation of patients with An1792 was associated with a long term reduction in 
Aβ load and a variable degree of plaque removal. Unfortunately the study also found 
no support for immunisation improving cognitive function. Two individuals with the 
highest  levels of Aβ antibodies and almost complete elimination of plaques still had 
clear end stage dementia before death, and there was no evidence of immunisation 
having an effect on long-term survival (Holmes, et al. 2008). However the authors 
themselves concede that the small numbers of participants in the study may have 
masked potential smaller benefits of the treatment, thus it may be too early to write 
off immunisation as a possible AD therapeutic. 
 
Another approach is decreasing Aβ production by targeting the secretases. γ-
secretase inhibitors can be characterised into two generations of therapeutics. Firstly, 
administration of a γ-secretase cleavage site peptidomimetic resulted in a lowering 
of Aβ production (Wolfe, et al. 1998). This substrate-based difluoro ketone was 
designed based on the APP γ –secretase cleavage site for Aβ(1-42) and was 
demonstrated to be a specific inhibitor of Aβ biosynthesis in APP-transfected cells.  
However the peptidic and bulky properties of these mimics make them unlikely 
therapeutics for further development in in vivo studies, although they have provided 
valuable information on characterising γ-secretase’s catalytic core (Lundkvist, et al. 
2007).  
 
The second wave of therapeutics targeting γ-secretase are mostly structurally related 
through containing either sulphonamide/sulfone or benzodiazepine/benzolactam 
moieties (Harrison, et al. 2004). Early therapeutics had unfortunate side-effects with 
profound changes in gastrointestinal tract tissue morphology and altered lymphocyte 
development, probably due to impaired Notch signalling (Wong, et al. 2004). The 
Notch signalling pathway is essential during embryogenesis (Artavanis-Tsakonas, et 
al. 1995) and in adult life (Radtke, et al. 2004) for controlling cellular 
differentiation. The Notch receptor undergoes proteolytic cleavage at two sites, S2 
and S3 before translocating to the nucleus and regulating transcription (Lundkvist 
and Naslund 2007). However it has now been found that cleavage at S3 is carried 
out by γ-secretase (De Strooper, et al. 1999), and in fact there are more than 30 
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substrates of γ-secretase  (Nyborg, et al. 2006). However developing γ-secretase 
therapeutics that avoid Notch associated toxicity is possible. Indeed a recent  
benzodiazepine-derived γ-secretase inhibitor named LY-450137, developed in a  
collaboration between Washington University, St Louis and Eli Lilly has avoided 
these side-effects. The group measured central nervous system Aβ production and 
clearance rates through stable isotope labelling kinetics (SILK) (Bateman, et al. 
2009). They found that LY-450137 significantly decreased production of Aβ in 
human central nervous system, with up to 84 % inhibition at a 280 mg dosage.   
 
A different strategy to using γ-secretase inhibitors is the development of γ-secretase 
modulators.  Tarenflurbil is an enantiomer of a non-steroidal anti-inflammatory drug 
(NSAID). NSAIDs include drugs such as ibuprofen and aspirin. NSAIDs interact 
directly with the γ-secretase complex. The mechanism is unclear but the proteolytic 
cleavage site is altered, resulting in less Aβ(1-42) and more Aβ(1-38). NSAIDs are 
attractive as therapeutics as they already have well-characterised toxicity profiles.  
However a large 18 month phase III trial of an NSAID showed no benefit, perhaps 
because taking the drug via oral administration resulted in insufficient brain 
concentrations (Eriksen, et al. 2003). There are also the same concerns with 
modulating γ-secretase activity as there is for inhibiting it, due to the presenilin 
component of γ-secretase’s role in the Notch signalling pathway. 
 
In contrast, deletion of the β-secretase gene does not result in any serious toxicity 
and β-secretase is essential in generating Aβ, thus β-secretase inhibitors are 
considered to be one of the most promising targets for an AD therapeutic (Harrison, 
et al. 2003, Roberds, et al. 2001). There are several encouraging studies using β-
secretase inhibitors. GSK188909 is a BACE-1 inhibitor which was the first 
therapeutic shown to reduce brain amyloid levels in transgenic mice following oral 
administration (Hussain, et al. 2007). Inhibitors of β-secretase have mainly been 
designed to block the active site of the enzyme, for example there is a crystal 
structure of the protease domain of BACE complexed to an eight-residue inhibitor at 
1.9 angstrom resolution (Hong, et al. 2000). However despite having high activity 
against the enzyme many have failed in cellular studies, and one suggestion is that 
inhibitors need to be designed to be able to target organelles within the cell where 
BACE is active, for example endosomes (Rajendran, et al. 2008). In this study, 
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membrane anchoring of the inhibitor resulted in the inhibitor gaining access to 
endosomal β-secretase as well as enhancing the interaction between the inhibitor and 
the enzyme, both of which had a dramatic effect in amplifying the potency of a β-
secretase inhibitor (Rajendran, et al. 2008).  Additionally conjugating a β-secretase 
inhibitor to a carrier peptide to aid blood brain barrier penetration reduces Aβ in the 
brain (Chang, et al. 2004). Indeed targeting BACE still seems to be the most viable 
approach for a single therapeutic in AD (Hunt, et al. 2009) 
 
 
Mechanism of 
Action of drug 
Example of Drug Stage of Development 
Acetylcholinesterase 
inhibitors 
Donepezil 
(Aricept)/ 
Rivastigmine, 
Galantamine 
Recommended by NICE 
for use in patients with 
moderate AD 
NMDAR antagonist Memantine Not recommended by 
NICE 
Directly bind Aβ and 
inhibit aggregation or 
enhance clearance of 
plaques 
Tramiprosate and 
ACC-001 
At phase II and III in 
clinical trials 
Secretase modulator NSAIDs, 
GSK188909, 
statins 
At various stages in 
clinical trials. 
Metal chelation Clioquinol (PBT2) Entering Phase III  
Tau aggregation 
inhibitor 
Rember Entering Phase III 
 
Table 1.3. Selected AD drug development programs. Each of the 
categories is discussed in more detail in the text, adapted from Rafii et 
al. 2009.
 
 
As well as developing drugs that directly inhibit BACE1 activity, statins, a class of 
drug which lower cholesterol, have also been proposed as a therapeutic in AD. 
Interestingly a study of individuals of 50 years and older who were prescribed 
statins, a cholesterol lowering drug, showed that they had a substantially lowered 
risk of developing dementia (Jick, et al. 2000). Statins are competitive inhibitors of 
the enzyme that regulates the synthesis of cholesterol. High cholesterol has been 
suggested to affect APP processing through increased formation of intracellular lipid 
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rafts, inside of which APP and BACE1 processing occurs (Cordy, et al. 2003, 
Sidera, et al. 2005, Won, et al. 2008). Statins have also been shown to decrease the 
risk of dementia through up-regulating the expression of the α-secretase ADAM10 
(Kojro, et al. 2001). However, it is not clear still whether disturbed cholesterol 
metabolism may be a consequence of AD rather than a cause, and thus whether 
statins are a potential treatment target. 
 
Metal chelators have been shown to solubilise amyloid plaques through metal 
depletion (Cherny, et al. 1999) and treatment with a copper-zinc chelator inhibited 
Aβ accumulation in transgenic mice (Cherny, et al. 2001). The Bush/Tanzi group 
have been particular champions of metal chelators based on 8-hydroxyquinoline 
derivatives such as clioquinol and PBT2. PBT2 showed a time and dose-dependent 
improvement in AD patients in a preliminary clinical trial compared to patients on a 
placebo (Lannfelt, et al. 2008).  
 
However clioquinol was linked to an outbreak of subacute myelo-optic neuropathy 
in the 1960s in Japan, thus the proposed long-term administration of clioquinol to 
AD patients has some risks associated with it. Despite this two more phase 3 trials 
being planned with PBT2. Additionally metal chelators may remove Cu2+ from Aβ 
when administered, but once Cu2+ is bound to the chelator, there would be nothing 
to prevent further Cu2+ binding to Aβ, thus metal re-distribution, for example 
through induction of metallothionein expression, rather than chelation may be a 
more effective strategy. 
 
Finally there are also drugs being developed that are not focused on preventing Aβ 
production, but act on tau instead. Both methylene blue (tradename Rember), a 
histological dye and a small peptide called NAP, have shown promising results due 
to their ability to interfere with tau aggregation and dissolve the neurofibrillary 
tangles (Gozes, et al. 2005, Gura 2008). Targeting both tau and amyloid-β 
formation/aggregation seems wise, as it is likely that there will not be one 
“superdrug” to cure AD, but instead a synergistic combination of drugs which will 
need to target both Aβ and tau pathology. Indeed a recent study using a cocktail of 
four drugs, including NSAIDS, statins, β and γ inhibitors found that the cocktail 
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resulted in the drugs actually having an additive effect, and importantly producing 
no detrimental effects in respect to the notch pathway (Asai, et al. 2010).  
 
1.10. The Chemistry of Copper  
The interaction between Aβ and Cu2+ is the major theme of this thesis, thus this 
section of the introduction discusses copper in the body, its redox chemistry and 
aspects of metal-ligand binding. Copper is a crucial cofactor in enzymes such as 
cytochrome c and superoxide dismutase, and it can drive a range of processes in the 
body that are essential for life. It can exist in biological systems in two states: Cu+ 
(reduced) and Cu2+ (oxidised). Defects in copper homeostasis are directly 
responsible for human disease, for example mutations in the ATP7a or ATP7b genes, 
which encode Cu+ transporting ATPase pumps, result in Menkes and Wilson’s 
disease respectively. Menkes disease is a lethal disorder of intestinal copper 
hyperaccumulation with severe copper deficiency in peripheral tissues. Wilson’s 
disease results in hepatic and neuronal copper overload, which requires chronic 
therapy to enhance copper excretion or reduce copper absorption. 
 
1.10.1. Copper Life Cycle 
We ingest ~ 1 mg of copper daily (Linder, et al. 1998). Based on studies in rats, a 
brief summary of copper’s fate upon leaving the intestine is as follows. Once copper 
crosses the intestinal membrane it enters the blood. Almost all the copper then 
rapidly leaves the blood and enters the liver and kidney before re-emerging into the 
blood plasma for the second time. The copper is then taken up by other tissues and 
organs, such as the brain. After copper has left the kidneys/liver it can also enter the 
bile for excretion. The concentration of ionic copper and amino acid chelates in 
plasma is low (~ 11 pmol/L and 0.55 µmol/L respectively (Linder, et al. 1998)). 
Instead copper is mainly bound to proteins such as albumin, transcuprein and 
ceruloplasmin (Linder, et al. 1998).  
 
1.10.2. Copper in the Brain 
Interestingly, in comparison to Cu2+ in the blood, studies comparing radiolabelled 
free copper, copper-albumin, and copper-ceruloplasmin showed that free copper was 
the major species entering the brain (Choi, et al. 2009). The blood brain barrier 
(BBB) is the major entrance for copper to the brain, whereas the blood - 
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cerebrospinal fluid (BSF) barrier regulates copper homeostasis in the cerebrospinal 
fluid (CSF).  
 
Once copper has crossed the BBB/BSF barrier the high affinity copper transporter 
Ctr1 mediates Cu+ transport into neurons. The mammalian mechanism of reducing 
extracellular Cu2+ to Cu+ is still unclear. Interestingly, APP possesses a copper 
binding domain capable of reducing Cu2+ to Cu+ and has been suggested as the 
metalloreductase responsible (Multhaup, et al. 1996). This is supported by a study 
using S. cerevisiae where the endogenous cell surface metalloreductase Fre1 was 
replaced with APP, resulting in restored Cu2+ reductase activity and copper uptake 
(Suazo, et al. 2009).  
 
Although free Cu2+ may be the major species entering the brain, once inside the cell 
redox active metals such as Cu+ are usually tightly chaperoned – there are no free 
Cu+ ions in the cell (Rae, et al. 1999). However the concentration of copper in the 
synaptic cleft of rat cortical synaptosomes (isolated terminals of neurons) was 
calculated to reach local concentrations of 100- 250 micromolar (Kardos, et al. 
1989). Both Aβ and Cu2+ are released at the glutamatergic synapse, and 
subsequently this has implications which are explored further in Chapter 7.  
 
1.10.3. Redox Chemistry of Copper 
Copper is a redox active metal as it can change its valence state under biological 
conditions. The one electron difference between Cu+ and Cu2+ allows copper to 
promote radical reactions. Dissolved molecular oxygen in the body is liable to react 
with redox active metals such as copper to produce ROS. Superoxides (O2
●-) are one 
type of ROS that are produced in the mitochondrial transport chain, and dealt with 
by superoxide dismutase (SOD). SOD is a copper-containing enzyme which 
catalyses dismutation of O2
•- to hydrogen peroxide (H2O2) by the copper ions in 
SOD undergoing oxidation and reduction: 
Enzyme–Cu2+ + O2
•- 
 Enzyme-Cu+ + O2 
Enzyme-Cu+ + O2
•- + 2H+  Enzyme–Cu2+ + H2O2 
 
Hydrogen peroxide is widespread in the cell and is only a weak oxidising or 
reducing agent, and generally poorly reactive. However it can react with iron and 
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copper to form damaging species, such as the hydroxyl radical (OH•), via Fenton’s 
cycling and the Haber-Weiss reaction (below).  
 
Cu+ + H2O2  Cu
2+ +  OH• + OH- (Fenton reaction) 
         
O2
●-
 + H2O2                     O2 + OH
• + OH- (metal-catalysed Haber Weiss-reaction) 
 
Thus, through redox cycling, copper has the potential to produce a range of harmful 
species which can go on to generate a variety of oxidative damage in the cell (Figure 
1.14). Accumulation of ROS can result in the modification of proteins, lipids and 
DNA leading ultimately to cell death. 
Figure 1.14. Diagram of Cu2+ induced oxidative stress. Dissolved molecular 
oxygen is liable to react with redox active metals (Mx) such as Cu and Fe. In 
the reduced state Mx-1 will reduce O2 to superoxide O2
•- which is then 
dismutated or disproportionated to H2O2, for example by superoxide dismutase. 
If H2O2 is not cleared by scavenging mechanisms (e.g. catalase or glutathione 
peroxidase) it can generate the highly reactive hydroxyl radical (OH˙) upon 
reaction with an encountered reduced metal Mx-1 (adapted from Strozyk 2006).
O2 O2
•-
OH˙
Lipid peroxidation
Protein oxidation
Protein aggregation
DNA/RNA adducts
Mx-1
Mx
Mx-1
Reducing 
agents
e-
H2O2
 
 
Metal-Ligand Binding 
The potential complexes that may form between Aβ and Cu2+ is covered in some 
detail in Chapter 4. Below is a brief summary of the principles behind metal-ligand 
binding, including different metal-ligand geometries, why Cu2+ preferentially binds 
Metal catalyst 
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to nitrogen atoms, and why certain amino acids are more likely to take part in the 
binding complex.  
 
1.10.4. Crystal Field Theory-Copper-Ligand Complex Geometry 
The interaction between a transition metal, such as Cu2+, with ligands can be 
described using crystal field theory. Cu2+ is a d-block element with five degenerate 
d-orbitals (all five d-orbitals have the same energy level), see Figure 1.15. 
Hypothetically, if a spherically symmetrical field of negative charges was placed 
around Cu2+, all five d-orbitals would be raised equally in energy as a result of the 
repulsion between the applied negative field and the negative electrons in the orbital, 
and the five d-orbitals would remain degenerate.  
 
Figure 1.15. The d-orbitals of copper. Spatial arrangements of the 5 d-orbitals.  
z
y
x
 
 
However this degeneracy is lost when a real ligand approaches the metal ion. For 
example, six ligands approaching to form an octahedral complex along the axes of 
the coordinate system: z, -z, x, -x, y and –y. Under these conditions the ligand 
electrons will interact strongly with the electron orbitals lying along the x, y and z 
axes, the dz2 and dx2-y2 orbitals. These two orbitals will be raised in energy to the 
same extent. Less repulsion will be felt by the three remaining orbitals which do not 
lie exactly along the x, y and z axis (dxy, dxz, dyz). Thus the d-electrons closer to the 
  Chapter 1. Introduction 
65 
ligands will have a higher energy than those further away, resulting in the d-orbitals 
splitting in energy. 
 
Figure 1.16. The splittings of the d-orbitals of copper. Splitting of d-orbitals in  
(a) an octahedral field, (b) a tetrahedral field and (c) a square planar field.
(a)
Energy
Octahedral
Square planar(c)
(b) Tetrahedral
 
Depending on how the energy levels split, different complexes result (Figure 1.16). 
The splitting is affected by the following factors: 
 
• the nature of the metal ion. 
• the metal's oxidation state. A higher oxidation state leads to a larger splitting. 
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• the arrangement of the ligands around the metal ion. 
• the nature of the ligands surrounding the metal ion.   
 
The most common type of complex is octahedral. In octahedral symmetry the d-
orbitals split into two sets with an energy difference, ∆oct (the crystal-field splitting 
parameter). An example of an octahedral coordination geometry is in Cu(H2O)6. 
Tetrahedral complexes are the second most common type of complex. Four ligands 
form a tetrahedron around the metal ion. The d-orbitals again split into two groups, 
with an energy difference of ∆tet where the lower energy orbitals will be dz
2 and dx
2
-
y
2, and the higher energy orbitals will be dxy, dxz and dyz - opposite to the octahedral 
case. Furthermore, since the ligand electrons in tetrahedral symmetry are not 
oriented directly towards the d-orbitals, the energy splitting will be lower than in the 
octahedral case. These tetrahedral complexes are an intense blue, due to strong 
absorption ~ 600 nm and are described as type I copper complexes. Tetragonal 
complexes can be square planar or square pyramidal and are often referred to as type 
II copper complexes. In square planar conformations four ligands are distributed 
close to Cu2+ in the equatorial plane. Two other ligands are further away and 
perpendicular to the equatorial plane and are more weakly bonded to the Cu2+ and 
subsequently are less important when considering their role in the complex. Human 
serum albumin and the prion protein both coordinate Cu2+ in this conformation. The 
complex formed by Aβ-Cu2+ is investigated in Chapter 4. 
 
1.10.5. Hard and Soft Metal Ligands- Cu2+’s “Preference” for Certain 
Ligands 
Metal ions will bind preferentially to certain ligands, and this can be predicted 
through the hard and soft metal ligand theory, which classes ligands and metals as 
“hard” or “soft” (Pearson 1963). Hard metals include group 1 and 2 of the periodic 
table, and lighter transition metals in higher oxidation states e.g. Fe+3. They are 
small, often have a high oxidation state and are weakly polarisable. Soft metal ions 
include those of the heavier transition metals and those in lower oxidation states e.g. 
Cu+. They are large and have low oxidation states and are highly polarisable. 
Likewise ligands can be classified as hard or soft, depending on their preference for 
hard or soft metal ions. Hard metals react faster and form stronger bonds with hard 
ligands, and likewise for soft metals and ligands, all other factors being equal. 
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Cu2+ and Zn2+ are both classified as borderline metals as they tend to have lower 
oxidation state and larger size than hard metals but a lower oxidation state and 
smaller size than soft metals. Corresponding borderline ligand donor atoms are N or 
Cl. Ca2+ on the other hand is a hard metal and binds preferentially to hard bases such 
as H2O, OH
-, ROH, and RO-. Thus Cu2+ will “prefer” to bind to nitrogen ligands and 
Ca2+ will “prefer” to bind to oxygen ligands. 
 
1.10.6. Potential Binding Ligands 
In addition to Cu2+ ‘preferring’ certain atoms, the protonation state of an amino acid 
will influence the propensity of Cu2+ to bind. Cu2+ will bind preferentially to amino 
acids that are deprotonated and thus have a low pKa, for example histidine’s pKa is ~ 
6.5 and the N- terminus pKa is ~ 8. Thus at around neutral pH both will mainly be 
deprotonated, compared to say, arginine whose pKa is ~12.5.  
 
1.11. Evidence for a Role for Copper in AD 
Some interactions between APP, Aβ and Cu2+ have been mentioned already, but a 
summary of the key pieces of evidence for a role for Cu2+ in AD are discussed 
below. 
 
A notable characteristic of both AD and Down’s syndrome patients is altered metal 
ion concentrations in the brain (Bayer 2006). Copper levels are significantly 
elevated in the brains of AD patients, from 4.4 ±1.5 µg/g in the neuropil of control 
patients to 19.3 ±6.3 µg/g in AD neuropil and up to 30.1±11.0 µg/g in the senile 
plaque core (Lovell, et al. 1998). Raman microscopy of senile plaque cores isolated 
from AD brains displayed vibrational frequencies arising from copper and zinc ions 
directly bound to the histidine imidazole rings of Aβ in the plaques (Dong, et al. 
2003). In addition, synchrotron X-ray fluorescence has identified hot spots in which 
Cu2+ and Zn2+ are concentrated within Aβ associated amyloid plaques (Miller, et al. 
2006). Finally copper levels in serum are 54 % higher in patients with AD than 
controls (Squitti, et al. 2002). This all indicates that disrupted metal ion homeostasis 
occurs in AD (Bush 2003, Cuajungco, et al. 1997). 
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Normal levels of Cu2+ in the brain are more than sufficient to be neurotoxic if Cu2+ 
homeostasis and compartmentalisation of Cu2+ is impaired (Gaggelli, et al. 2006, 
Opazo, et al. 2002). Oxidative damage is a key feature of the pathogenesis of AD 
(Barnham, et al. 2004, Behl, et al. 1992, Butterfield, et al. 2007) and Cu2+ Fentons 
cycling is the probable source of ROS. A recent key study shows transfer of copper 
from Aβ to a redox inactive form bound to metallothionein negates Aβ’s neurotoxic 
properties (Meloni, et al. 2008). Likewise neurons with lower antioxidants are more 
susceptible to Aβ-Cu toxicity (White, et al. 1999) and cells can be rescued from Aβ-
Cu toxicity by the presence of catalase, an enzyme that catalyses the decomposition 
of hydrogen peroxide into water and oxygen (Behl, et al. 1994, Loew 1900, Opazo, 
et al. 2002). 
 
Soluble Aβ(1-40) and Aβ(1-42) are present in the cerebrospinal fluid (CSF) and 
blood plasma from birth, (Lambert, et al. 1998, Vigo-Pelfrey, et al. 1993), but the 
trigger that promotes oligomerisation and fibril formation is a subject of debate. 
Physiological levels of Cu2+ and Zn2+ will cause marked aggregation of 
Αβ  (Atwood, et al. 1998, Atwood, et al. 2004, Bush, et al. 1994) and while some 
studies suggest Zn2+ and Cu2+ promote amorphous aggregation of Aβ (Bush, et al. 
1994) but inhibit fibril formation (Raman, et al. 2005, Yoshiike, et al. 2001), others 
have suggested fibril assembly only occurs in the presence of Cu2+ ions (Huang, et 
al. 2004) and this is investigated further in Chapter 5. Specific Cu2+ chelators can 
reverse the aggregation that occurs in AD, and cause solubilisation of amyloid 
deposits from post-mortem AD brain tissue (Cherny, et al. 1999) and thus Cu2+ 
chelators represent a possible therapy for Alzheimer’s disease (Bush 2002, Cherny, 
et al. 2001, Ritchie, et al. 2003).   
 
Recent studies in a Drosophila model of Alzheimer's disease show that the iron-
binding protein ferritin and also catalase are potent suppressors of the Aβ toxicity. 
Likewise, treatment with the iron-binding compound clioquinol increased the 
lifespan of flies expressing Aβ(1-42). These studies suggest that oxidative stress, 
probably mediated by the hydroxyl radical and generated by the Fenton reaction, is 
essential for Aβ(1-42) toxicity in vivo and provide strong support for a role for metal 
ions in Alzheimer's disease (Rival, et al. 2009). Additionally it has been shown that 
trace amounts of copper in a cholesterol high diet induces amyloid plaques and 
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learning deficits in a rabbit model of Alzheimer's disease (Marx 2003, Sparks, et al. 
2003). 
 
However, despite these findings there are two commonly expressed objections to the 
role of copper in AD. The first objection is that AD is not associated with elevated 
exposure to environmental copper. It is important to clarify this misconception. The 
total concentration of copper within the brain is potentially more than sufficient to 
be neurotoxic. As a consequence, the brain has efficient homeostatic mechanisms in 
place to maintain compartmentalisation of metal ions, which when compromised 
cause neurodegenerative diseases such as Wilson's and Menkes' disease. However as 
outlined above there is evidence to suggest that homeostatic mechanisms for metal 
ions are impaired in AD patients, and AD is characterised by altered metal ion-
dependent processes and metal ion concentrations in the brain.  
 
The second objection is that the affinity of Aβ for Cu2+ is too low to bind these 
metals at their extracellular concentrations. The affinity of Cu2+ for Aβ is key to its 
physiological significance and there are large discrepancies between the affinities 
reported for monomeric Aβ, and no reports of Cu2+ affinities for fibrillar Aβ. 
Dissociation constants for monomeric Aβ range from µM to nM (Garzon-
Rodriguez, et al. 1999, Hatcher, et al. 2008, Syme, et al. 2004, Tougu, et al. 2008), 
and in one report up to atto-molar Kd ~ 10
-18 M (Atwood, et al. 2000). This is 
investigated further in this thesis in Chapter 3.   
 
1.12. Aims of this Thesis 
Thus from this chapter it is clear that, although a great deal of progress has been 
made since 1985 when Aβ was first isolated, many important details are missing, 
and a great deal of controversy as to the role of Cu2+ remains. The four main aims of 
this thesis are outline below, but more detailed aims are within each of the four 
results chapters. 
 
1. Determine the affinity of both monomeric and fibrillar Aβ to ascertain if the Aβ-
Cu2+ complex has a high enough affinity to make it physiologically relevant.  
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2. Investigate if the Cu2+ binding complex and stoichiometry differ between 
monomeric and fibrillar Aβ to see if the process of fibril formation results in a 
different binding complex.  
 
3. Compare the fibril formation rates of Aβ in the presence and absence of Cu2+, to 
establish the role of Cu2+ ions in fibril formation. 
 
4. Study the toxic effects of Aβ monomeric and fibrillar Aβ in the presence of Cu2+ 
to see if Cu2+ ions enhance or reduce Aβ toxicity. 
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2. Materials, Methods and
Method Theory
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2.1. Materials
2.1.1. Peptide Synthesis and Purification
Peptides representing various fragments of A were synthesised by employing solid
phase F-moc chemistry and produced by either the ABC facility at Imperial College,
London or Zinisser Analytic, Maidenhead. After removal from the resin and de-
protection, the samples were purified using reverse phase HPLC and characterised using
mass spectrometry and 1H NMR. Synthesised peptides were supplied lyophilised and
stored in the freezer at – 18 C or – 70 C.
2.1.2. Design of Peptides and Peptide Sequences
Peptides were synthesised of the human sequence of A(1-40) and A(1-42) in which
the N-terminus and C-terminus were left as the native amino and carboxyl groups
respectively. In the A fragments used, the truncated C-terminus was blocked as the
corresponding ethyl ester while at the N-terminus Asp1 retains a free amino group.
Together with the wild-type A(1-28) fragments, four analogs of A(1-28) were
synthesised in which His6, His13 and His14 residues are replaced by alanine and one in
which the N-terminus was acetylated - A(Ac1-28). Two shorter fragments were also
synthesised: A(1-11) and A(Ac10-16). Sequences are given below:
A(1-42):     DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
(H6A):           DAEFRADSGYEVHHQKLVFFAEDVGSNK
(H13A):         DAEFRHDSGYEVAHQKLVFFAEDVGSNK
(H14A):         DAEFRHDSGYEVHAQKLVFFAEDVGSNK
(Ac1-28): Ac-DAEFRHDSGYEVHHQKLVFFAEDVGSNK
A(Ac10-16): Ac-YEVHHQK
2.1.3. General Chemicals and Suppliers
Chemicals
Alamar blue (Invitrogen); Copper(II)Chloride dihydrate (99.9%) (Aldrich);  Deuterium
Oxide (99.9% atom D min, D2O) (Goss Scientific); N-ethylmorpholine (C6H13NO)
(Sigma); Glycine (H2NCH2COOH) (BDH); HEPES (N-[2-hydroxyethyl] piperazine-N’-
[2 ethanesulfonic acid]) (Sigma); L-Histidine (99 %, L--Amino--[4-imidazolyl]
propionic acid) (Sigma); Horse Serum (Sigma); Hydrochloric acid (SpectrosoL, 11.6 M,
HCl) (BDH); Methanol (99.93%, HPLC grade, CH3OH) (Aldrich); MTT ((3-(4,5-
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Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma); Nitrilotriacetic acid
(C6H9NO6) (Sigma); Opti-MEM Reduced Serum Media (Invitrogen); Potassium
Chloride (saturated solution, KCl) (Sigma-Aldrich); Potassium phosphate dibasic (1.0
M, HK2O4P) (Sigma); Potassium phosphate monobasic (1.0 M, H2KO4P) (Sigma);
RPMI-1640 + glutamine no phenol red (Sigma); DSS (sodium 2,2 dimethyl-2-
silapentane -5-sulphonate) (Goss Scientific); Sodium Hydroxide (NaOH) (Sigma);  T
(C17H19ClN2S) (Aldrich); Tris(hydroxymethyl)methylamine (H2NC(CH2OH)3 (BDH);
Trypan Blue (Sigma), Uranyl acetate (obtained with kind permission from Norbert
Krauss); Zinc Chloride (ZnCl2) (Sigma). All chemicals were of analar grade or better.
Other
Carbon coated 300 mesh copper grids (Agar Scientific)
PC12 cells (Health Protection Agency Culture Collection)
EPR tubes 178 mm in length, 4 mm diameter (Fluorochem Limited)
2.2. General Experimental Methods
General experimental methods used throughout this thesis are described here.
Additionally the theory of the major techniques used, circular dichroism, fluorescence
and electron paramagnetic resonance are also discussed in this chapter. Methods
specific to each chapter can be found at the start of each individual chapter.
2.2.1. Peptide Solubilisation
Theoretical Background
There are several different methods currently used for the solubilisation of A.
Chaotropic agents such as dimethylsulfoxide (DMSO) (Stine, et al. 2003), organic acids
such as trifluoroacetic acid (TFA) (Zagorski, et al. 1999), organic cosolvents, usually
trifluoroethanol (TFE) and hexafluoroisopropanol (HFIP) (Chen, et al. 2001, Zagorski,
et al. 1992) are common in the literature. Alternatively basic conditions, such as using
sodium hydroxide (NaOH) to obtain a pH of ~10.5 have also been shown to effectively
solubilise A (Fezoui, et al. 2000).
A problem with using strong acids or organic solvents such as HFIP is that they can
cause conformational changes that may influence fibrillogenesis. This adds to the
variability that is already a major problem in fibril growth studies (Shen, et al. 1995). In
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addition the presence of these organic solvents or acids can be directly cytotoxic and
thus interfere with toxicity studies, such as in Chapter 6 of this thesis. Using strongly
basic conditions for solubilisation avoids these problems. An additional advantage of
using high pH solubilisation conditions is that it avoids A being near its isoelectric
point. Synthetically produced A contains bound trifluoroacetate or fluoride ions
(depending on whether F-moc or t-BOC peptide synthesis is used), which, when Aβ is
solubilised, will create an acidic environment. When Aβ is subsequently added to buffer
at a neutral pH the solution passes through the isoelectric point of Aβ (5.3), where the
potential for Aβ aggregation and precipitation is maximised. This can result in highly
variable kinetic behaviour and fibril morphologies (Wood, et al. 1996). However, by
using strongly basic conditions Aβ avoids the transition from low pH via its pI to
physiological pH and thus escapes the problems that can result from Aβ being at its pI
(Fezoui, et al. 2000, Teplow 2006).
The NaOH method has been shown to be as effective as two other commonly used
methods, the DMSO/water/Tris method and the NaCl/PO4 method (Lashuel, et al. 2003)
and also HFIP (Hortschansky, et al. 2005). Furthermore, the Teplow lab has found that
NaOH pretreatments results in fewer aggregates and diminishes variability (Fezoui, et
al. 2000). Because of this, NaOH was used to solubilise lyophilised A in the studies in
this thesis.
Other methods that are used to try to achieve a homogenous population of monomers in
Aβ samples are centrifugation, sonication and filtration. Centrifugation was used on one
solubilised batch of A(1-40) to see if the light scatter was reduced, however there was
no improvement. Sonication was not used, as any form of agitation such as pipetting or
shaking was found to accelerate fibril formation. Filtration, such as through 0.2 µM
filters, has been used by groups to remove large aggregates from Aβ stocks, however
this is insufficiently exclusive as assemblies of 200 nm are generally already fibrillar.
There are filters with smaller pores such as a 10 kDa exclusion limit which are more
effective. Although these filters will initially create populations of only monomers and
dimers, the stock solution will still rapidly (within seconds (Teplow 2006)) reach an
equilibrium comprised of a population of low order assemblies. Thus filtration was not
used in the solubilisation method in this thesis.
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Experimental Specifics
For experiments described in this thesis, lyophilised full length A(1-40) or A(1-42)
was solubilised at 0.7 mg/mL in NaOH in water (ultra high quality, >18 . cm
resistivity) at pH ~10.5 and gently rocked at 5 C for a minimum of 48 hours. The pH
was checked during this period and kept at pH 10.5. Peptide concentrations were
determined using the extinction coefficient of 1280 M-1 cm-1 (due to the single tyrosine
residue) at 280 nm (Gill, et al. 1989). Typically, the freeze-dried peptides contained ~
10% moisture by weight. UV/visible electronic absorption spectra were obtained with a
Hitachi U-3010 double beam spectrophotometer, using a 1 cm path length quartz
cuvette. The peptides were then aliquoted and frozen at -20 °C.
Evidence that the method used in this thesis to solubilise Aβ was successful in creating
seed free Aβ is:
 The minimal light scatter as observed by UV-Vis absorbance spectroscopy.
 The lack of an absorbance band at 217 nm which is indicative of -sheet secondary
structure, and a strong band at 198 nm, indicative of irregular conformations, as
measured by circular dichroism.
 The baseline levels of thioflavin T (ThT) fluorescence of the solubilised batches,
indicative of a lack of fibrils present. The readings in the lag phase are comparable
to the readings of buffer with ThT.
 The long lag time for both A(1-40) and A(1-42) (~75 hours) at pH 7.4 which is
in contrast to the effect of deliberate seeding which removes the lag phase.
 Size exclusion chromatography of solubilised batches shows the population is
predominantly dimeric and trimeric (courtesy of Hannah Wright/Nadine Younan).
After Aβ is solubilised it is referred to in this thesis as either soluble or monomeric Aβ.
However it is likely that freshly solubilised Aβ exists as a mixture of monomers and
low-order oligomers, and that these species are in equilibrium. The presence of low
order oligomers is not as much of a concern as the ability to prepare peptide stock
solutions which all resemble each other in their distribution of peptide assembly states
and thus give reproducible experimental results.
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2.2.2. Cu2+ and Competing Ligand Addition
A Cu2+ stock was made to a concentration of 25 mM in water as CuCl2 (ultra high
quality, >18 . cm resistivity) and then subsequently diluted down to a concentration
that allowed a small volume (10 l – 50 l) to be added to the peptide sample to allow
limited dilution of the peptide sample. The addition of competing ligands to the A
peptides was also performed using small aliquots from stock aqueous solutions (10 – 50
mM) of glycine, L-histidine or nitrilotriacetic acid (NTA).
2.2.3. Buffers
The spectroscopic techniques used in this thesis have some influence on the choice of
buffer. The affinity studies in Chapter 3 were typically performed in the absence of
buffer and performed in ultra high quality (>18 .cm resistivity) water with 160 mM
NaCl, pH 7.4. 10 mM phosphate buffer, 10 mM N-Ethylmorpholine (EM) buffer and 10
mM N-(2-Hydroxyethyl) piperazine-N’[2-ethanesulfonic acid]) (HEPES) were used in
the EPR pH dependence study in Chapter 4. The fibril growth studies in Chapter 5 and
6 used 50 mM HEPES buffer with 160 mM NaCl, pH 7.4. Buffers were made to their
respective concentration in water (ultra high quality, >18 . cm resistivity). The
structures of the buffers used in this thesis, their pKa, and their affinity for Cu2+ are
shown in Figure 2.1 and Table 2.1.
Tris-HCl
Figure 2.1. Structure of four buffers commonly used in this thesis. N-2-
hydroxyethylpiperazine-N’-ethanesulphonic acid (HEPES), N-ethylmorpholine
buffer (EM), Tris-HCl and phosphate buffer.
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Table 2.1. Properties of buffers commonly used in this thesis. aMolecular
formulas and pH ranges taken from (Dawson 1986). bCu affinities taken from
(Sokolowska et al. 2005). pKa values taken from cthe Sigma website, d
http://www.cnr.berkeley.edu/soilmicro/methods/phosphate%20buffer.pdf and
e(Hall 1957).
Buffer name Molecular
Formula a
pH range a Log K Cu b pKa at
(25°C)
N-2-
hydroxyethylpiperazin
e-N’-ethanesulphonic
acid buffer (HEPES)
C8H18N2O4S 7.2–8.2 at21 °C
3.22 7.48 c
Phosphate Buffer
(mono and dibasic
potassium phosphate
combination)
K2HPO4/KH2PO4
5.8–8.0 at
25 °C
3.20 7.20 d
Tris-HCl buffer NH2C(CH2OH)3 7.1-8.9 at 25°C
4.05 8.10 e
N-Ethylmorpholine
buffer (EM)
C6H13NO 7.0-8.2 at 20°C
Not available 7.70 e
2.2.4. pH Measurements and Adjustments
The pH was adjusted using small amounts of 10-100 mM NaOH or HCl and measured
using a Thermo Electron Orion 3 Star pH benchtop with an electrode with a 3 mm stem
diameter and 55 mm in length (catalogue number KCMAW11) to allow the pH of
samples to be read whilst in 1 cm path length quartz cuvettes. For the EPR and multi-
well plate fluorescence experiments, the pH of the samples was determined before and
after the experiment was carried out. The pH of most experiments was pH 7.4, unless
stated otherwise, to recreate physiological conditions as much as possible.
2.2.5. Fibril Growth Conditions
The solubilised peptide (described in Section 2.2.1) was unfrozen, diluted to the correct
concentration and used immediately. A range of buffers were used, depending on the
spectroscopic technique.
For experiments in Chapters 3 and 4, the solubilised peptide was diluted to 50 μM in the
appropriate buffer, with 160 mM NaCl at pH 7.4. The peptide was then left for 72 hours
at 37 C with agitation. Cu2+ was added at the end of fibril formation. Fibril growth was
monitored using a Hitachi F-2500 fluorescence spectrophotometer and confirmed by the
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sigmoidal Thioflavin T fibril growth curve. An excitation wavelength of 444 nm was
used and data collected over the range of 455 – 520 nm with an average of 3 scans and
gentle magnetic stirring.
In fibril growth experiments in Chapters 5 and 6 fibrils were grown in the presence of
Cu2+ and lower concentrations (typically 5 μM) of Aβ were necessary. The fibrils were
typically grown at 30 °C, as this was found to be the optimum temperature to allow the
growth curve to have both a lag phase and still form within a week. Additionally 30
seconds agitation was performed every 30 minutes, before a reading was taken. Fibril
growth was typically monitored using 10 μM ThT and were grown in a BMG fluostar
galaxy fluorescence spectometer. An excitation filter wavelength of 440 nm and an
emission filter wavelength of 490 nm were used. For further information on the theory
of fibril formation please refer to Chapter 5.
2.3. Spectroscopy Introduction
Multiple spectroscopies were used in this thesis to study the relationship between Aβ
and Cu2+, see Figure 2.2. The basis of the spectroscopic techniques is well covered in a
number of books and reviews, see individual sections for references. However each of
the main techniques used in this thesis has been outlined in brief.
Electromagnetic radiation is composed of coupled oscillating electric and magnetic
fields. In optical spectroscopy, such as UV-Vis (Section 2.3.1), circular dichroism
(Section 2.4) and fluorescence (Section 2.5) the radiation is at shorter wavelengths (the
UV and visible) and will typically excite valence electrons to a higher energy orbital.
Alternatively in EPR (Section 2.6) longer wavelength are used (microwaves) and are of
a low enough energy that they can only ‘flip’ the spin orientations of electrons (EPR)
between two energy levels.
Populations of the various energy levels in spectroscopy will adopt a Boltzmann
distribution, so that at temperature T (kelvins), the number of molecules in an upper
state (nupp) relative to the number in a lower state (nlow) is given by equation 1 below:
(nupp/nlow) = exp(-[ΔE/kT]). (eq 1)
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Where k is the Boltzmann constant and ΔE is the energy difference between the states.
Each of the spectroscopic techniques monitors the absorption and excitation of
molecules at certain wavelengths, to the upper state, followed by the molecule’s return
to the lower state.
400 500 600 700Wavelength (nanometres)
Visible light
ThT Fluorescence /  Visible region Circular
Dichroism /  Alamar Blue assay
Gamma
rays X-rays
Ultraviolet
rays
Infrared
rays
Microwaves FM TV AM
10-14 10-12 10-10 10-8 10-6 10-4 10-2 1 102 104
Wavelength
(metres)
UV Circular
Dichroism/
Fluorescence
Quenching
EPR NMR
Figure 2.2. Electromagnetic spectrum with corresponding spectroscopic
techniques.
2.3.1. Ultraviolet-Visible Spectroscopy
Ultraviolet-visible (UV/Vis) electronic absorption spectra were obtained with a Hitachi
U-3010 double beam spectrophotometer. Peptide concentration determinations were
carried out using a 1 mL volume, 1 cm path length quartz cuvette (Hellma). Subtraction
of a baseline using a blank sample, containing water, was performed. Spectra were
recorded at room temperature, at a scan rate of 300 nm min-1. For wavelength scans
(800 nm to 200 nm) a 1 nm sampling interval was used. Aβ has an extinction coefficient
of 1280 M−1 cm−1 at 1280 nm (Gill and von Hippel 1989)and the concentration
determined using the Beer-Lambert law.
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2.4. Circular Dichroism (CD) spectroscopy
A brief over-view of the theory of CD is provided below. For further information Alex
Drake is an excellent reviewer of this technique (Drake 1994).
Theoretical Background
2.4.1. Circularly Polarised Light
Figure 2.3. Principles of Circular Dichroism. (a) Left and (b) right circularly
polarised light. (c) The basic components of a circular dichroism spectrometer.
Adapted from Drake 1994.
Anticlockwise wave propagation
(Left circularly polarized light)
Clockwise wave propagation
(Right circularly polarized light)
CD spectrum
Light Source
(lamp)
Photoelastic
modulator Sample
Photomultiplier
Polaroid
Plane
polarised
light
Alternating left/right
circularly polarised light
CD Spectrum
(a) (b)
(c)
Plane polarised light can be divided into two forms of circularly polarised light of equal
intensity (Figure 2.3a and b). The differential absorbance of left (L) and right (R)
circularly polarised light by a chromophore is the fundamental principle behind circular
dichroism spectroscopy. Left-handed circularly polarised light rotates in a counter-
clockwise direction, and right-handed (R) circularly polarised light rotates in a
clockwise direction. For an optically inactive chromophore the difference between
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absorption of R and L circularly polarised light will be zero. The degree of optical
activity is determined by a molecules asymmetry. A simple diagram of how a CD
spectrometer works is shown in Figure 2.3c.
2.4.2. Monitoring Secondary Structure Changes Using CD in the UV region.
CD spectroscopy of the secondary structure of peptides arises from the amide group of
the peptide bond within the polypeptide backbone. The peptide bond is slightly shorter
than a standard single bond, reflecting the partial delocalization of  electrons from the
carbonyl group into orbitals shared with the lone pair electrons of the amide nitrogen.
This partial double bond character inhibits rotation around the peptide bond and
provides the π electrons required for the transitions studied in CD.
Two electronic absorptions occur, with electrons in n or π orbitals transitioning to the
higher energy π* orbital. π  π* transitions give a strong absorption (molar
absorbtivities between 1000 – 10,000 mol-1 cm-1) around 190 nm. Molar absorptions
from n  π* transitions are relatively low (10-100 mol-1 cm-1) and absorb ~ 210 nm,
(often masked by the π – π* transition). These transitions define the spectral range 250-
170 nm for secondary structure analysis.
2.4.3. Circular Dichroism Secondary Structure Determination
CD in the far-UV region represents the super-position of a variety of secondary
structure elements. The different proportions of the various secondary structures that
compose the spectra can be defined using various computer packages if needed (e.g.
Dichroweb). There are distinct CD spectra bands for both α-helix and β-sheet structure
(see Figure 2.4). Two negative bands of similar magnitude with maxima at 222 nm and
208 nm, and a positive band at 192 nm, are characteristic of an α-helix CD spectrum. β-
sheet CD spectra are much weaker than α-helix CD and have a negative band at 217 nm
± 5 nm and a positive band near 195 nm. Irregular conformations give a negative band
at ~ 198 nm and a very weak positive band at 218 nm.
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Figure 2.4. Typical CD bands of -helix and -sheet secondary structure
and random coil (unstructured). Adapted from Brahms et al. 1980.
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2.4.4. Secondary Structure Studies Experimental Specifics
CD spectra were recorded on a Chirascan (Applied Photophysics) CD spectrometer at
25 C. A cell with a 0.1 cm path length was predominantly used for spectra recorded
between 185 and 270 nm with sampling points every 0.5 nm. A minimum of 3 scans
were recorded for all spectra including baseline spectra which were subtracted from
each spectra. Applied Photophysics Chirascan Viewer was used to apply minimal
smoothing to the data if required. Direct CD measurements (θ, in millidegrees) were
converted to molar ellipticity, Δε (M-1 cm-1), using the relationship Δε = θ/(33000cl),
where c is the concentration and l the path length.
2.4.5. Calculating Aβ-Cu2+ Affinity Using Ligand-Metal Charge Transfer
Studies
In addition to secondary structure, CD is also useful at studying the ligand coordination
geometry around a metal ion. Ligand-metal charge transfer transitions and d-d
transitions occur in the near-UV and visible region (270-800 nm). Ligand metal charge
transitions, in A-Cu2+ for example, occur when the electron in Cu2+’s d-orbital absorbs
Chapter 2. Materials and Methods
83
light at ~ 300 nm resulting in a transition to the  orbital of a histidine in A. d-d
transitions occur when the electrons in the lower d-orbitals absorb light (~ 600 nm) and
are excited to a higher energy d-orbital. It has been shown that although Cu2+-A does
not give rise to CD bands from d-d electronic transitions, the positive CD band at 320
nm can be assigned to A-Cu2+-imidazole charge-transfer transitions (Syme, et al.
2004).
There are three main sources of optical activity that allow CD spectra of the transition
metal ions, such as Cu2+, in the visible region (Klewpatinond, et al. 2007, Martin, et al.
1966):
a) The configurational effect is usually responsible for the majority of the optical
activity. It occurs when the distribution of donor atoms coordinating the metal
ion are not symmetrical, and explains why free Cu2+ is CD silent.
b) The conformational effect is due to ring puckering. However this effect is less
applicable to tetragonal peptide complexes such as Aβ-Cu2+ where coordination
tends to be planar (see Chapter 4- Structure of the Aβ-Cu2+ complex).
c) The vicinal effect. This effect gives the strongest optical activity when a chiral
carbon atom is in the backbone of a ring between two chelated donor atoms,
typically main chain amides. In peptide complexes such as A-Cu2+ which are
fairly planar, the main determinant of optical activity is the vicinal affect of
chiral substituents.
An advantage of circular dichroism over absorption spectroscopy is that CD spectra in
the visible region are only produced when the metal ion is in a chiral environment. Thus
free Cu2+ in water or Cu2+ bound to non-chiral molecules such as glycine does not have
chirality and thus is CD silent, while Cu2+ bound to L-histidine will give a very different
CD spectrum, with a weak band at 320 nm and a stronger band at 700 nm. This was
exploited in calculating an affinity for the Aβ-Cu2+ complex, see Chapter 3.
2.5. Fluorescence Spectroscopy
The theory of fluorescence is briefly described below. For further details on the
technique there are a number of good textbooks (e.g. (Varley 1994)) and a good review
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specifically on fluorescence quenching (Section 2.5.6) is pages 238 – 265 of (Lakowicz
1999).
Theoretical Background
2.5.1. Fluorescence Signal
Substances that contain delocalised electrons, in the form of conjugated double bonds,
typically exhibit fluorescence, e.g. a fluorescent dye such as Thioflavin T – see Section
2.5.4 or a tyrosine residue – see Section 2.5.5. Generally, the molecule of interest has a
ground electronic state (a low energy state), and an excited electronic state of higher
energy. Within each of these electronic states are various vibrational levels. When the
molecule absorbs light, its orbital electrons are excited to one of the various vibrational
states in the excited electronic state. The electrons will then lose energy, partly through
collisions but mainly as heat (vibrations) until it reaches the lowest vibrational state of
the excited electronic state. The electron will then drop down to one of the various
vibrational levels of the ground electronic state again, emitting a photon in the process.
Because the emitted radiation has less energy than the original absorbed light (e.g. due
to heat loss) it will be of a longer wavelength (see Figure 2.5).
Figure 2.5. State Diagram of Fluorescence. Electrons have two excited states
composed of vibrational levels. Upon absorption of a photon the electron is
raised to the excited state. Through collisions and heat loss energy is lost and re-
emitted at a longer wavelength. Adapted from Lakowicz 1999.
Absorbed hv (high energy)
Excited
State
Heat
Ground
State
Emitted hv (low energy)
2.5.2. Fluorescence Units
Unlike in other types of spectroscopy, in fluorescence it is difficult to gain machine-
independent values and thus to compare exact values between fluorescence
spectrophotometers. For example, the percentage of the fluorescence picked up by the
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detector is dependent upon the system, it will vary between different detectors, and with
wavelength and time, as the detector inevitably deteriorates. Thus although the
concentration of the fluorophore will generally be related to the intensity of the
fluorescence signal, the units used in fluorescence are usually described as arbitrary
fluorescence units, or AFU.
2.5.3. Instrumentation for Fluorescence Spectroscopy
Two different fluorescence spectrophotometers were used in this thesis:
Single Cell Fluorescence
For single cell experiments, a light beam from the xenon lamp is converged onto the
entrance slit of the excitation monochromator through two lenses (see Figure 2.6). After
monochromation the excitation beam is converged on to the sample cell. The beam is
then directed to the computer resulting in a fluorescence spectrum.
Figure 2.6. Simplified scheme for a single sample holder spectrofluorometer
(adapted from Lakowicz 1999).
Light Source
(Xenon lamp)
Sample
Holder
Excitation
Monochromator
Emission
Monochromator
Monochromator
Controller
(Computer)
Ex      Em
Multiwell Fluorescence
For fibril growth studies, a BMG Fluostar galaxy was used. This fluorometer allows
multiwell plates to be used. An outline of the set up of a multiwell plate reader is shown
in Figure 2.7. It is essentially the same as a single cell fluorescence spectrometer, except
that filters are used and the emission from the sample is detected above the plate, rather
than at 90  as in single cell readers. The BMG Fluostar galaxy allows both agitation
and temperature of the sample to be controlled, this is described further in Chapter 5.
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Figure 2.7. Optical path for a microplate reader (adapted from Lakowicz
1999).
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2.5.4. Thioflavin T Assay Theory
Fluorescence was used in this thesis for two major purposes. Firstly, the use of the
fluorescent dye Thioflavin T (ThT) will be discussed.
ThT is a positively charged dye at pH’s between 5 and 9 and interacts with the cross-
sheet structure common to amyloids (Sunde, et al. 1997). The structure and size of ThT
is shown in Figure 2.8. ThT exhibits enhanced fluorescence emission at ~ 482 nm upon
binding to amyloid when excited by light of a wavelength of 455 nm. Binding of ThT to
the peptide occurs with apparent Kd’s of 0.54 and 2 M for aggregated A(1-28) and
A(1-40) respectively (LeVine 1993). Salts such as NaCl have no effect on ThT
binding (LeVine 1993).
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Figure 2.8. Structure and size of a ThT molecule (adapted from Krebs et
al. 2005).
N
S
N
CH3 Cl
6.1 ± 0.1Å
15. 2 ± 0.1Å
2.5.5. Mechanism of ThT Fluorescence
Several different models have been proposed to explain why ThT only fluoresces when
bound to -sheet fibrils and not in the presence of monomers or amorphous aggregates.
Monomeric Model (Krebs, et al. 2005)
ThT binding to amyloids has been studied by confocal microscopy and has been shown
to bind in a specific and regular fashion, with the short axis of ThT (6.1 Å)
perpendicular to the fibril axis closely surrounded by side chains. In this model the ThT
binds in a monomeric form in the grooves formed by the residues n and n+2 of the -
strands on the surface of the fibril. Krebs et al suggest that it is the steric interactions
between the dye and the side chains of the fibrils that result in fluorescent enhancement.
Excimer Model {Groenning, 2007 #925}
The binding of ThT was observed using anisotropy methods. Significant increases in
the anisotropy are observed using between bound and unbound ThT, suggesting that
ThT has less rotational motion in the presence of the binding compounds compared to
free ThT. In this model it is the ability of ThT to bind as a dimer and form an “excimer”
that results in the characteristic fluorescence.
Micelle Model (Khurana, et al. 2005)
At the ThT concentrations commonly used in experiments (10 – 20 M) ThT will form
micelles, with a critical micelle concentration of 4 M and a micelle diameter of 3 nm.
Atomic force microscopy (AFM) was used to visualise the micelles along the fibril
length, and in this model fluorescent enhancement occurs due to hydrogen bond
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formation between the charged nitrogen in the thiazole group of the ThT micelle and the
amyloid fibrils.
Lateral Stacking Model (Wu et al. 2008)
The binding of ThT to model fibrils of A(16-22) was studied via molecular dynamics.
ThT was found to bind preferentially in the grooves of the  sheets rather than at the
ends of the sheets, and bind to hydrophobic and aromatic residues rather than to
negatively charged residues. Hydrophobic and ring-ring interactions were the main
mode of binding between ThT and the fibrils. ThT was found to bind with the positively
charged nitrogen parallel to the  sheet surface and exposed to the solvent. Fluorescent
enhancement results from ThT binding firstly as a monomer then additional ThT
molecules laterally stacking onto the bound ThT molecule to form an oligomer of up to
seven monomers.
Of the four models, the lateral stacking model is attractive as it incorporates some of the
other mechanisms outlined above, including reduction of the internal motion of
monomeric ThT by binding to the grooves of fibrils, excimer formation and hydrogen
bonding of a ThT micelle.
2.5.6. Tyrosine Fluorescence Quenching by Cu2+ Ions
The second application for fluorescence was establishing the affinity of A for Cu2+ by
monitoring the intrinsic fluorescence of the tyrosine residue. There are three aromatic
amino acid residues (tryptophan, tyrosine, and to a lesser extent phenylalanine) which
can contribute to the intrinsic fluorescence of peptides. These three residues have
distinct absorption and emission wavelengths. Aβ does not contain tryptophan residues
but does contains a tyrosine at position 10, which, when solvent exposed in H2O, will
absorb at around 280 nm and emit fluorescence at around 308 nm.
The intrinsic fluorescence of a peptide can be quenched. Cu2+ is a well known quencher
of fluorescence. The probable method of quenching is by the donation of an electron
from the fluorophore (in this case Tyr10) to the quencher (Cu2+). The quenching results
from the formation of a nonfluorescent complex between the tyrosine and Cu2+. When
this complex absorbs light, it immediately returns to the ground state without emission
of a photon.
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2.6. Electron Paramagnetic Resonance (EPR) Spectroscopy
Below is a description of the main principles of EPR that are relevant to this thesis.
However for further detail, two excellent books on EPR are (Bersohn 1966) and (Weil
2007).
Theoretical Background
2.6.1. What is EPR?
EPR (also known as Electron Spin Resonance, ESR) studies the resonant transitions
between energy levels of electron magnetic dipole moments. An external magnetic field
is applied to align the magnetic dipole moments of the electrons. The magnetic field
also increases the gap between the two electron spin energy states until the difference
between them matches the energy of the applied electromagnetic radiation (a fixed
microwave source), thus allowing the electrons to move between their two energy
states. Since there are normally more electrons in the lower energy state there is a net
absorption of energy which is converted into an EPR spectrum.
2.6.2. What Can be Studied in EPR?
Each electron possesses an intrinsic magnetic dipole moment that arises from its spin. In
most systems electrons occur in pairs and thus the net magnetic dipole moment equals
zero. Only species which contain unpaired electrons (e.g. Cu2+ which has one unpaired
electron in its outer shell) possess the net spin moment necessary for suitable interaction
with an electromagnetic field. Although electrons of paramagnetic materials have
permanent magnetic moments even in the absence of an applied field, they are
randomly orientated due to thermal agitation resulting in zero net magnetic moment.
But when a magnetic field is applied the dipoles will align.
2.6.3. The Magnetic Dipole Moment and Spin of the Electron
The magnetic dipole moment is an important vector quantity in EPR. Magnetic dipole
moments placed in a magnetic field tend to be aligned so that they point in the same
direction as the field, a “parallel” orientation. This is the minimum energy orientation
for a magnetic dipole moment. The intrinsic angular momentum of an electron is
another vector, and is also known as the spin “S”. All elementary particles of a given
kind have the same spin quantum number which is always unitless. For example, an
electron has spin ½, whereas the copper nucleus has a spin of 3/2.
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2.6.4. Energy levels and Why Microwave Electromagnetic Radiation Is Used
A simple energy level diagram for an electron with spin ½ is shown in Figure 2.9. By
varying the applied magnetic field B, the energy level separation can be changed.
Resonant absorption occurs if the frequency is adjusted so that ΔE = hv.
This ties into the basic phenomena of EPR, shown in equation 2, where the application
of the correct electromagnetic resonance radiation (hv), whose quanta have energy
equal to the difference in energy levels (ΔE) between the two electron orientations (+
gµBBz and - gµBBz), will result in transitions between these two states. The two states
are described by the g-factor (g), the Bohr Magneton (µB) and the strength of the
experimental magnetic field (Bz) in gauss.
ΔE = hv =gµBBz (eq 2)
For example, if Bz is about 3400 gauss, and g has the value for an unbound electron
2.002319, and the Bohr magneton is 0.92732 * 10-20 erg/gauss, all divided by Planck’s
constant of 6.63 x 10-27 then v is 9.5 x 109 cycles per second. This frequency is in the
microwave region and explains why microwave radiation is used in EPR. Specifically
in this thesis microwave radiation is used in the X-band region of 8 to 12 GHz.
The generation of microwaves is such that, experimentally, it is easier to vary the
magnetic field by small increments than vary the frequency of the radiation. The
position of the line in an EPR spectrum is indicated by the value of the magnetic field at
which absorption of energy by the sample has occurred. Due to differences in EPR
spectrometers and experimental conditions neither field or frequency is used to denote
line position, instead line positions are stated in g-factors (see Section below). To
minimise the noise the magnetic field is usually modulated, and as a result the detected
signal appears as a first derivative.
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Figure 2.9. Energy level diagram for a free electron with spin ½. An
unpaired electron can move between the two energy levels by either absorbing
(+ ½ gµBBz) or emitting (- ½ gµBBz) electromagnetic radiation such that the
resonance condition, hv = ΔE, is obeyed. The two states are described by the g
factor (g), the Bohr Magneton (µB) and the strength of the experimental
magnetic field (Bz) in gauss. Adapted from Weil 2007.
+ ½ gµBBz
“B” (Applied
magnetic field)
ΔE = hvE
- ½ gµBBz
2.6.5.  The g-factor
The g-factor (g) is a dimensionless quantity which can be thought of as a unique
fingerprint for identification of a compound. Comparisons between the g-factor for a
free electron in a vacuum (ge = 2.002319) and the g-factor for an electron in an
experimental system (calculated using equation 2) can be used to obtain information on
the nature of the atomic or molecular orbital containing the unpaired electron. This is
particularly relevant to studies with transition metal ions, such as in this thesis, where
interactions between the electron spin and orbitals can drastically affect the g-factors.
The magnetic interactions involving the orbital angular momentum of the unpaired
electron are the sole cause for the deviations of g-factors from 2.002319. Since the
orbital angular momentum of the unpaired electron depends on its chemical
environment in an atom, molecule or crystal the g-factor also depends upon these
factors. Thus the g-factor deviations have some similarity to the property of chemical
shifts in NMR spectroscopy. The two magnetic interactions involving the orbital
angular momentum are spin-orbit coupling and also the interaction of the orbital angular
momentum with the external magnetic field. The spin-orbit interaction arises from the
nucleus “orbiting” around the electron (from the electron’s point of view) and the
motion of this positive charge generates a magnetic field at the electron. Additionally
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the orbital motion of the electron produces a magnetic moment which interacts with the
external magnetic field.
2.6.6. Anisotropy of g
When the electron is orbiting close to nuclei, the orbital motion of the electron is
quenched because of the electrostatic effect between the negatively charged electron
and the lattice of nuclei. The orbital motion of the electron will be affected differently
depending on whether the orbital motion is about the x, y, or z axes of the molecular
system, i.e. whether the electrostatic effect is equal along all the axes or whether
anisotropy occurs. Some examples of potential molecular geometries for Aβ-Cu2+ are
shown in Figure 2.10. Octahedral geometry is isotropic (Figure 2.10a), whereas axial
geometry has only linear rotational symmetry and anisotropy is observable except when
the applied magnetic field is in the plane perpendicular to the axis of symmetry (Figure
2.10b). Tetrahedral geometry is anisotropic for all rotations (Figure 2.10c).
Figure  2.10. Anisotropy of g. (a), (b), and (c) are potential coordination geometries
for the Aβ-Cu2+ complex and their resulting EPR spectra.
x = y = z
x = y = z
Octahedral
Axial/Square-
planar
Tetrahedral
x = y = z
(a)
(b)
(c)
gII
g
g
The EPR spectra in Figures 2.10 a, b and c illustrate how the anisotropy of g affects the
EPR spectra. Cu2+-EPR is usually of the axial type (Figure 2.10b). Two components of
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the EPR spectrum shown are the gII (the parallel g factor) and g (the perpendicular g-
factor). These are the g-factors appropriate to the magnitudes BII and B of the applied
magnetic field, when it is parallel or perpendicular to the molecular system’s symmetry
axis respectively. Figure 2.10b shows a major absorption at g (high field) and a lesser
absorption at gII (low field). The gII and g components of the spectra are further
complicated by the anisotropy of the hyperfine splittings (A), described in the next
section.
2.6.7.  Splitting and Hyperfine Splitting
After unpaired electrons are placed in a magnetic field the number of energy levels are
increased from one to two (E = + ½ gµBBz and E = - ½ gµBBz) (Figure 2.11). Increasing
the number of energy levels through exposing the electrons to a magnetic field is called
splitting.
Figure 2.11. Hyperfine splitting of the Cu2+ electron. Ms = angular momentum
vector of electron, MI = angular momentum vector of nucleus. Only certain
transitions from the ground state (- ½ gµBBz) to the excited state (+ ½ gµBBz) are
allowed and/or detected by EPR. Allowed transitions are 8  1, 7  2, 6  3
and 5  4. This results in four splittings which, if the magnetic field is kept
constant, results in the smaller difference between energy states (e.g. 5  4)
occurring at a lower frequency and the largest energy difference (e.g. 8  1)
occurring at a higher frequency.
+ ½ gµBBz
- ½ gµBBz
Ms = +1/2   MI = +3/2
Ms = +1/2   MI = +1/2
Ms = +1/2   MI = -1/2
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In addition to the interaction between an electron spin and the external magnetic field is
the further interaction between the electron spin and internal magnetic fields, e.g. the
magnetism of nearby nuclei. The magnetic moment of the nucleus is restricted to a few
particular orientations relative to the external magnetic field e.g. the copper nucleus has
a spin of 3/2, and thus has nuclear spin orientations of +3/2, +1/2, -1/2 and -3/2. The
magnetic energy of the electron will subsequently be affected by the nuclear magnetic
moment orientation, and rather than one resonance absorption line obtained for a given
value, there will be absorption lines obtained over a range of values of magnetic field.
This causes the EPR spectrum to consist of a number of lines rather than just one (see
Figure 2.12). The further splitting in energy levels from the interaction between the
nucleus and electrons is called hyperfine splitting, analogous to J-coupling in NMR.
As well as the anisotropy in g there may be an anisotropy in the hyperfine splittings (A)
as well. Typically for Cu2+-EPR, the hyperfine splitting A (the nuclear hyperfine
splitting at g) is poorly resolved, while the AII (the nuclear hyperfine splitting at gII), is
typically much larger, around 10 – 25 mK, with the four features at gII resolved.
An idealised Cu2+-Aβ EPR spectra is shown in Figure 2.12 with its two component
parts arising from the axial coordination of Cu2+, and the anisotropy of the g and A
factor resulting in parallel and perpendicular components, with the parallel components
at a lower field to the perpendicular ones. The hyperfine splitting (A) results in four
splittings within both components of the spectra.
E= - ½ gµBz
Ms= +1/2 MI= +3/2
Ms= +1/2 MI= -1/2
Ms= +1/2 MI= -3/2
Ms= -1/2 MI= -3/2
Ms= -1 MI= -
2 1 56 7
E
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Figure 2.12. An idealised EPR spectrum for Aβ-Cu2+. Axial geometry
gives gII and g which are then split into four by the orientation of the
copper nucleus with its 3/2 spin.
2.6.8. Using EPR to Indicate Coordination Ligands
The magnitude of AII and gII values can be used to infer the binding ligands in the
complex. Peisach and Blumberg published an influential paper describing how EPR
spectra of Cu2+ tetragonal complexes could be used to infer the identity of the ligands in
the equatorial plane (Peisach, et al. 1974). They noted that two components of the EPR
spectra, the AII and gII could be related to the ligand type. They studied the relationship
between the AII and gII values for different classes of model compounds and produced a
guide that can be used to suggest binding ligands in the complex, see Figure 2.13. For
example all nitrogen ligands (4N) might typically give AII values of between 20 and 24
mK and gII of between 2.1 and 2.2, whereas all oxygen ligands (4O) would have AII
values in the range 12 –14 mK and gII values between 2.35 and 2.45. 0
4
8
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Figure 2.13. Relationship between A and g for Type 2 axial complexes
of copper proteins (Figure adapted from (Peisach et al 1974)).
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2.6.9. Line Widths and Relaxation Times
When studying transition metals with EPR, a problem arises due to the very short
relaxation time τ1. This is the characteristic lifetime of the electron in its excited state
and represents reorientation of the electron spin. The process of exciting the electrons
starts with the spin system being irradiated by microwave radiation and the electrons
being excited to their higher energy state. The absorbed radiation is then lost by energy
diffusion which allows continuing absorption of photons to occur. However the short τ1
that occurs with transition metals can result in line broadening beyond detection.
Because of this EPR experiments as described here were taken at low temperatures, (~
15-20 kelvin), since relaxation times tends to increase with decreasing temperatures.
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2.7. Transmission Electron Microscopy Experimental Specifics
Following incubation and fibril formation (as described in 2.2.5) aliquots were taken
from test samples and frozen at –80 °C. Samples were then freeze-dried and
resuspended to a concentration of approximately 0.5 mg/mL. A 10 µL aliquot of each
sample was then spotted onto a carbon coated copper grid (Agar Scientific) and
negatively stained using the single droplet procedure with 2 % (w/v) aqueous uranyl
acetate. TEM images were recorded on a JEOL JEM 2010 transmission electron
microscope.
2.8. Software packages
The Kaleidagraph spreadsheet/graph package was used to present data. Origin and
Microsoft Excel were both used for data manipulations. See individual experimental
sections for equipment software.
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Abstract
The affinity of Cu2+ for monomeric A is strongly disputed and there have been no
reports of Cu2+ affinity for fibrillar A. Determining the affinity of Aβ for Cu2+ is
highly important in evaluating if there is a role for Cu2+ in AD. Additionally there
are currently metal chelators being developed as therapeutics in AD, thus
determining the correct affinity is extremely important to ensure their efficacy.
In this chapter the affinity of Cu2+ for both monomeric and fibrillar A(1-42) was
measured using two independent methods: fluorescence quenching and circular
dichroism. Interestingly the binding curves were almost identical for both fibrillar
and monomeric forms. Competition studies with free glycine, L-histidine and
nitrilotriacetic acid (NTA) indicate an apparent dissociation constant of 10-11 M, at
pH 7.4 for both forms of Aβ. There was excellent agreement between the two
techniques. Previous studies of Cu-A have typically placed the affinity two or more
orders of magnitude weaker, largely because the affinity of competing ligands or
buffers has been under-estimated.
A picomolar Cu2+ dissociation constant for A makes Aβ a physiologically relevant
Cu2+ chelator, with this dissociation constant much lower than Cu2+ concentrations
at the synapse. Thus the work in this chapter supports a modified amyloid cascade
hypothesis in which Cu2+ is central to A neurotoxicity.
Studies in this chapter have recently been published in (Sarell, et al. 2009).
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3.1. Introduction
3.1.1. Why Determine the Affinity?
Determining the affinity of the Aβ-Cu2+ complex is important to give physiological
relevance to the hypothesis that Cu2+ has a role in AD. A low binding affinity would
suggest that the Aβ-Cu2+ complex in vivo is unlikely, given the presence of other
physiological ligands with a higher affinity and the total levels of extracellular Cu2+
ions. Furthermore, understanding affinities can give a greater understanding of how
Cu2+ might interact with Aβ. For example a recent paper determined the apparent
Cu+ binding affinities for intracellular copper proteins (such as the cytoplasmic
copper chaperones CCS) and showed that affinity gradients are key to driving
copper to its destination within the cell (Banci, et al. 2010).
Additionally chelation therapy is used to treat some metal-related illnesses such as
β-thalassemia sufferers, where iron chelation drugs are administered. Likewise
excess copper in Wilson’s disease can be removed by Triethylenetetramine (TETA)
or penicillamine. However selectivity is extremely important, if the chelator’s
affinity is too weak it will be inefficient, too high and it might withdraw metal ions
from essential metalloproteins, leading to metal deficiency and a range of severe
consequences. Thus the chelation therapy ligand is chosen on the basis of the
affinity of the complexes formed, and if metal chelators are to be used in AD (see
Chapter 7) a reliable affinity of Cu2+ for Aβ must be obtained.
Currently there are large discrepancies between the affinities reported for
monomeric A, and no reports of Cu2+ affinities for fibrillar A. Dissociation
constants for monomeric A range from M to nM (Garzon-Rodriguez, et al. 1999,
Hatcher, et al. 2008, Syme, et al. 2004, Tougu, et al. 2008), and in one report up to
atto-molar Kd ~ 10-18 M (Atwood, et al. 2000). In Section 3.5.3 some explanations
are offered for these large discrepancies.
3.1.2. Background Theory to Affinity and Dissociation Constants
Any reaction or binding event can be thought of as an equilibrium between the
reactants and products. In the case of a metal (M) binding to a ligand (L) to form a
metal-ligand complex (ML) then:
Chapter 3. Fibrillar and Monomeric Aβ have a Picomolar Affinity for Cu2+
101
M+L ML       (eq 1)
The affinity (Ka) for this binding event is given by the ratio of the products formed
relative to the reactants remaining:
[M][L]
[ML
][Reactants
[Product]Ka  (eq 2)
In this case the units of affinity (Ka) are Molar –1. The reverse reaction, where the
metal dissociates from the ligand, is given by:
[ML]
[M][L]Kd  (eq 3)
Here the dissociation constant (Kd) is given in Molar concentrations. Ka and Kd are
related by:
d
a K
1K  (eq 4)
The smaller the dissociation constant, the higher the affinity between the two
components of the complex. The dissociation constant Kd is useful as it indicates at
what concentration of metal half of the ligand’s (e.g. protein’s) binding site will be
occupied by the ion. For example a Kd of 1 nM for a complex means that the metal
concentration must be equal to 1 nM for half the protein binding sites to be filled. If
the metal is at a pM concentration the protein binding site will not be significantly
occupied, even if the protein is added in excess. Alternatively at metal
concentrations greater than nM, additions of the protein will result in the metal
occupying the protein binding sites until the binding sites are saturated.
Thus in the case of a single Cu2+ binding site in A:
]ACu[
]A][Cu[K 2
2
d 
 

(eq 5)
Chapter 3. Fibrillar and Monomeric Aβ have a Picomolar Affinity for Cu2+
102
3.1.3. Absolute and Apparent Stability Constants
pH independent stability constants
Stability constants can be pH-independent (the absolute affinity). For example, in
one commonly used reference book the stability constants are expressed as absolute
affinities. They are quoted at 25-30 C at ionic strengths between 0.01 to 0.5
(Dawson 1986), and they are independent of pH. The absolute affinities of glycine,
histidine and nitrilotriacetic acid (NTA) are shown in the first column of Table 3.1.
pH dependent stability constants
The pH-dependent stability constant is called the apparent dissociation constant or
the apparent affinity, and in this chapter it is the experimentally measured affinity. It
is calculated from the absolute affinity, see experimental. It is more useful to know
the affinity at a particular pH, e.g. at physiological pH 7.4, as the affinity of a metal
for a protein can be strongly influenced by pH. At lower pH values H+ ions compete
with the metal ion for binding sites. Thus the affinity of the metal for a protein can
be many orders of magnitude higher at pH 8, for example, compared to pH 6. The
apparent affinity and apparent dissociation constants at pH 7.4 are shown in columns
3 and 4 of Table 3.1 respectively. Buffers can also compete for metal ions and
although their affinity is usually quite low, they are often present at relatively high
concentrations thus they must be accounted for when calculating a meaningful
affinity.
3.1.4. Influences on Affinity
The affinity of an ion such as Cu2+ for a ligand is strongly influenced by its
surroundings. Molecules in solution interact, either to attract or to repel each other.
It is generally agreed that this interaction can be ignored if the stability constants are
determined in the presence of a background electrolyte at high ionic strength.
However, because of this, stability constants will vary depending on the specific
electrolyte used, and the concentration of the electrolyte.
The Ka is also temperature dependent, for exothermic reactions Ka will decrease
with increasing temperature, but for endothermic reactions, Ka increases with
increasing temperature. Finally the in vivo environment is more crowded than the
dilute conditions that most in vitro experiments are performed in. Total
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macromolecule concentrations in the cell are as high as 400 mg/mL (Ellis 2001), and
although the interactions between A and Cu2+ occur extracellularly, which is less
crowded than intracellular conditions, this is still a factor that should be considered
when assessing the probability that the complex will form.
3.1.5. Affinity (K) Vs Reaction Rates (kf/kr)
An interesting side-point is that although affinity is crucial in determining if two
species will form a complex, it does not necessarily reflect how fast the reaction will
occur or how permanent the complex will be. For example metallothionein has a
high affinity for zinc ions (0.1 picomolar), yet will exchange zinc readily with
proteins with weaker affinities (Jacob, et al. 1998, Maret, et al. 1999). On the other
hand, carbonic anhydrase has a dissociation constant of 4 pM but exchanges zinc
extremely slowly, with a half-life of 1 year (Lindskog, et al. 1962).
Reaction rates can be calculated as follows:
The rate of the forward reaction is given by vf and the rate of the reverse reaction is
given by vr.
]L][M[kv ff  (eq 6)
Where kf is the proportionality constant in the forward direction. Likewise, the rate
in the reverse reaction is:
]ML[kv rr  (eq 7)
Where kr is the rate constant for the reverse reaction. At equilibrium vf= vr and:
r
f
k
k  = ]L][M[
]ML[  = Ka (eq 8)
Thus this equation shows that the affinity, Ka is equal to the ratio of the forward and
reverse reaction.
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3.1.6. Methods of Calculating Affinity
The methods and equations used to calculate the affinity of A for Cu2+ in this
chapter are described in the experimental section. However there are multiple
different ways the affinity of a complex can be determined, with any technique that
can quantitatively measure the levels of products or reactants present potentially able
to measure the affinity. A few common techniques are listed below:
 Equilibrium dialysis
 Isothermal titration calorimetry
 Surface plasmon resonance
 Spectroscopy
 Gel filtration chromatography
 Membrane filtration
Binding Curves
A common method of presenting affinity data is as a binding curve. Binding curves
are graphs of ligand concentration on the x axis against the saturation of the binding
site () on the y axis (see Figure 3.1a). The dissociation constant Kd can be
calculated when  = 0.5, i.e. half the ligand is bound and half is not. Before
nonlinear regression programs were widely available it was necessary to transform
the curves into a linear form and then analyse the data by linear regression. The most
popular method to do this was to create a Scatchard plot. This is done plotting θ/ [L]
on the y axis and θ on the x axis, where [L] is the concentration of free ligand This
gives a straight line slope of -1/Kd (see Figure 3.1b). A non-linear regression line
indicates that there is cooperativity occurring in the binding.
3.1.7. Competitive Metal Capture
To calculate an affinity an equilibrium needs to be achieved where half the Aβ
molecules have Cu2+ bound. The equipment used in this thesis to measure affinity
requires micromolar concentrations of A and Cu2+. At these concentrations the
binding curves show that tight binding is occurring. Examples of weak and strong
binding curves are shown in Figure 3.1c.
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Figure 3.1. Binding curves. (a) shows a typical binding curve with saturation
of the binding site θ on the y axis and ligand concentration ([L]) on the x axis.
The Kd is calculated at 50 % binding site saturation. (b) shows a Scatchard plot
of the data. Strong and weak binding curves are shown in (c). (d) shows tight
binding and illustrates that given the same metal and ligand concentrations the
titration curve for a binding equilibrium with even tighter binding, e.g. a Kd of
0.5 pM or 0.05 pM would be identical to this graph (when Kd = 50 nM).
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The problem with tight binding is that all of the added Cu2+ is bound to A as it is
titrated in, and no detectable free Cu2+ remains in solution, i.e. there is no free Cu2+
in equilibrium with bound Cu2+, thus the protein binding sites are filled until
saturated. This is illustrated in Figure 3.1d, where at a protein concentration of 50
M, at one equivalent Cu2+, the binding site is full, thus no equilibrium is observed
and the titration curve can only show that the affinity is higher than 50 nM, but it
would be identical if the protein had a pM or fM dissociation constant.
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 If the spectrometers used in this thesis were more sensitive, very low concentrations
of Aβ and Cu2+ could be used to observe the affinity, however micromolar
concentrations are necessary. Thus to generate an observed equilibrium between free
(or chelator bound) Cu2+ and Cu2+ bound to A, competing chelators with known
copper affinities were used.
3.2. Aims
 Compare the affinity of Cu2+ for both monomeric and fibrillar A(1-42).
 Compare affinities obtained with three different chelators and from circular
dichroism and fluorescence spectroscopy.
 Determine if the affinity of Cu2+ for A(1-42) is physiologically relevant.
3.3. Experimental
For peptide synthesis, purification and solubilisation, please refer to Chapter 2.
3.3.1. Peptide and Buffers in both Circular Dichroism and Fluorescence
Affinity Experiments
Two different spectroscopic methods – fluorescence quenching and circular
dichroism, and three different competitive Cu2+ chelators were used, glycine,
histidine and NTA, to assess the accuracy and precision of the experimentally
determined Kd.
50 M A(1-42) was added to water (ultra high quality, >18 . cm resistivity) with
160 mM NaCl, pH 7.4. For experiments with fibrillar Aβ, the fibril formation
method is described in Chapter 2. The pH was monitored after every addition of
Cu2+ or competing chelator, before and after each spectrum was recorded. The pH
was adjusted using small volumes (typically < 10 µL) of 10-100 mM NaOH or HCl.
The addition of metal ions or competing ligands to the A peptides was performed
using small aliquots from stock aqueous solutions (10 – 50 mM) of CuCl2, glycine,
L-histidine or nitrilotriacetic acid (NTA), all obtained from Sigma Aldrich, analar
grade or better.
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3.3.2. Circular Dichroism Measurements in the near-UV and Visible Region
Circular dichroism (CD) bands associated with Cu2+ bound to A are used to
quantitatively measure the amount of Cu2+ bound to A, the theory of this method is
discussed in Chapter 2 Section 2.4.5.
 CD spectra were recorded on a Chirascan (Applied Photophysics) CD spectrometer
at 25 C. A cell with a 1 cm path length was used for spectra recorded between 280
and 800 nm with sampling points every 2 nm and 2 seconds recording time per
point. A minimum of 3 scans were recorded for all spectra including baseline spectra
which were subtracted from each spectra. Applied Photophysics Chirascan Viewer
was used to apply minimal smoothing to the data. Direct CD measurements (θ, in
millidegrees) were converted to molar ellipticity, Δε (M-1 cm-1), using the
relationship:
)lc33000( 

where c is the concentration and l the path length (Greenfield, et al. 1969).
Sequential additions of 0.2 mol eq Cu2+ were added up to a final concentration of 1
mol eq of Cu2+ to 50 M A(1-42) (the stoichiometry of Cu2+:A for full-length A
is 1:1, see Chapter 4 for supporting experimental results). Three competing ligands
glycine, histidine and nitrilotriacetic acid (NTA) were titrated in from stocks of
between 10 – 50 mM. Glycine and NTA are CD silent and thus as the Cu2+ is
removed from Aβ by these chelators the CD band at 320 nm is correspondingly
reduced.
3.3.3. Fluorescence Experimental Specifics
For fluorescence quenching experiments a single cell, Hitachi F-2500 fluorescence
spectrophotometer was used with an excitation wavelength of 280 nm, and emission
wavelengths starting at 290 nm and finishing at 400 nm. Both the excitation and
emission slitwidths were 5 nm. 1 cm pathlength quartz cuvettes were used with no
agitation. 4 traces were taken at each reading and readings were taken at room
temperature.
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Sequential additions of Cu2+were added up to 1 mole equivalent to 50 M A in the
conditions outlined above in Section 3.3.1. This caused a linear reduction of the A
tyrosine fluorescence signal. A non-fluorescent competing Cu2+ chelator (glycine,
histidine or NTA) was then titrated in until the maximal tyrosine fluorescence signal
had returned. The affinity can thus be calculated from the tyrosine fluorescence at
half the maximal fluorescence value.
Affinity Calculations
The fraction of Cu2+ bound to A (θ) was calculated assuming this relates directly to
either the circular dichroism signal at 320 nm or the fluorescence signal at 307 nm.
The affinity can thus be calculated from binding curves of circular
dichroism/fluorescence signal intensity at half the maximal value. Under these
conditions (θ = 0.5) the dissociation constant (Kd) is equal to the concentration of
Cu2+free. Free Cu2+ refers here to Cu2+ not bound to Aβ.
3.3.4. Competitive Metal Capture Analysis
The Kd at pH 7.4 of A for Cu2+ can be calculated from the observed Kd in the
presence of a competing ligand, this is called competitive metal capture analysis
(Atwood, et al. 1998). This method uses Cu2+ chelators to compete with Aβ to form
Cu2+ complexes. This method is required because, as mentioned previously, for an
affinity to be measured there must be a measurable equilibrium between the free and
bound states. Binding curves were constructed with concentration of added ligand
on the x axis and the CD or fluorescence signal on the y axis. The binding curves
were normalised and at 50 % maximal signal the concentration of ligand added was
determined from the binding curves.
3.3.5. Calculating the Apparent Affinity of the Competitive Ligands
The absolute (Abs Ka) and apparent (App Ka and App Kd) stability constants for
Cu2+(Gly)2, Cu2+(His)2 and Cu2+(NTA) are shown in Table 3.1.
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Table 3.1. Affinities and Dissociation constants for competing chelators. Log
Absolute affinity (Log Abs Ka) is pH-independent and obtained from Dawson 1986.
Apparent (App) Ka and Kd values calculated as shown in equations 9 and 10 of text.
Log Abs
Ka
Log App
Ka App Ka App Kd App Kd
Cu-Gly
Ka1 8.1 5.87 7.4 * 105 M -1 1.35 * 10-6 M 1.35 M
Ka2 7.1 4.87 7.4 * 104 M -1 1.35 * 10-5 M 13.5 M
Ka1 8.1 6.07 1.2 * 106 M -1 8.33 * 10-7 M 0.83 M
Ka2 7.1 5.07 1.2 * 105 M -1 8.33 * 10-6 M 8.33 M
Ka1 8.1 6.27 1.9 * 106 M -1 5.26 * 10-7 M 0.526 M
Ka2 7.1 5.27 1.9 * 105 M -1 5.26 * 10-6 M 5.26 M
Cu-His
Ka1 10.2 8.43 2.7 * 108 M -1 3.7 * 10-9 M 0.0037 M
Ka2 8.1 6.33 2.1 * 106 M -1 4.7 * 10-7 M 0.47 M
Ka1 10.2 8.83 6.8 * 108 M -1 1.48 * 10-9 M 0.00148 M
Ka2 8.1 6.73 5.4 * 106 M -1 1.86 * 10-7 M 0.186 M
Cu-NTA
pH 7.4 Ka 13.1 10.7 5.0 * 1010 M -1 1.99 * 10-11M 0.0000199 M
pH 7.8
pH 7.4
pH 7.6
pH 7.8
pH 7.4
Due to differences in experimental details, Cu2+(Gly) stability constants are
calculated at pH 7.4, pH 7.6 and pH 7.8. Likewise Cu2+(His)2 stability constants are
calculated at pH 7.4 and pH 7.8.
To calculate the pH dependent apparent affinity (App Ka1) of Cu2+ for the competing
ligands the following calculation is used:
log = pKa- pH (eq 9)
And then:
log App Ka =  log Abs Ka – log     eq
E.g. The pKa of NTA is 9.8 and the absolute affinity of NTA for Cu2+ is 13.1
(Dawson 1986) so using the above equations 9 and 10 the apparent affinity (pH
dependent) at pH 7.4 can be calculated.
log = 9.8-7.4 = 2.4
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log App Ka at pH 7.4 = 13.1 – 2.4 = 10.7
This gives an apparent affinity at pH 7.4 of 5.0 * 1010 M-1 or a dissociation constant
of 19.9 picomolar.
3.3.6. Calculating the Affinity of the Aβ-Cu2+ Complex
At equilibrium, where 0.5 equivalents of Cu2+ are bound to A and 0.5 equivalents
are bound to the competing chelator, it can be assumed that the competing ligand-
Cu2+ complexes exist predominantly as Cu2+(Gly)2, Cu2+(His)2, Cu2+(NTA).
 Equation 11 below was used to calculate the Kd of the Aβ-Cu complex (the value of
[Cu2+free]), when NTA is the competing chelator. NTA only forms a 1:1 complex
with Cu2+. Alternatively equation 12 was used when glycine or histidine were the
competing chelators (Hatcher, et al. 2008).
)])NTA[K(1
])Cu[]Cu([(]freeCu[
free1a
boundtoA2total22

 

 (eq 11)
))]Gly([KK(])Gly[K(1
]Cu[]Cu[]freeCu[ 2
free2a1afree1a
boundtoA2total22

 

 (eq 12)
Additionally the Kd at pH 7.4 of A for Cu2+ can also be calculated from the
observed Kd in the presence of the competing ligand glycine by using equation 13
(Wells, et al. 2006).
]Gly[
)AppK(
]Gly[
)AppK()observed(KK
free
2d
free
1d
dd  (eq 13)
Worked Example for Calculating Aβ Affinity Using Glycine as a Competing
Chelator.
The binding curve in Figure 3.2b shows that at  = 0.5, 55 * 50 M total glycine has
been added. Because:
[Glyfree] = [Glytotal]-[Glybound to A]
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[Glyfree] = [55 * 50 M] – [50 M]
[Glyfree] = 2700 M is the free glycine present.
Histidine and glycine have two Cu2+ binding sites and generally form a Cu(His)2 and
Cu(Gly)2 complex, thus their affinity is given by Ka1 and Ka2 (Dawson 1986), see
Table 3.1. It is assumed that all Cu2+ not bound to A forms a Cu(Gly)2 or Cu(His)2
complex with the excess chelator present.
Using the above equation (12) and the experimental specifics of one of the
fluorescence experiments:
[A total] = 50 µM (5 x 10-5M)
[Cu2+ total] = 50 µM (5 x 10-5M)
[Cu2+ boundtoAβ] = 25 µM (2.5 * 10-5 M)
Apparent Ka1 at pH 7.4 for glycine = 7.4 * 105M-1
Apparent Ka2 at pH 7.4 for glycine = 7.4 * 104M-1
 [Glyfree] = = 2.70 * 10-3M
))]Gly([KK(])Gly[K(1
]Cu[]Cu[]freeCu[ 2
free2a1afree1a
boundtoA2total22

 


)))107.2)((104.7)(104.7()107.2)(104.7((1
105.2105]freeCu[ 254535
5-5
2





)1029.7)10476.510998.1((1
105.2]freeCu[ 6103
5
2




)10992.310035.2(1
105.2]freeCu[ 53
5
2




4.401236
000025.0]freeCu[ 2 
[Cu free]= 6.2 * 10-11 = Kd= 62 pM
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Similarly using equation 13:
Kd (observed in presence of Gly) = 25 M (observed Kd is equal to the concentration
of [free Cu2+] at θ = 0.5)
[Total Gly free]= 54* 50 M = 2.7 * 10-3 M
Apparent Kd1 at pH 7.4 for glycine = 1.35 * 10-6M-1  = 1.35 M
Apparent Kd2 at pH 7.4 for glycine = 1.35 * 10-5M-1 = 13.5 M
]Gly[
)AppK(
]Gly[
)AppK()observed(KK
free
2d
free
1d
dd 
]M2700[
)M5.13(
]M2700[
)M35.1(M25K d 


)M105()M105(M25K 34d  
Kd =  6.2 * 10-5 M = 62 pM
In the original paper published (Sarell, et al. 2009), the concentration of the total
ligand added at  = 0.5 was used rather than the concentration of the free ligand in
calculating the affinities. This had a subtle effect on the Kd calculated, for example
in the case illustrated above, 60 pM rather than 62 pM was obtained, see (Xiao, et al.
2010).
3.4. Results
3.4.1. Calculating the Affinity from Cu2+ Fluorescence Quenching
The affinity of Cu2+ for A is vital in understanding the physiological significance of
Cu2+ in Alzheimer’s disease. There is currently conflicting experimental data for the
affinity of Cu2+ binding to monomeric A and no data on the Cu2+ affinity of
fibrillar A. To determine if the large (eleven orders of magnitude) differences in
Cu2+ binding to A reported (Atwood, et al. 2000, Syme, et al. 2004) might reflect
the difference in Cu2+ affinity for different oligomeric forms of A, two independent
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methods were used to measure Cu2+ affinity to both monomeric and fibrillar A(1-
42).
The competitive effects of glycine, L-histidine and NTA were used to measure the
Cu2+ affinity for both monomeric and fibrillar A(1-42) by fluorescence
spectroscopy. Figure 3.2a shows that the addition of increasing amounts of Cu2+ to
A(1-42) causes marked quenching of the single tyrosine (Tyr10) fluorescence
signal at 307 nm. A plot of fluorescence versus mole equivalents of Cu2+ (Figure
3.2a insert) indicates a linear reduction in fluorescence up to 1 mole equivalent Cu2+
addition. By 1 mole equivalent Cu2+ the fluorescence intensity has reduced by ~75
%. A breakpoint at 1 mole equivalent indicates 1:1 stoichiometry, as continued
addition of Cu2+ causes only a slight further reduction in fluorescence attributed to
non-specific interaction of Cu2+ with the tyrosine. The 1:1 stoichiometry is
confirmed by EPR studies (Chapter 4).
Figure 3.2b shows the effect of glycine addition on a 1:1 Cu-Aβ(1-42) complex. As
glycine is added, it competes with A(1-42) for the Cu2+ ions and the tyrosine
fluorescence signal at 307 nm reappears. Maximum tyrosine fluorescence signal, for
both soluble and fibrillar A(1-42), only returns after more than 200 mole
equivalents of glycine are added. Half the maximal quenching is achieved at 55
equivalents of glycine for soluble A(1-42), and similarly 56 mole equivalents for
fibrillar A(1-42). Free glycine will bind to Cu2+ ions in a Cu(Gly)2 complex,
coordinating via the amino and carboxylate groups. The step-wise apparent affinity
for glycine is known to be Ka1 = 7.4 * 105 M-1 and Ka2 = 7.4 * 104 M-1 at pH 7.4
(Dawson 1986). It is sometimes not appreciated that the affinity of glycine for Cu2+
is the product of the affinities of the K1K2 and related to [Gly]2. The apparent
dissociation constant for the Cu-A(1-42) complex at pH 7.4 may be calculated
using equation 12. Using this method a Kd at pH 7.4 of 62 pM and 60 pM for both
monomeric and fibrillar A(1-42) respectively was calculated. Almost identical
values are calculated using the alternative approach equation 13.
The experiment was then repeated using either the competing ligands L-histidine or
NTA, which have a higher affinity for Cu2+ than glycine (Figure 3.2c and d). NTA
has an apparent dissociation constant for Cu2+ at pH 7.4 of 19.9 pM (Dawson 1986)
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and binds Cu2+ to form a 1:1 complex, making determination of the Kd more
straightforward.
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Figure 3.2. Fluorescence spectra of monomeric and fibrillar A(1-42) with Cu2+;
glycine, L-histidine and NTA competition. a) Increasing additions of Cu2+ (0.2, 0.4,
0.6, 0.8 and 1.0 mole equivalence) to 50 µM of A(1-42) in water at pH 7.4 causes
quenching of the tyrosine fluorescence signal. The tyrosine fluorescence signal at 307
nm returns with additions of mole equivalents of (b) glycine, (c) L-histidine or (d)
NTA. Monomeric A (1-42) (filled circles) and fibrillar A (1-42) (unfilled circles)
with 50 µM Cu2+ present are both shown. ΔF = F - Fo, ΔFmax = Fmax - Fo, where Fo =
fluorescence at 307 nm at 1 mole equivalent Cu2+ addition.
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It is clear from Figure 3.2d that addition of 1 mole equivalent of NTA removes just
over half the Cu2+ from A(1-42), indicating that Cu2+ has a very similar affinity for
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A(1-42) as for NTA. Using equation 11 and the concentration of NTA added at
half the maximal fluorescence (0.70 mole equivalents), the dissociation constant at
pH 7.4 for monomeric A(1-42) can be calculated. An apparent Kd of 50 pM for
both monomeric and fibrillar A(1-42) is determined, which is similar to that
determined using glycine as the competitive ligand.
L-Histidine is known to bind Cu2+ with step-wise apparent Kd’s at pH 7.4 of Kd1 =
3.7 nM and Kd2 = 0.47 M. Two molecules of histidine will bind a single Cu2+ ion
using the amino and imidazole nitrogens as ligands. The tyrosine fluorescence signal
at 307 nm returns to its maximum value for both soluble and fibrillar A after only 5
mole equivalents of L-histidine are added, as shown in Figure 3.2c. Half-maximal
quenching is achieved at close to 1.7 mole equivalents for soluble A(1-42) and 1.5
mole equivalents for fibrillar A. This is below the 2 mole equivalents of histidine
required to bind 1 mole equivalent of Cu2+ and indicates that Cu2+ will bind to A(1-
42) with a comparable affinity to that of L-histidine. Again the affinity can be
calculated using equation 12, this time using the Ka1 and Ka2 of histidine at pH 7.4
and the concentration of histidine at half maximal quenching. The histidine
competition experiment indicates an apparent dissociation constant of 36 pM for
monomeric and 69 pM for fibrillar A at pH 7.4. Again these values are similar to
those calculated using NTA as the competing ligand. Although there is some
variation, the Kd values are within a single order of magnitude; between 36-69 pM.
All the values discussed here are summarised in Table 3.2a
3.4.2. Calculating the Affinity from CD Measurements
Importantly, similar Cu2+ affinities for Awere obtained with a second independent
method using near-UV-CD spectroscopy. These near-UV experiments have the
advantage in that they measure a CD signal directly associated with the Cu-A
complex. Figure 3.3 shows the CD spectrum of A(1-28) loaded with 1 mole
equivalent Cu2+ ions at pH 7.4. It was previously shown that although Cu-A does
not give rise to CD bands for d-d electronic transitions, there is a positive CD band
at 320 nm assigned to A Cu-imidazole charge-transfer transitions (Syme, et al.
2004). This CD band increases in intensity with Cu2+ addition. Figure 3.3 shows that
as the competing ligand NTA is added the intensity of the band decreases. A plot of
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ellipticity at 320 nm, shown as an insert, indicates the band is reduced to half its
maximal intensity only after 0.75 mole equivalents of NTA are added. The binding
curve using NTA as a competitor bears a striking resemblance to the NTA
competition studies using fluorescence quenching, shown in Figure 3.2d. Like the
fluorescence data, the CD data indicates Cu2+ has a similar affinity for A as that of
NTA, with a Kd of 40 pM.
Figure 3.3. CD spectra of A(1-28) with Cu2+; NTA competition. Increasing mole
equivalence of NTA added to 50 µM A(1-28) and 50 µM Cu2+ causes a decrease in
the intensity of the CD signal at 320 nm. Insert shows the normalized CD signal at
320 nm of Cu2+- A(1-28) with increasing mole equivalent additions of NTA.
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A similar experiment was performed using glycine. Here the intensity of the Cu-A
CD bands at 320 nm were reduced to half their maximal intensity at ca. 35 mole
equivalents of glycine. Using equation 12 or 13 the apparent Cu2+ dissociation
constant for A(1-28) at pH 7.6 was calculated to be 60 pM. This value is
comparable to a Kd of 96 pM determined using glycine competition and fluorescence
quenching of A(1-28) at pH 7.8 previously reported (Syme, et al. 2004) (Table
3.2b). It was not possible to repeat this experiment for A(1-42) as the CD band at
320 nm was not of sufficient intensity.
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3.4.3. Summary of Results
In summary, using both direct measurements of Cu2+ from CD bands of the Cu-A
complex and fluorescence quenching methods, it is shown that one mole equivalent
of Cu2+ ions bind to A with a dissociation constant similar to NTA. An
apparent Kd at pH 7.4 of between 36-69 pM for A(1-42) is calculated. Significantly
comparisons of A(1-40) and A(1-42) in the monomeric and fibrillar form shows
almost identical affinity for a single Cu2+ ion at pH 7.4. The apparent Kds calculated
using the different competitive ligands are given in Table 3.2.
Table 3.2. Dissociation constants for A. (a) Apparent (conditional) dissociation
constants taken from fluorescence quenching experiments using three different
chelators: NTA, glycine and histidine. [Ltot] is the total concentration of ligand at
θ=0.5 and [Lfree] is the concentration of ligand not bound to Cu2+. All A(1-42)
experiments were conducted at pH 7.4. (b) Dissociation constants for A(1-28).
Dissociation constants taken from fluorescence quenching and near-UV CD. *
denotes a Kd at pH 7.8, raw data previously reported (Syme et al 2004).
Peptide Technique Chelator pH Kd
Fluorescence
Quenching Glycine pH 7.8 96 pM *
Fluorescence
Quenching His pH 7.8 44 pM *
near-UV CD NTA pH 7.4 40 pM
near-UV CD Glycine pH 7.6 60 pM
Aβ(1-28)  WT
Kd(sol)/pM Kd(fib)/pM
Competing
ligand L
[Ltot]
(mol eq)
[Lfree]
(mol eq) Calculated
[Ltot]
(mol eq)
[Lfree]
(mol eq) Calculated
Gly 55 54 62 56 55 60
His 1.7 0.7 36 1.5 0.5 69
NTA 0.7 0.2 50 0.7 0.2 50
Soluble A Fibrillar A(a)
(b)
3.5. Discussion
3.5.1. Affinity of Cu2+ for Monomeric and Fibrillar A
Despite the range of studies that link Cu2+with A neurotoxicity, a role for Cu2+ ions
in the etiology of Alzheimer’s Disease has often been met with some scepticism. A
common objection has been the relatively low affinity of Cu2+ for A. Typically
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micromolar, or nanomolar, Kd’s are reported (Garzon-Rodriguez, et al. 1999,
Guilloreau, et al. 2006, Hatcher, et al. 2008, Tougu, et al. 2008). The re-evaluation
of Cu2+ affinity for A described here places the affinity several orders of magnitude
higher than previously believed. A picomolar affinity for Cu2+ now allows A to
compete for Cu2+ ions with other extracellular Cu2+ chelators, such as human serum
albumin (1.0 pM Kd) (Masuoka, et al. 1993), particularly during neuronal
depolarisation. The biological significance of a picomolar affinity is discussed later.
Two independent methods of determining the affinity of Cu2+ for monomeric and
fibrillar A(1-42) were used. The fluorescence quenching experiments show that
both soluble and fibrillar A(1-42) have an identical affinity, and are comparable to
that of the Cu2+ chelator NTA (20 pM) for Cu2+ ions. There were some small
differences in the affinities calculated depending on the competing ligand used
(NTA, histidine or glycine) but all three competitors indicated an affinity of Cu-A
to within less than an order of magnitude, placing the apparent Kd between 36 pM -
69 pM at pH 7.4. Near UV-CD was also used to directly monitor the location of
Cu2+ ions competing between NTA or glycine and A(1-28). Again this indicated an
affinity of Cu2+ for A(1-28) comparable to that of NTA at pH 7.4. Glycine
competition detected by fluorescence or near UV-CD revealed very similar affinities
validating the fluorescence quenching method.
3.5.2. A Ternary Complex is Unlikely
The possibility that a ternary complex is formed between Cu2+, A and the
competing ligands; NTA, L-histidine or glycine was considered, see for example
(Rozga, et al. 2009) and (Burns, et al. 2001). However a number of pieces of
evidence suggest this is unlikely. In particular, competition for Cu2+ ions between
A and L-histidine detected by Vis-CD indicates that when sufficient (~ 4 mole
equiv) L-histidine is added to the Cu2+-A complex a Vis-CD spectra identical to
Cu-(His)2 alone is observed (Figure 3.4.)
The visible CD spectra are very sensitive to Cu2+ coordination geometry and the free
Cu-(His)2 complex produces a characteristic visible CD spectra with a positive CD
band at 700 nm irrespective of the presence of A, suggesting a ternary complex
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does not form. Furthermore the Cu2+ induced quenching of the Tyr10 of A almost
completely returns upon the addition of NTA (or other competing ligands). If Cu2+
remained bound to A forming a ternary complex, one might expect some if not all
of the Cu2+ induced quenching to persist. In addition, the CD band at 320 nm
attributed to the Cu2+-A imidazoles is completely lost with the addition of a
competing ligand. If a ternary complex remained, one might expect the Cu2+
imidazole band fromCu2+-A to also be retained.
Figure 3.4. Vis-CD spectrum of Cu(His)2. Cu(His)2 complex (black) compared to
Cu2+ with A(1-40) and L-His (grey). 50 µM Cu2+ and 50 µM A(1-40) at pH 7.4 in 20
mM ethylmorpholine buffer and 160 mM NaCl.
3.5.3. Accounting for the Discrepancies in the Reported Affinities
Previously reported affinities of Cu2+ for A are only for the monomeric form. There
are no Cu2+ affinity studies for A fibrils. Garzon – Rodriguez et al. (1999) found
that Cu2+ had an affinity for monomeric A(1-42) of ~2 M (Garzon-Rodriguez, et
al. 1999). However the Garzon-Rodriguez study was performed in Tris-buffer,
which has a weak, but appreciable affinity for Cu2+ ions (see Table 2.1 in Chapter
2). This would lower the observed affinity. Two recent studies have shown that
apparent Kd’s reported in the literature of Cu-A, once corrected for coordination by
Tris-buffer, produce Kd’s of 35 nM or 625 pM depending on the approach (Hatcher,
et al. 2008, Tougu, et al. 2008). Hatcher et al. suggest that as many as four step-wise
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Cu2+ dissociation constants must be considered for Tris-buffer. Hatcher et al used
iso-thermal calorimetry (ITC) and determined an apparent dissociation constant of
0.4 nM for the Cu-A complex at pH 7.4. This affinity is ~ 10 times weaker than
that determined here. The discrepancy might be explained by the use of high levels
of Tris-buffer as a competitor which might exaggerate systematic errors in the
measurements. Phosphate buffer is also occasionally used in the literature
(Danielsson, et al. 2007, Hou, et al. 2006), however there is the risk of the insoluble
Cu3(PO4)2 species forming, especially at high pH. This species is likely to precipitate
out, thus reducing the concentration of available Cu2+ and invalidating the results.
Because of the complications arising from the competing effects of buffers, the
experiments in this chapter (and others conducted by various research groups) were
conducted in the absence of a buffer (Curtain, et al. 2001, Guilloreau, et al. 2006,
Kowalik-Jankowska, et al. 2003, Ma, et al. 2006, Syme, et al. 2004).
An additional complication with these types of experiments, highlighted by Hatcher
et al is a failure to account for both of glycine’s affinities (Hatcher, et al. 2008).
When the step-wise affinity, Ka1Ka2 for the Cu(Gly)2 is used rather than simply Ka1,
comparable affinities as to those reported here may be calculated.
The in-register stacking of successive monomeric units within fibres results in
histidines at positions 13 and 14 aligning adjacent to each other along the length of
the fibres, (Tycko 2004, Whittemore, et al. 2005) thus groups of four histidine
residues would be in close proximity. A particularly intriguing possibility was that
the very different affinities reported for Cu-A within the literature (Kd’s between
1018 and 106) (Atwood, et al. 2000, Garzon-Rodriguez, et al. 1999, Tougu, et al.
2008) might reflect differences in the A oligomeric form studied. Importantly the
studies described in this chapter find no difference in affinity between monomeric
and fibrillar A. It now seems clear that the atto-molar dissociation constant
proposed by Atwood et al. (Atwood, et al. 2000) is out of line with other
measurements and can not be explained by the oligomeric state of A.
3.5.4. Biological Significance
The dissociation constant reported here for A(1-42)-Cu2+ at pH 7.4 of ~50 pM, is a
number of order of magnitudes lower than recent reports. Simplistically, this
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dissociation constant suggests that for the Aβ-Cu2+ complex to form, only picomolar
concentrations of Cu2+ are needed. This is considerably lower than the extracellular
Cu2+ concentration within cerebrospinal fluid (CSF) and extra-cellular brain
interstitial fluid, which is typically 250 nM (Geigy 1984, Joergstuerenburg, et al.
1999). Furthermore levels of Cu2+ are found to be as much as 1000 times higher at
the synapse (Lovell, et al. 1998) and within plaques (Kardos, et al. 1989, Lovell, et
al. 1998).
However the dissociation constants of other copper chelators must be considered,
and although serum albumin is at relatively low levels in the CSF compared to its
concentration in blood plasma, it has a Kd of 1.0 pM for Cu2+ ions at pH 7.4
(Masuoka, et al. 1993, Rozga, et al. 2007). Thus much of the Cu2+ is still likely to be
bound to serum albumin. However it is notable that the difference in affinity
between albumin and A is only a single order of magnitude. Additionally at the
synaptic cleft fluxes of Cu2+ ions may be as high as 250 M during neuronal
depolarisation (Kardos, et al. 1989) which is two orders of magnitude higher than
the concentration of albumin. In these instances albumin, and other copper binding
proteins such as metallothionein-3, may be saturated with Cu2+ ions. A is cleaved
from APP at the synapse (Lacor, et al. 2004) and would be able to bind fluxes of
Cu2+ released during cellular depolarisation.
The strong affinity of Aβ for Cu2+ also has implications for the current interest in
Cu2+ chelators, which have shown some efficacy as a treatment for AD (Bush 2002,
Cherny, et al. 2001, Ritchie, et al. 2003). Potential chelators should have an affinity
for Cu2+ an order of magnitude higher than A, placing an ideal affinity at 1012 M-1,
comparable to human serum albumin.
These studies have made a significant contribution to understanding the Cu2+ affinity
of Aβ in both the monomeric and fibrillar form. The re-evaluation of the dissociation
constant of Cu2+ for A to pM levels adds weight to Cu2+ playing a central role in the
formation of fibres, as well as the neurotoxic affects of redox active Cu2+ ions bound
to diffusible A oligomers.
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Abstract 
Cu2+ ions are found concentrated within senile plaques of Alzheimer’s disease 
patients directly bound to amyloid-β peptide (Aβ), and are linked to the 
neurotoxicity and self-association of Aβ. However the nature of the Aβ-Cu2+ 
complex for both monomeric and fibrillar Aβ fibres is not fully resolved. 
Continuous wave-electron paramagnetic resonance (cw-EPR) spectroscopy is used 
in this chapter to show that Aβ fibres are able to bind a full stoichiometric 
complement of Cu2+ ions. This suggests that Cu2+ ions are able to diffuse into all 
parts of the fibre to give precisely a 1:1 stoichiometry and with little change in fibre 
structure. EPR spectra are typical for a type II axial spectra indicating tetragonal 
geometry. Additionally the AII and gII values from the EPR spectra show that 
fibrillar Aβ has identical coordination geometry to monomeric Aβ. The pH 
dependence of EPR spectra indicates two tetragonal complexes are present at pH 7.4 
containing N and O ligands.  
 
EPR of Aβ analogs, where histidine residues are substituted for alanines, were also 
studied using EPR. The spectra suggest a dynamic model of the tetragonal Cu2+ 
complex, with axial as well as equatorial coordination of imidazole nitrogens, 
creating an ensemble of coordination geometries in exchange between each other. 
Furthermore the N-terminal amino group is essential for the formation of the high 
pH complex. Finally this study examines why the Aβ(1-28) fragment binds an 
additional Cu2+ ion compared to full length Aβ. This second binding site is revealed 
in Aβ(1-42) upon addition of methanol, indicating hydrophobic interactions from the 
long hydrophobic tail of full length Aβ blocks the formation of this second, weaker 
carboxylate-rich binding site.  
 
The data presented in this chapter was recently published in (Sarell, et al. 2009). 
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4.1. Introduction 
There has been extensive examination of the coordination geometry and 
stoichiometry of the Cu2+ binding site of Aβ, especially in truncated peptides such as 
Aβ(1-16) and Aβ(1-28). There has been a lack of consensus however on the nature 
of both the binding ligands and the number of binding sites, especially in full length 
Aβ. This is likely to be due to a variety of reasons, including aggregation of the full 
length peptide, the buffer used, solvents present and pH effects. 
 
4.1.1. Reasons for Resolving the Cu2+-Aβ Complex 
A clear understanding of the coordination geometry of the Aβ-Cu2+ complex 
includes defining the nature of the binding ligands, stoichiometry, and the pH-
dependency of the complex.  
 
The coordination geometry will influence the affinity of a complex, by determining 
the ligands involved, the geometry in which they form bonds with the ion and also 
how tightly the ion is bound. Additionally coordination of copper may involve the 
backbone of Aβ, which will influence secondary structure and possibly nucleus 
formation, fibril elongation or fibril stability. Moreover, knowing which ligands are 
involved in the complex can aid in understanding how the overall charge of the 
protein will change when Aβ binds Cu2+. 
 
Finally the coordination geometry can also affect the redox properties of the protein 
by determining whether the copper is free to cycle or not. For example, plastocyanin 
is a copper binding protein with distorted trigonal pyramidal coordination geometry 
(Gewirth, et al. 1988). Two nitrogen atoms from two separate histidines and a sulfur 
from a cysteine (S1) compose the trigonal plane of the pyramidal base. Sulfur from a 
methionine (S2) forms the apex of the complex. The Cu-S1 bond is shorter (207 
picometres) than Cu-S2 (282 picometres). The elongated Cu-S2 bonding increases 
the redox potential of the protein by destabilising the Cu2+ form. The redox potential 
is highly important as it affects the ability of the copper to undergo redox cycling, 
and thus influences free radical production. For example metallothionein will 
undergo a metal swap with Aβ, but in contrast to Aβ, metallothionein binds copper 
in a redox inactive form and thus has been suggested to be neuroprotective (Meloni, 
et al. 2008).  
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4.1.2. Previous Research on the Monomeric Aβ-Cu2+ Complex 
The Aβ-Cu2+ complex has been studied in some detail. It is generally agreed that the 
Cu2+ binding ligands of Aβ all reside in the first 16 residues of the peptide (Karr, et 
al. 2005, Kowalik-Jankowska, et al. 2003, Minicozzi, et al. 2008, Syme, et al. 2004), 
thus many of the studies have been done on either Aβ(1-16) or Aβ(1-28), which are 
more soluble than the longer Aβ(1-40) or Aβ(1-42) peptides.  
 
A number of biophysical techniques have been applied to probe the coordination 
geometry of monomeric Aβ and its metal coordinating fragments, for reviews see 
(Brown, et al. 2004) and in particular (Faller, et al. 2009). Key research using EPR 
indicate a tetragonal complex with N and O ligands, although the precise geometry 
or ligands is not clear (Karr, et al. 2005, Syme, et al. 2004). Recent studies include 
pulse EPR (Drew, et al. 2009, Shin, et al. 2008) potentiometry (Damante, et al. 
2008, Kowalik-Jankowska, et al. 2003), extended X-ray absorption (Streltsov, et al. 
2008) and 1H NMR (Hou, et al. 2006).  
 
Previous examination of the coordination complex of monomeric Aβ suggest that 
the peptide can bind two mole equivalents of Cu2+ sequentially, with the first site 
having a much stronger affinity than the second (Atwood, et al. 2000, Karr, et al. 
2008, Syme, et al. 2004). A dimeric complex, composed of two metal ions bridged 
by an imidazole (Cu2(Aβ)2) has been suggested (Curtain, et al. 2001), but this is 
disputed by other group’s data, including the work in this chapter. Further details on 
the nature of the Cu-Aβ complex and how the work described in this chapter relates 
to other studies are discussed in Section 4.6. 
 
4.1.3. Previous Research on the Fibrillar Aβ-Cu2+ Complex 
Potentially the Cu2+ complex formed by Aβ in a fibrillar state may be very different 
from that formed by monomeric Aβ in solution. Current models of Aβ fibrils 
indicate in-register stacking of Aβ monomers (Petkova, et al. 2002). This causes 
histidine side chains (which have a high affinity for Cu2+ ions) at positions 13 and 14 
to stack close together in successive peptides creating a potential Cu2+ coordination 
site containing four histidine residues. Thus potentially, fibrils may be created or be 
stabilised by inter-residue histidines linking together via Cu2+ ions. Data on the 
coordination of Cu2+ binding to Aβ(1-42) in its fibrillar form has been obtained 
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previously by EPR (Antzutkin 2004, Karr, et al. 2005, Karr and Szalai 2008), solid 
state NMR (Antzutkin 2004) and Raman spectroscopy (Miura, et al. 2000) 
(performed on aggregates rather than fibrils). However the pH dependence of Cu2+ 
coordination to Aβ fibrils has not been reported, and it is still unclear whether one or 
two Cu2+ ions bind to full-length Aβ, and whether this differs depending on the 
oligomeric state of Aβ. Thus many questions regarding the structure and 
stoichiometry of the Aβ-Cu2+ complex remain unanswered, and this chapter attempts 
to shed some light on this area. 
  
4.2. Aims 
• Determine the pH dependence of Cu2+ binding in full length Aβ(1-42) and Aβ(1-
28) 
• Investigate if the oligomeric state of Aβ(1-42) affects the coordination geometry 
of the Aβ(1-42)-Cu2+ complex 
• Determine the coordination ligands of the Aβ(1-28)-Cu2+ complex 
• Compare the stoichiometry of fibrillar Aβ, monomeric Aβ and Aβ(1-28) 
 
4.3. Experimental 
Peptide preparations, fibril formation and the theory of electron paramagnetic 
resonance (EPR), and transmission electron microscopy (TEM) and circular 
dichroism (CD) experimental details are discussed in Chapter 2. 
 
In these studies 50 µM Aβ(1-42) was used, in both monomeric and fibrillar forms. A 
range of buffers was used; phosphate buffer, ethylmorpholine buffer, and HEPES, 
all at 10 mM with 160 mM NaCl. The structures of the buffers and further details are 
described in Chapter 2. Aβ(1-42) samples were not incubated with Cu2+ during fibril 
growth, thus for studies with monomeric Aβ(1-42) Cu2+ was added to the peptide 
then the sample was frozen immediately. For studies with fibrillar Aβ(1-42) Cu2+ 
was added after fibril formation had occurred. Likewise in studies with Aβ(1-28) 
Cu2+ was added to the freshly solubilised peptide then the sample was frozen 
immediately. 
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4.3.1. Electron Paramagnetic Resonance 
Continuous wave X-band EPR data was recorded using a Bruker ELEXSYS 500 
spectrometer, operating at a microwave frequency of ~9.3 GHz. Spectra were 
recorded using a microwave power of 4.012 mW across a sweep width of 2000 G 
(centred at 3200 G) with a modulation amplitude of 7 G. Samples were frozen in 
quartz tubes and experiments conducted at typically 20 K using a liquid helium 
cryostat. A minimum of four scans were recorded per spectrum. All EPR spectra 
shown have been background subtracted from a buffer blank with subsequent 
baseline correction in the EPR software package using third or fourth-order 
polynomial splines.  
 
To analyze EPR data using the method described by Peisach and Blumberg (Peisach, 
et al. 1974), it is necessary to convert values from gauss (G) to millikaysers (mK) by 
using the formula A(mK)= 0.046686g∆H, where g = 2.0023 and ∆H is the AII 
splitting measured in gauss. Double integration was carried out on the signal 
between 3200 and 3400 G to determine signal intensity.  
 
4.4. Results 
4.4.1. pH Dependence of Cu2+ Binding 
The Cu2+-Aβ(1-42) coordination geometry may be affected by changes in pH. 
However preliminary studies suggested that the choice of buffer affects the pH 
dependence behaviour of the complex. There are a variety of buffers commonly used 
when studying the coordination chemistry of Cu-Aβ (Karr and Szalai 2008, 
Streltsov, et al. 2008, Syme, et al. 2004). EPR spectra of monomeric Aβ(1-42) 
loaded with one mole equivalent of Cu2+ ions were therefore obtained over a range 
of pH values under four different sample conditions: 10 mM HEPES, 10 mM 
ethylmorpholine (EM), 10 mM phosphate buffer or just water as shown in Figure 4.1 
and Figure 4.2. It is notable that repeat EPR (or CD) scans recorded over time 
showed no change in the appearance of the spectra indicating Cu2+ coordination to 
Aβ(1-42) reaches a thermodynamic equilibrium rapidly, within minutes.  
 
The EPR spectrum at pH 5 for Cu-Aβ(1-42) under all four buffer conditions gives a 
single set of signals typical of type II Cu2+, square-planar or square pyramidal 
coordination geometry, as shown in Figure 4.1a. Regardless of the buffer, the AII, gII 
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and g⊥ values are 171 gauss (16.0 mK), 2.27 and 2.02 respectively (designated 
complex I). At pH 7.4 a new set of hyperfine peaks can be observed at a higher field 
with AII, gII and g⊥ values of 154 gauss (14.4 mK), 2.23 and 2.01 respectively 
(designated complex II), as shown in Figure 4.1b.  
Figure 4.1.  pH and buffer dependence of Cu2+ binding to monomeric Aβ(1-42).  Cu-
EPR spectra of 50 µM Aβ(1-42) plus 1 mole equivalent Cu2+ at (a) pH 5.0  (b) pH 7.4 and 
(c) pH 9.0. Spectra were recorded in four different buffering conditions at each pH: i) 
water ii) 10 mM ethylmorpholine iii) 10 mM phosphate and iv) 10 mM HEPES. Plots (d), 
(e) and (f) show relative percentage intensities of EPR signals from complex I (low pH) 
(purple) and complex II (high pH) (green). (d) shows Aβ-Cu-EPR spectra in water and 
phosphate buffer (average values used as both buffers produced almost identical spectra). 
Aβ-Cu-EPR spectra in (e) 10 mM HEPES buffer (purple circles complex I, green circles 
complex II) and (f) in EM buffer. All samples contained 160 mM NaCl and were recorded 
at 20 K. The midpoint of the transition between complex I and II is pH ~ 9 for water, 
HEPES and phosphate buffer but lowered to 8.0 for EM.
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At pH 7.4 complex I remains the more intense of the two under all four conditions 
and notably in water, phosphate or HEPES buffer ~ 80 % of the Cu2+ forms complex 
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I. At pH 9 (Figure 4.1c) the low and high-field sets of signals of complex I and II are 
of comparable intensity in water, phosphate and HEPES buffers. However for 
ethylmorpholine buffer (EM) the low-field species observed exclusively at pH 5 is 
considerably less intense than the high-field species. The relative intensities of the 
two complexes is shown in Figure 4.1 d, e and f. The pH dependence of the 
formation of complex I and II is very similar for phosphate, water and HEPES 
(Figure 4.1d and e) with a midpoint of pH ~9, however the midpoint in EM buffer 
(Figure 4.1f) is lower at pH 8.0. 
 
This behaviour is also observed for Aβ(1-28) (Figure 4.2). Comparison of EPR 
spectra for Aβ(1-28) and Aβ(1-42) show a close correspondence at all pH values. 
The midpoint of the transition for Aβ(1-28) was ~ pH 9, similar to Aβ(1-42), and 
again in EM buffer this was reduced to pH 8.0.  
 
The effect of EM buffer on the mid-point of the transition between complex I and II 
was unexpected as EM has a very low affinity for Cu2+ ions. Buffers can have a 
temperature dependence to their pH. A recent study has shown that some buffers pH 
can vary by as much as one pH unit between room temperature and 10 K (liquid 
helium temperatures) (Sieracki, et al. 2008, Williams-Smith, et al. 1977). This may 
well account for the discrepancies between EM buffer and the other buffers tested.  
 
Peisach and Blumberg have shown that a combination of AII and gII values can 
indicate the ligand type that coordinates the Cu2+ in tetragonal/ square-planar 
complexes (Peisach and Blumberg 1974), see Chapter 2 for more details. The AII 
and gII values for complex I and II are shown in Figure 4.2d. Complex I is most 
typical of two nitrogen and two oxygen ligands (2N2O) although 3N with 1O 
coordination cannot be ruled out. The AII and gII values of the high-field species 
observable at pH 7.4 and pH 9 (complex II) do not fall into the standard Peisach and 
Blumberg plot areas suggesting some distortion in the axial plane (perhaps 
suggesting a more square pyramidal character). The AII and gII values are shifted 
away from the oxygen boundaries suggesting a probable 3N1O or 4N coordination. 
Details of proposed coordinating ligands are described in Section 4.5.2. 
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Figure 4.2. pH dependence of Aβ(1-28)-Cu binding. One mole equivalent Cu2+, 50 µM 
Aβ(1-28) at (a) pH 5 (b) pH 7.4 and (c) at pH 9 measured by EPR. Spectra were recorded 
in three different buffering conditions at each pH: i) water ii) 10 mM Ethylmorpholine and 
iii) 10 mM phosphate. Spectra were recorded at 20 K. The low pH complex is highlighted 
in purple, the high pH complex in green. (d) Peisach-Blumberg plot for the AII and gII 
values of Aβ(1-28), Complex I (purple) and Complex II (green), see Table 4.1 for exact 
values.
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4.4.2. Comparison of Aβ Monomeric and Aβ Fibrillar  
The in-register stacking of Aβ monomers in amyloids has raised the possibility that 
the Cu2+ coordination formed with amyloid fibres could be very different from the 
                                       Chapter 4. Structure and Stoichiometry of the Cu2+-Aβ Complex 
 
131 
coordination with Aβ monomers. Figure 4.3 compares the EPR spectra of both 
monomeric and fibrillar Aβ loaded with 1 mole equivalent of Cu2+ ions.  
Figure 4.3. Cu2+ and different oligomeric species of Aβ(1-42). (a) EPR 
spectra of monomeric (dashed line) and fibrillar (solid line) Aβ(1-42) 50 µM
with 50 µM Cu2+ in 10 mM phosphate buffer with 160 mM NaCl at pH 7.4, 20 
K. Insert (b) shows additions of Cu2+ to 50 µM Aβ(1-42) at 0, 3 and 8 days 
incubation. The Cu2+ coordination for monomeric and fibrillar Aβ is strikingly 
similar. Figure (c) shows a UV-CD spectra of the predominantly β-sheet Aβ(1-
40) fibrils with the addition of up to 15 mole equivalents (750 µM ) Cu2+. 
Aβ(1-40) fibrils without (d) and with (e) Cu2+ present. Cu2+ is added in a 1:1 
stoichiometry once fibrils are formed. TEM Images achieved with assistance 
of Louise Serpell and Kyle Morris, University of Sussex.
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It is clear almost identical EPR line shapes are obtained for the fibrillar and 
monomeric forms of Aβ(1-42), as shown in Figure 4.3a. Of particular note is that 
there is no detectable line broadening of the fibrillar form compared to monomeric 
Aβ. EPR spectra reveal a type II axial coordination with an AII of 16.0 mK (171 
gauss) and a gII of 2.27 which are typical for a 3N1O or 2N2O complex at pH 7.4. 
There are no significant differences in the hyperfine splitting between monomeric 
and fibrillar Aβ(1-42) and the AII and gII are the same for both forms of Aβ(1-42). 
 
It is notable that Cu2+ addition has little detectable affect on the secondary structure 
of fibres once formed, as determined by UV-CD. The CD spectra of fibres are 
dominated by a strong negative band at 217 nm, indicative of β-sheet. The 
appearance of the spectra is unaffected by the addition of up to 15 mole equivalents 
of Cu2+ ions as shown in Figure 4.3c.  
 
Figure 4.3b shows the effect of different oligomeric states of Aβ(1-42) on the Cu2+ 
coordination environment. At different times during Aβ(1-42) fibril growth a sample 
of the peptide preparation was removed and Cu2+ added, then the samples frozen. By 
monitoring growth using ThT fluorescence an estimate of the degree of 
oligomerisation could be obtained at different time points (Naiki, et al. 1989). At 
zero days, fresh Aβ(1-42) represents the largely monomeric form of Aβ(1-42), with 
very low ThT fluorescence signal. The Aβ(1-42) species at 3 days represents early 
fibres, while 8 days represents more mature fibres. Again the spectra are almost 
identical for all three forms of Aβ. A TEM image of Aβ(1-40) fibres is shown is 
Figure 4.3d. The fibres were grown without Cu2+ present, then one mole equivalent 
of Cu2+ added to the Aβ(1-40) sample shown in Figure 4.3e. Fibrils with and 
without Cu2+ present show a periodic twist, characteristic of amyloid fibres. 
 
4.4.3. pH Dependence and Coordination Geometry of Aβ(1-28) and Analogs 
To identify the residues directly involved in the coordination of Cu2+, five peptide 
analogs have been synthesised. In three analogs of Aβ(1-28) one of the three 
histidines have been replaced with an alanine residue, Aβ(H6A), Aβ(H13A) and 
Aβ(H14A). An additional peptide has also been synthesised in which the N-terminus 
of Aβ(1-28) is blocked by acetylation. Under physiological conditions it is believed 
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that nitrogens from these four loci (the three imidazole rings and the N-terminal 
amino group) are the most likely candidates for Cu2+ coordination. Comparisons of 
EPR spectra shown in this chapter, and previously by Karr et al, confirms that Aβ(1-
28) contains all the ligands involved in coordinating the first mole equivalent of 
Cu2+ in Aβ(1-42). Finally a shorter fragment, Aβ(Ac10-16), was also studied in 
which His6 and the N-terminal amino group are absent. The sequence of all five 
analogs is shown in Chapter 2. 
 
The EPR spectra of all five analogs with one mole equivalent of Cu2+ added were 
obtained over a range of pH values to probe the nature of the coordinating ligands 
and are shown in Figure 4.4. The Cu2+ complex for each analog was studied at pH 5, 
6, 7, 8, 9 and 10. All spectra indicate axial Cu2+ coordination containing N and O 
ligands. All but two of the analogs produced two sets of axial peaks.  
 
At pH 5 only one set of AII and gII values is present in all five peptide analogs. All 
have a similar appearance to the low-pH species described for Aβ(1-28), Aβ(1-40) 
and Aβ(1-42). There are however subtle variations in the appearance of the spectra. 
The AII and gII values for the five peptides and wild-type Aβ(1-28) are given in 
Table 4.1. All fall within a small range of AII values between 170 to 164 gauss for 
complex I (predominant at pH 5 and pH 7.4) except for Aβ(Ac10-16) which has a 
larger AII of 178 gauss. The gII of complex I ranges from 2.26 for Aβ(Ac10-16) to 
2.29 for N-terminally acetylated Aβ(Ac1-28).  
 
As the pH is raised to pH 7.4 the appearance of the EPR spectra differs between the 
analogs. A second, higher field species is obtained for Aβ(1-28) wild-type sequence 
and all the His substituted analogs, with an AII and gII of ~ 165 gauss (15.4 mK) and 
2.22, but significantly it is not apparent in the N-terminally acetylated analog 
Aβ(Ac1-28) or Aβ(Ac10-16). Furthermore the relative intensities of the two species 
is different between the analogs. The pH dependencies for complex I and II are 
plotted as relative intensity versus pH for the five analogs and compared to the wild 
type Aβ(1-28), as shown in Figure 4.4d and e.  
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At pH 9 the high-field species (complex II) are of similar or greater intensity than 
the low-field species for wild-type Aβ(1-28), H6A, and H13A. But for H14A ~ 60 
% remains as complex I and there is still no observable signal for the higher pH 
complex II spectra in the N-terminally acetylated analogs.  
 
 
Figure 4.4. Cu2+-pH dependence of Aβ(1-28) analogues.  Cu-EPR spectra of
Aβ(ac10-16) (purple), Aβ(ac1-28) (orange), Aβ(H14A) (red), Aβ(H13A) (blue), 
Aβ(H6A) (black), and Aβ(1-28) wild type (WT) (green) at 50 µM with one mole 
equivalent of Cu2+ at (a) pH 5, (b) pH 7.4 and (c) pH 9. Figures (d) and (e) show the 
relative percentage intensities of complex 1 (d) and complex 2 (e) of the six peptides 
over a wider range of pH values. It is clear the N-terminally acetylated analogs will 
not form the high pH, complex II. 
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In Table 4.1 the AII and gII values for the five analogs and wild-type Aβ(1-28) are 
given and also the affinities of Cu2+ for the Aβ analogs studied, obtained from 
fluorescence quenching experiments in Chapter 3 and also from raw data previously 
reported (Syme, et al. 2004). The dissociation constants were calculated from the 
glycine concentration at half-maximal quenching at pH 7.8 using equation 13 in 
Chapter 3. It is notable that all analogs have reduced affinity for Cu2+ ions, 
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indicating that all four nitrogen ligands identified have a role in stabilising the Cu2+ - 
Aβ complex. The N-terminal blocked and His6Ala analogs show the most marked 
reduction in affinity, while the H13A and H14A analogs show less pronounced 
change in affinity for Cu2+ ions relative to the wild-type Aβ(1-28). 
 
Table 4.1. AII and gII values and dissociation constants for Aβ fragments and 
analogs. Complex I pH 5 - 8, complex II > pH 9. Apparent (conditional) dissociation 
constants taken from Gly competition fluorescence quenching data at pH 7.4. 
* denotes a Kd at pH 7.8, raw data previously reported (Syme et al 2004). Values shown 
were calculated using equation 13 in Chapter 3.
♦ denotes where the Kd at pH 7.6 has been calculated, using glycine competition and 
near-UV – CD. 
 Complex I (pH 7.4) Complex II (pH 9)  
Peptide AII gII AII gII Kd 
Aβ(1-42) mono 16.0 mK (171 G) 2.27 14.4 mK (154 G) 2.23 62 pM  
Aβ(1-42) fibrillar  16.0 mK (171 G) 2.27 not measured 60 pM 
Aβ(1-28)  WT  15.9 mK (170 G) 2.27 14.7 mK (156 G) 2.22 96 pM * 
60 pM ♦ 
Aβ(1-28)  NB  15.7 mK (168 G) 2.29 not present 915 pM 
Aβ(1-28)  H6A 15.7 mK (168 G) 2.28 15.8 mK (169 G) 2.22 277 pM * 
Aβ(1-28) H13A  15.3 mK (164 G) 2.28 15.1 mK (162 G) 2.22 141 pM * 
Aβ(1-28)  H14A  15.5 mK (166 G) 2.28 15.6 mK (167 G) 2.22 141 pM * 
Aβ(10-16) 16.7 mK (178 G) 2.26 not present 6.9 nM * 
Aβ(1-11) 13.6 mK (146 G) 2.30 not measured - 
Aβ(1-28) 2nd mole eq 16.4 mK (175 G) 2.28 not measured - 
 
 
 
 
In summary all the peptide analogs have slightly different AII and gII values, and 
perturbed pH dependence compared to wild type Aβ(1-28). In addition all analogs 
have reduced affinity for Cu2+ ions. Most striking is the N-terminally blocked 
analogs, Aβ(Ac1-28) and Aβ(Ac10-16), both of which will not form complex II 
even at pH 9. 
 
4.4.4. Stoichiometry of Cu2+ Binding to Monomeric and Fibrillar Aβ(1-40) 
and Aβ(1-42).  
The process of fibril formation could lead to an intermolecular Cu2+ complex, for 
example fibrillar Aβ might potentially form a Cu(Aβ)2 1:2 complex. To identify any 
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differences in Cu2+ binding stoichiometry for monomeric and fibrillar forms of 
Aβ(1-42) and Aβ(1-40), EPR spectra were obtained with increasing mole 
equivalents of Cu2+ at pH 7.4, shown in Figure 4.5 and 4.6.  
 
Figure 4.5. Cu2+ titration of monomeric Aβ(1-40) and Aβ(1-42). (a) EPR spectra 
recorded with 0.4, 0.6, 0.8, 1.0 and 2.0 mole equivalents of Cu2+ and 50 µM Aβ(1-42) in 
10 mM phosphate buffer at pH 7.4, 20 K.  Double integration of the EPR spectra of 
monomeric Aβ(1-40) (circles) and Aβ(1-42) (squares) with increasing mole equivalents of 
Cu2+ is shown in panel (b). Best fit straight lines are fitted through 0-1 mole equivalents 
Cu2+ and 1-4 mole equivalents Cu2+ data points. The EPR signal intensity is (I/Imax).  
Both Aβ(1-40) and Aβ(1-42) monomeric indicate that saturation of Aβ occurs at 1 mole 
equivalent Cu2+.
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Increasing amounts of Cu2+ added to monomeric Aβ(1-40) and Aβ(1-42), (Figure 
4.5), gave identical line shapes up to one mole equivalent, with a commensurate 
increase in intensity indicating a single binding mode. Addition of a further mole 
equivalent of Cu2+ (and up to ten mole equivalents) results in no further increase in 
the intensity of the EPR spectra for either Aβ(1-40) or Aβ(1-42) in its monomeric 
form. This was a surprise as previous studies within our lab on Aβ(1-28) reported a 
2:1 stoichiometry; 2 Cu2+ ions binding a single Aβ(1-28) molecule (Syme, et al. 
2004). Spin integration of the EPR spectra has been plotted versus Cu2+ addition as 
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shown in Figure 4.5b. Both Aβ(1-40) and Aβ(1-42) show a linear increase in 
intensity up to one mole equivalent of Cu2+ ions followed by saturation of the signal. 
The clear break point at one mole equivalent Cu2+ indicates that at 50 µM Aβ(1-40) 
and Aβ(1-42) Cu2+ binds tightly with a 1:1 stoichiometry. It should be noted that 
free Cu2+ ions in water at neutral pH give a largely EPR silent signal (Aronoff-
Spencer, et al. 2000). This observation was confirmed by obtaining EPR spectra of 
50 µM CuCl2 in EM, PB, HEPES and water buffer at pH 7.4 which showed that 
Cu2+ EPR signals are drastically attenuated relative to Cu2+ bound to Aβ(1-40) and 
Aβ(1-42).  
 
Next, the stoichiometry of Cu2+ binding to the fibrillar form of Aβ(1-40) and Aβ(1-
42) was investigated, as shown in Figure 4.6. Cu2+ binding curves (Figure 4.6c-d) 
for fibrillar Aβ(1-40) and Aβ(1-42) also show a maximal Cu2+ EPR signal at one 
mole equivalent. After one mole equivalent of Cu2+, both Aβ(1-40) and Aβ(1-42) in 
their fibrillar form became saturated with Cu2+ at physiological pH. Because of the 
necessity of the long incubation of Aβ(1-40) and Aβ(1-42) at 37 °C, 0.05 % (v/v) 
sodium azide was added to some samples, this had no effect on stoichiometry or the 
gII value, although the AII was reduced by approximately 2 gauss. Aβ(1-42) shows a 
slight reduction in signal with further Cu2+ addition (above 1 mole equivalent) due to 
some precipitation (~ 20 %) of the less soluble Aβ(1-42) prior to freezing. As with 
monomeric Aβ, the EPR data indicates fibrillar Aβ(1-40) and Aβ(1-42) also bind a 
single Cu2+ ion. This is in contrast to the shorter soluble Cu2+ binding fragment 
Aβ(1-28). This was suspected to be due to the hydrophobic tail of Aβ(1-42) 
blocking the second Cu2+ binding site. Thus to investigate this, methanol, an 
intramolecular hydrogen bond promoter was added.   
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Figure 4.6. Cu2+ titration of fibrillar Aβ(1-40) and Aβ(1-42). (a) Increasing mole 
equivalents of Cu2+ with 50 µM Aβ(1-42) in phosphate buffer solution up to two mole 
equivalents at pH 7.4, 20 K. (b) hyperfine splitting showing the AII of fibrillar Aβ(1-42). 
Panel (c) shows the double integration of the EPR spectra of fibrillar Aβ(1-40) with 
sodium azide (open circles) and fibrillar Aβ(1-40) with no sodium azide (squares). Panel 
(d) shows the double integration of fibrillar Aβ(1-42) with no sodium azide (black circles) 
plotted versus mole equivalent of Cu2+ ions. All indicate that saturation occurs at 1 mole 
equivalent of Cu2+.
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4.4.5. Differences in Stoichiometry Between Full Length Aβ(1-42) and 
Fragments  
The addition of 20 % (v/v) methanol has a profound influence on the stoichiometry 
of full-length Aβ(1-42). It is clear from the Cu2+ binding curve in Figure 4.7a that 
Aβ(1-42) has a 2:1 stoichiometry in the presence of methanol rather than the 1:1 
stoichiometry observed in 100 % water.  
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Figure 4.7. Effect of methanol on Aβ(1-42) stoichiometry. (a) A double integration of 
Aβ(1-42) in 100 % water  (squares) and water/methanol mixture (80/20 % v/v) (circles). 
(b) Double integration of Aβ(1-28) with (circles) and without (squares) 20 % methanol. 
Cu2+- Aβ(1-42) changes from 1:1 to 2:1 stoichiometry in the presence of methanol. Cu2+-
Aβ(1-28) retains 2:1 stoichiometry irrespective of the presence of methanol. The 
concentration of Aβ(1-42) and Aβ(1-28) was 50 µM.
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As a direct comparison Aβ(1-28) was also studied in 20 % (v/v) methanol (Figure 
4.7b) but this had no effect on the binding stoichiometry, and Aβ(1-28) still bound 
two Cu2+ ions both with or without 20 % v/v methanol present. The EPR spectra for 
Cu2+- Aβ(1-28)  in methanol/water are identical to Cu2+- Aβ(1-28) in water alone. 
 
The effect of methanol on the secondary structure of monomeric Aβ(1-42) was 
further studied by UV-CD. Measurements indicated no significant change in 
secondary structure from the peptide’s random coil conformation with addition of 20 
% methanol (Figure 4.8a). Affinity of the complex in 20 % methanol was also 
measured using fluorescence with L-His as a competing ligand (Figure 4.8b). The 
half-maximal quenching occurs at close to 3 (~3.25) mole equivalents of L-His for 
soluble Aβ(1-42) in 20 % methanol, which is comparable to soluble Aβ(1-42) 
without methanol (1.7 mol equivalents).  
                                       Chapter 4. Structure and Stoichiometry of the Cu2+-Aβ Complex 
 
140 
Figure 4.8. Aβ(1-42) with 20 % (v/v) methanol. (a) UV- CD spectra of the secondary structure 
of Aβ(1-42) with 20 % (v/v) methanol (pink) or with no methanol (black). 50µM Aβ(1-42) in 10 
mM phosphate buffer at pH 7.4. The spectra indicate monomeric Aβ(1-42) remains 
predominantly random coil even after the addition of 20 % (v/v) methanol. (b) Fluorescence 
spectra of Cu2+ -monomeric Aβ(1-42) in 20 % methanol L-histidine competition. The tyrosine 
fluorescence signal at 307 nm returns with additions of L - histidine. Only half of the maximal 
fluorescence intensity has returned after 2 mole equivalents of histidine is added.
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4.4.6. Cu2+ binding of the Second Mole Equivalent to Aβ(1-28) 
The nature of the binding site for the second mole equivalent of copper bound to 
Aβ(1-28) also warranted further investigation. Figure 4.9 shows EPR spectra of one 
and two mole equivalents of Cu2+ ions bound to Aβ(1-28), at pH 7.4. As Cu2+ was 
titrated in beyond one equivalent a new set of signals appear to low field, while 
signals for the first equivalent of Cu2+ remain unaffected. A difference spectra is 
shown of Cu2Aβ(1-28) minus Cu1Aβ(1-28), emphasising the appearance of the new 
set of signals at 2 mole equivalents of Cu2+. The copper type-II spectrum gives AII 
and gII values of 16.36 mK (175 gauss) and 2.28 respectively. These values are more 
typical of an oxygen rich complex such as 1N3O. An interesting possibility is that 
this second, weaker binding site originates from ligands found in the first 11 
residues of Aβ. Thus for comparison an EPR spectra of Aβ(1-11) with 1 mole 
equivalent of Cu2+ added is also shown in Figure 4.9.  
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Figure 4.9. Comparison of the second Cu2+ binding site with Aβ(1-11). Aβ(1-28) with 0.5, 
1.0, 1.5 and 2.0 mole equivalents Cu2+ present. The difference spectra is the two mole 
equivalent spectra minus the 1 mole equivalent spectra. The difference spectra highlights the 
3O1N nature of the second binding site which is very different from Aβ(1-11). See Table 4.1 
for AII and gII values.  
It is clear that the weaker second binding site does not, in fact, mimic binding to the 
Aβ(1-11) fragment, which has AII and gII values of 144 gauss (13.6 mK) and 2.30 
respectively, typical of 2N2O. Indeed the weaker second binding site does not 
resemble EPR spectra of any of the analogs studied (Table 4.1). 
 
4.4.7. Temperature Dependence of Cu2+-Aβ(1-28) EPR; A Bridging Cu-His-
Cu Dimer is Unlikely 
 It has previously been suggested that there is histidine bridging between two Cu2+ 
ions in the Aβ complex (Curtain, et al. 2001, Smith, et al. 2006). A g value of ~ 4 in 
the EPR spectra of Aβ-Cu2+ in addition to a broad g ~ 2 line was observed. Such 
EPR spectra are diagnostic for the existence of binuclear Cu2+ centers where the 
Cu2+ ions are coupled by dipolar interactions, and the authors suggest the atoms are 
6.2 Å apart. This study was repeated using the same conditions used by Smith et al 
(Smith, et al. 2006) but no line broadening in the spectra was observed, shown in 
Figure 4.10. EPR spectra in which electron coupling is taking place are very 
temperature dependent and will be effectively decoupled at lower temperatures (20 
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K) (Valentine, et al. 1979). The Aβ(1-28)-Cu2+ complex was observed at a range of 
temperatures and no resonances at g ~ 4 were observed. Without such an 
observation the possibility of a bridge complex must be questioned. 
 
Figure 4.10. Temperature dependence of Aβ(1-28). 100 µM Aβ(1-28) and 0.6 mole 
equivalents Cu2+ (Cu2+ stock used was 1 part Cu2+ to 6 parts glycine) in phosphate buffered 
saline (PBS) to mimic the parameters of (Smith et al 2006). Spectra at 20 K and 40 K were 
taken at 2 mW microwave power. All subsequent spectra were at 4 mW microwave power. 
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4.5. Discussion 
4.5.1. Cu2+ Binding to Fibrils  
Fibrils, once formed, retain their structure with Cu2+ additions, as judged by UV-CD 
and unperturbed ThT binding, and also TEM (Karr and Szalai 2008). In agreement 
with previous studies (Karr and Szalai 2008) the EPR spectra shown here suggest 
that the fibrillar Cu2+ complex forms the same coordination geometry and ligands as 
observed with monomeric Aβ. This is strongly supported by the observation that 
Cu2+ affinity for the two Aβ forms is almost identical (discussed in Chapter 3). 
Interestingly, Aβ fibres are able to accommodate a full stoichiometric complement 
of Cu2+ ions, suggesting Cu2+ ions are able to diffuse into all parts of the fibre giving 
precisely a 1:1 stoichiometry. The nature of the ligand's coordination geometry and 
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pH dependence of the Aβ-Cu2+ complex is discussed later but is shown in Figure 
4.11. The data shown in this chapter does not suggest an inter-molecular Cu-Aβ 
complex for the fibrillar form of Aβ.  
 
Karr et al. have reported Cu2+–EPR spectra of fibrils for the low pH species similar 
to those observed here (Karr, et al. 2005, Karr and Szalai 2008). However, they also 
argue, based on the solid state NMR models of Aβ fibres, that both His13 and His14 
cannot bind a single Cu2+ ion in Aβ(1-40) because the β-sheet structure would be 
disrupted by the simultaneous coordination of two adjacent residues (Karr, et al. 
2005). However the data in this chapter shows that the Cu2+ affinity is the same in 
the fibres as in the monomers, which would be unlikely if either His13 or His14 
were not part of the complex. Indeed, deuterium exchange experiments indicate that 
stable hydrogen bonds are not present between residues 1-14, suggesting a more 
flexible picture of Aβ fibres up to and including residue His14 (Olofsson, et al. 
2007, Whittemore, et al. 2005). This explains why the Cu2+ coordination geometry is 
unaffected by the formation of fibrils and can contain both His13 and His14.  
 
The β-strands are 4.7 Å apart in the fibril β-sheets (Serpell 2000). This, on average, 
would place adjacent His residues 4.7 Å apart. The EPR studies shown here 
demonstrate that Aβ(1-40) and Aβ(1-42) can bind up to 1 equivalent of Cu2+ ions. 
Dipolar through-space interactions of Cu2+ ions are typically felt between Cu2+ ions 
that are 7 Å or less apart and usually result in broadened spectra. It is therefore 
perhaps a surprise that some broadening of the EPR spectra is not observed, 
although it is certainly possible that the broadening is too small to be detected.  
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Figure 4.11. Proposed model of high affinity Cu2+ binding site to Aβ(1-42) in both 
fibrillar and monomeric forms. Complex I and II are tetragonal and complex I 
dominates below pH 9.  Complex I is square planar while complex II may be more 
square pyramidal. Coordinating ligands include all three histidine imidazole nitrogens 
but with two histidine ligands in the equatorial plane and a third as a weaker axial 
ligand. In addition, the N-terminal amino group coordinates at pH 7.4 as well as pH 9, 
but as an axial ligand at pH 7.4.  The oxygen ligands are likely to arise from the 
carboxylate side-chains of Asp1 and Asp7. At room temperature the Cu2+ complex may 
be quite dynamic exchanging between ligands in the equatorial and axial plane. 
Without crystallographic data this proposed coordination geometry is tentative.
Complex I pH 5-8
Complex II  pH >9
Asp1 Asp1
N-term
O
O
N
N
HN
N
NH
His6
His13
His14
N
Asp7
Asp1
N
O
O
N-term
N
HN
N
NH
His6
His14
His13
N
Asp7
Asp1
N
N
O
N
O
N
HN
N
NH
His6
His13
N-term
His14
N
Asp7
N
O
N
O
N
HN
N
NH
His6
His14
N-term
His13
N
Asp7
N
 
 
4.5.2. Coordination Geometry  
The EPR studies suggest two pH dependent species are formed with square-planar 
or tetragonal geometry. Based on gII and hyperfine splitting values complex I (at low 
pH) is composed of 2N2O or 3N1O ligands while complex II (at high pH) gives 
EPR spectra more typical of a complex with 3N1O or 4N ligands. A range of Aβ 
analogs have been used to further probe the nature of the coordination geometry. It 
is commonly believed that all three histidines within Aβ form equatorial imidazole 
nitrogen ligands with the Cu2+ ion (Shin and Saxena 2008). It is therefore surprising 
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that upon replacement of His6, His13, or His14 with alanine there is not more of a 
significant effect on the appearance of the EPR spectra, as alternative imidazole 
nitrogens are not available to compensate for the alanine substitution. In contrast, 
removal of His6, His13, His14 or N-terminal acetylation, all reduce affinity for Cu2+ 
(Table 4.1) and in addition cause perturbed Cu2+ loaded UV-CD spectra compared to 
the Cu2+-wild type spectra (Syme, et al. 2004). It is notable that the N-terminus has 
the most reduced affinity for Cu2+ followed by the H6A analog, while the affinity 
reduction observed for H13A or H14A is much less marked. An explanation for 
these seemingly conflicting observations is that the EPR spectra attributed to 
complex I is actually the result of a superposition of a mixture of species containing 
only two histidine ligands in the equatorial plane with a third histidine in the axial 
position. Removal of one of the histidine residues, or the N-terminal amino 
coordination, from the equatorial plane is replaced by the histidine that had 
originally occupied an axial position. At room temperature it might be more 
appropriate to think of the Cu2+ complex as quite dynamic with two histidines in the 
equatorial plane and a third histidine axially coordinating, exchanging between each 
other, as shown in Figure 4.11. Without crystallographic data the proposed 
coordination geometry is only a tentative model of the Cu-Aβ complex. In support 
of the model, the EPR spectrum of Aβ(Ac10-16), which only has two potential 
nitrogen ligands in the equatorial plane has a similar appearance to complex I. 
 
The presence of axial ligands contributing to the tetragonal Cu2+ complex has 
largely been ignored in the literature, as they have little influence on EPR spectra. 
However axial ligands will stabilise the Cu2+ complex and affect main-chain 
conformation and biophysical properties. A study using extended X-ray absorption 
fine structure spectroscopy (EXAFS) found a distorted six-coordinated (3N3O) 
geometry around copper in the Aβ-Cu2+ complex, including three histidines, 
glutamic, or/and aspartic acid, and axial water. Thus supporting a potentially 
important role for axial ligands in the complex (Streltsov, et al. 2008). 
 
A recent study using cw-EPR and 15N labelled His analogs together with 
HYSCORE-EPR presents some similarities with the model in Figure 4.11. The low 
pH complex observed contained a mixture of species with only two of the three 
imidazoles coordinating in the equatorial plane, and His6 was described as the 
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anchor in their complex (Drew, et al. 2009). Interestingly the results in this chapter 
show that the H6A analog had a more significant reduction in affinity for Cu2+ ions 
than H13A or H14A (Table 4.1), which supports this assertion. Other conclusions 
drawn by Drew et al for the equatorial ligands appear not to be compatible with this 
data, in particular, the lack of the inclusion of the N-terminal amino group in the 
high pH complex (Drew, et al. 2009, Drew, et al. 2009). The evidence in this chapter 
strongly supports the role of the N-terminus in complex II, as EPR spectra of two 
peptides which are N-terminal acetylated show that they will not form the high pH 
complex. This strongly indicates that complex II involves coordination from the N-
terminal amino group presumably within the equatorial binding plane, as shown in 
Figure 4.11.  
 
The pKa of N-terminal amino groups are typically 8.0. The pH at which the N-
terminal amino group deprotonates may match the formation of complex II 
(dominant at pH 9), particularly if the pKa for the N-terminus of Aβ is a little higher 
than is normally observed. A study by Karr and Szalai (Karr, et al. 2007) found that 
when Asp1 was replaced with Asn it favoured the formation of complex II. This 
might be explained by the stabilizing effect of the negative carboxylate of Asp1, 
which will raise the pKa of the N-terminal amino group closer to pH 9 compared to 
an Asn side chain at the same position. It seems probable that the mutation of Asp to 
Asn promotes the change of the N-terminal amino coordination from an axial 
position to the equatorial plane, thus supporting the model of coordinating ligands 
shown in Figure 4.11.  
 
Previous studies using visible-CD at physiological pH and below suggest main chain 
coordination is not taking part in the complex (Syme, et al. 2004). The CD spectrum 
at neutral pH shows a lack of d-d transition CD bands ~ 600 nm, suggesting minimal 
vicinal effects, which occur when the asymmetric α-carbon is held in a chelate ring 
between two chelating donor atoms (e.g. adjacent main-chain amides) (discussed in 
Chapter 2). This is indicative that main-chain amide coordination is not taking part 
in the complex at physiological pH and below, although it is possible it might take 
part at higher pHs.  
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There is much debate in the literature as to the source of the oxygen ligand in the 
equatorial plane, water is a possibility but Karr and Szalai found that substituting 
H2
17O for H2
16O did not affect hyperfine splitting in their spectra suggesting that 
water is not an equatorial ligand to Cu2+ in Aβ(1-40). The Tyr10 hydroxyl group has 
previously been suggested (Miura, et al. 2000) as a ligand but has since been shown 
to be unlikely by 1H NMR (Syme, et al. 2004) which shows no significant 
broadening of the tyrosine ring protons. This is also supported by a the lack of Cu2+ 
charge-transfer bands associated with Cu-Tyr (Guilloreau, et al. 2006, Kowalik-
Jankowska, et al. 2003). Carbonyl main chain Cu2+ coordination is also a possibility, 
however coordination of oxygen from one of the four carboxyl side-chains (Asp1, 
Glu3, Asp7 and Glu11) in the first sixteen residues is most probable. Karr et al. 
showed that the EPR spectra for D1N and E3Q analogs left complex 1 unchanged 
(Karr and Szalai 2007), although removal of Asp1 might simply result in it being 
replaced by an alternative carboxylate ligand which would give a very similar EPR 
spectrum. Asp1 and Asp7 (adjacent to His6) are favoured as potential oxygen 
ligands for complex I, as shown in Figure 4.11. This is because the H6A analog is 
more destabilised than H13A or H14A (see Figure 4.4 for pH dependence and Table 
4.1 for affinities), and coordination of the carboxyl and N-terminal amino group of 
Asp1 will form a stable six-membered chelate ring with the Cu2+ ion. A very recent 
study using 13C labelled Asp1 and HYSCORE EPR suggested Asp1 carboxylate 
coordination in the low pH complex (Drew, et al. 2009). 
 
Ab-initio molecular modelling of the His13-His14 Cu2+ binding site suggests a trans 
arrangement of the two imidazole rings with a main-chain carbonyl of His13 
coordinating between the two His residues (Raffa, et al. 2005, Rauk 2008). However 
this type of complex is likely to generate appreciable d-d transition signals which are 
not observed by CD (Syme, et al. 2004). In contrast a crystal structure of a model 
compound containing a di-peptide analog of two adjacent histidine residues has been 
reported (Hori 1979). In this compound, Cu2+ chelates to the εN of both imidazole 
rings making a cis-arrangement rather than trans coordination (90o rather than 180o) 
to the Cu2+ ion in a square-planar arrangement. Sterically, this type of ligand 
arrangement could facilitate the coordination of the N-terminus and His6 without 
any obvious restrictions, but would stop main-chain coordination to Cu2+, as implied 
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by the lack of visible-CD signal from d-d transitions lending support to the proposed 
model shown in Figure 4.11. 
 
4.5.3. Stoichiometry and the Second Binding Site  
It is well established that two Cu2+ ions bind to fragments Aβ(1-16) and Aβ(1-28) 
(Curtain, et al. 2001, Syme, et al. 2004). It was therefore surprising that the longer 
full length Aβ only binds one mole equivalent of Cu2+ ions with appreciable affinity, 
with a clear break point and saturation of the signal at one mole equivalent (at 50 
µM peptide concentration). The difference between Aβ(1-28) and Aβ(1-42) is the 14 
additional residues in the hydrophobic tail of Aβ(1-42); however the potential two 
Cu2+ binding sites are in the first 16 residues. A possible explanation for the 
decreased binding stoichiometry of Aβ(1-42) compared to Aβ(1-28) may be 
hindrance to the second Cu2+ binding site by the hydrophobic tail in Aβ(1-42). To 
test this hypothesis the hydrophobic interactions were disrupted. Alcohols, such as 
methanol, are thought to disrupt tertiary interactions and allow local interactions 
(hydrogen bonding) to dominate within the polypeptide chain (Kony, et al. 2007). 
After adding 20 % (v/v) methanol, Aβ(1-42) bound a second Cu2+ ion as seen for the 
shorter Aβ(1-28) peptide. 
 
In agreement with this study (in the absence of methanol) others have indicated a 1:1 
stoichiometry for Aβ(1-40) (Garzon-Rodriguez, et al. 1999, Tougu, et al. 2008). In 
contrast a recent study reported that Aβ(1-40) can bind two Cu2+ ions (Atwood, et al. 
2000). However for this study a cryoprotectant (50 % v/v glycerol) was used. This 
alcohol (a triol), like methanol is known to reduce hydrophobic interaction and 
promote intra-molecular hydrogen bonding (Jones, et al. 1996). Thus the glycerol 
has the same affect shown here for 20 % (v/v) methanol and explains the 
discrepancy in the stoichiometries reported. 
 
The nature of the second Cu2+ binding site is not well understood. It is clear that it is 
contained within the first 16 amino acids (Syme, et al. 2004). EPR suggests that this 
binding site is also tetragonal or square-planar with the AII and gII shifted to values 
more typical for oxygen than nitrogen ligands, perhaps 3O1N. It is possible that the 
first equivalent of Cu2+ binds to all 3 histidine residues, although one His is probably 
an axial ligand, it is notable that as the second mole equivalent of Cu2+ is added the 
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binding mode of the first equivalent does not appear to be perturbed. It is therefore 
likely that the second mode of binding is rich in carboxylate ligands (D1, E3, D7 and 
E11) and perhaps a single nitrogen ligand; the N-terminus or His13/14. Support for 
this comes from comparison of the EPR spectra of Aβ(1-11), which contains two 
potential nitrogen ligands. This fragment reveals a very different spectrum from that 
of the second mole equivalent spectra of Aβ(1-28). Thus this suggests a complex 
containing the N-terminus and His6 can be ruled out for the second weak-binding 
site on Aβ. The affinity of the second mole equivalent has been determined to be 10-
5 M (Guilloreau, et al. 2006). 
 
4.5.4. Biological Significance  
It seems clear that Aβ fibres once formed are able to accommodate the coordination 
of Cu2+ ions. Indeed Cu2+ ions are found concentrated within amyloid plaques bound 
directly to Aβ (Dong, et al. 2003, Miller, et al. 2006). The affinity, coordination 
geometry, and stoichiometry are unaffected by the form of Aβ; monomeric or 
fibrillar. In particular Aβ fibrils are able to accommodate a full stoichiometric 
complement of Cu2+ ions, and the β-sheet secondary structure is unperturbed. 
 
The studies described in this chapter have made a significant contribution to 
understanding Cu2+ coordination in both monomeric and fibrillar form. It is known 
that Cu2+ homeostasis within the brain is impaired in AD patients (Bush 2003, 
Cuajungco, et al. 1997). It is possible that increasing Cu2+ levels may promote Aβ 
oligomerisation and Cu2+ loaded fibres may be more resistant to clearance, thus 
explaining the elevated level of Cu2+ ions in amyloid plaques (Lovell, et al. 1998, 
Miller, et al. 2006).  
 
The data in this chapter suggests Cu2+ ions are not involved in Aβ cross-linking 
within fibres. Cu2+ is certainly able to bind Aβ fibres once formed, less well 
understood is the potential effect Cu2+ has on inducing fibre formation. It is well 
established that in vitro Cu2+ significantly reduces the solubility of Aβ (Atwood, et 
al. 1998, Bush, et al. 1994, Huang, et al. 2004, Sengupta, et al. 2003), but only 
induces the formation of amorphous aggregates rather than amyloids (Raman, et al. 
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2005, Yoshiike, et al. 2001). In the next chapter the effect of Cu2+ ions on the rate of 
formation of fibres is investigated. 
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Abstract 
The role of Cu
2+
 ions in AD is often disputed, as it has previously been shown in 
vitro that Cu
2+ 
ions inhibit fibre formation and only result in non-toxic amorphous 
aggregates of Aβ. In contrast, in this chapter it is shown that the presence of 
stoichiometric and sub-stoichiometric levels of Cu
2+
 ions profoundly increases the 
rate of production of amyloid fibres, doubling the rate of nucleation and elongation 
of amyloid formation. The stoichiometry of Cu
2+
 ions is shown to be crucial, up to 
and including 1 mole equivalent accelerates fibril formation. However at Cu
2+
 
concentrations higher than 1 mole equivalent amorphous aggregation is favoured 
and fibril formation does not occur.  
 
An explanation for the effect of Cu
2+
 ions on fibril growth is developed through pH 
studies. Fibril growth with or without Cu
2+
 is highly pH-dependent, strongly 
influencing the likelihood of Aβ self-association. Additionally Cu
2+
 coordinates to 
Aβ through Aβ’s histidines, and it is shown that the rate of fibril formation is closely 
related to the protonation state of histidine residues within Aβ. Thus it is found that 
the binding of Cu
2+
 ions at a physiological pH causes Aβ to approach its isoelectric 
point, inducing self-association and fibre formation. Finally it is found that as the pH 
drops closer to the pI of Aβ, or alternatively as the stoichiometry of Cu
2+
 binding 
increases, the rate of fibril formation increases until it is over-taken by amorphous 
aggregation. Thus a delicate balance between fibril formation and amorphous 
aggregation is found.   
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5.1. Introduction 
The factors affecting the rate of fibril growth are described in this introduction. 
Fibril formation, including detection methods, oligomeric species and monomeric 
and fibrillar structures are discussed in Chapter 1. 
 
5.1.1. Influences on Fibril Formation 
Determining the mechanisms of fibril formation is crucial in understanding and 
perhaps controlling AD onset and progression. Formation of fibrils requires a 
considerable amount of organisation of Aβ monomers, and unfavourable forces that 
would destabilise Aβ fibrils must be offset by forces that stabilise Aβ fibrils. There 
are a range of factors that can influence whether or not a protein will form fibrils, 
and how rapidly it will do so. Some of these factors have been optimised in the fibril 
growth studies described in this chapter, and so are discussed here in more detail.  
 
The propensity of fibril formation to occur is based on a range of intrinsic and 
extrinsic factors. Intrinsic factors refer to properties of the peptide or protein itself 
which favour fibril formation, whereas extrinsic factors refer to external conditions 
such as pH, ionic strength, and protein concentration. These factors have been 
studied in some depth by various groups, and equations have been developed which 
can predict the aggregation rate of a protein.  
 
DuBay et al included both intrinsic and extrinsic factors in their equation and found 
an impressive correlation coefficient of 0.92 of the predicted aggregation rate and 
the actual experimental aggregation rate. (DuBay, et al. 2004). A more recent 
algorithm is AGGRESCAN, which predicts aggregation-prone segments of protein 
sequences (Conchillo-Sole, et al. 2007). This method identifies areas of the 
polypeptide which have been identified experimentally as ‘hot spots’. An 
impressively large list of 24 different disease-linked polypeptides were studied and 
compared to existing experimental data. The authors conclude that blocking the hot 
spots of aggregation may be a strategy for designing therapeutics. A second method 
for predicting aggregation is the Zyggregator method, which uses three physico-
chemical properties, hydrophobicity, charge and the propensity to form α-helical or 
β-sheet structure in an equation (Tartaglia, et al. 2008). The Zyggregator algorithm 
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determines the effect of mutations in the polypeptide sequence upon protein 
aggregation rates. 
 
Log(k/k’) = αhydr∆I
hydr 
+ αSS∆I
ss 
+ αch∆I
ch 
 
Where the parameters α were obtained through fitting the above equation to a 
database of mutational variants with known aggregation rates from in vitro 
experiments. Log(k/k’) is the logarithm in base 10 of the ratio of k, the aggregation 
rate of the wild type and k’, the aggregation rate of the mutant, and the change in 
hydrophobicity (∆I
hydr
), secondary structure propensity (
 
∆I
ss
)
 
and charge (∆I
ch
). 
Experimental changes in aggregation rates correlated well (R = 0.85) with 
predictions produced through the Zyggregator method. Both AGGRESCAN and the 
Zyggregator method assume that the sequence of a protein is wholly responsible in 
determining the likelihood of aggregation, in contrast to DuBay et al’s equation 
which includes external factors such as ionic strength and pH.   
 
 
5.1.2. Intrinsic Factors 
Hydrophobic interactions play an important role in folding and misfolding. Protein 
folding is thermodynamically driven to result in the most stable structure, and 
subsequently hydrophobic residues are clustered and buried, rather than on the 
protein surface. Replacement of nonpolar residues with polar residues results in 
inhibition of Aβ(1-42) fibril formation and an increase in the peptide’s solubility 
(Wurth, et al. 2002). Additionally Wurth et al’s study showed that replacing 
nonpolar residues with other nonpolar residues had little or no effect, suggesting the 
hydrophobicity of residues is the most important factor in promoting fibril formation 
rather than specific amino acid interactions. 
 
NH and CO groups in the peptide backbone are thermodynamically more favourable 
in water compared to a nonpolar environment, which causes conflict when they are 
next to hydrophobic side chains. To solve this thermodynamic mismatch, NH and 
CO groups form hydrogen bonds. Hydrogen bonds play a crucial part in influencing 
the propensity of proteins with β-sheet secondary structure to form fibrils. Rational 
design of peptides shows that β-sheet proteins favour intermolecular aggregation 
over intramolecular folding (Wang, et al. 2002). This is due to the difference in 
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hydrogen bonding between the two different secondary structures. Whereas 
backbone hydrogen bonding in an α-helix can be mainly “satisfied” without needing 
to oligomerise, in β-strands the C=O and N-H groups form hydrogen bonds to N-H 
and C=O bonds on neighbouring strands.  
 
Hydrophobic patterns are also important in predicting aggregation rates. DuBay et al 
found that patterns of five consecutive hydrophobic and hydrophilic alternating 
residues correlated significantly with the experimental values of aggregation rates, 
i.e. the more patterns of this type the faster the aggregation rate. Based on this, it is 
unsurprising that β-strands which avoid hydrophobic patterns are much more 
common in nature than those which contain them (DuBay, et al. 2004). 
 
Charge is also highly important in affecting the propensity for fibril formation. Two 
reasons why this could be are: 
 
(1) Specific charge-charge interactions between imidizolium groups on histidine 
residues and the carboxylate groups on aspartate and glutamate could 
stabilise oligomers.  
(2) Electrostatic repulsion: when the protein has a net positive or negative charge 
it is less likely to dimerise. 
 
Experimental evidence suggests that electrostatic repulsion is more influential than 
specific charge-charge interactions. Fraser et al showed that substituting amino acids 
with opposite charges, e.g. histidine to aspartate, did not prevent fibril formation 
(Fraser, et al. 1994), suggesting a loss of specificity will not prevent fibril formation. 
Likewise four of the mutations that cause familial Alzheimer’s disease: Iowa Asp23 
 Asn, Arctic Glu22  Gly, Dutch Glu22  Gln and Italian Glu22  Lys result in 
a decrease in the net charge of Aβ at physiological pH. DuBay et al also found that 
fibril formation rates were inversely proportional to the absolute value of the net 
charge, i.e. the lower the net charge (the closer to 0) the faster the aggregation rates 
(DuBay, et al. 2004). Thus electrostatic repulsion must be overcome for fibril 
formation to occur. 
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5.1.3. Extrinsic Factors 
The influence of pH on fibril formation is closely linked to the importance of charge, 
as the external pH approaches a protein’s pI, i.e. a net charge of 0, electrostatic 
repulsion will decrease and aggregation will increase. Salt can also effect fibril 
formation: as salt concentration increases, protein solubility decreases (salting out). 
This is due to increasing additions of salt reducing the number of water molecules 
available to the hydrophilic residues on the surface of the protein, causing protein-
protein interactions to become stronger than solvent-protein interactions. 
Additionally salt ions can shield the ionic charges of the protein, reducing 
electrostatic repulsion. These two effects will increase protein self-association and 
the likelihood of fibril formation or protein aggregation. This is supported by fibril 
growth studies where monomer oligomerisation was found to be highly dependent 
on ionic strength (Johansson, et al. 2006) and protofibril association required salt to 
minimise electrostatic repulsion between the two axial sides of the fibrils and allow 
lateral association to take place (Lin, et al. 2008, Nichols, et al. 2002). DuBay et al 
found that the accuracy of the fibril growth rate predictions from their equation 
improved when ionic strength was included (DuBay, et al. 2004).   
 
In addition to controlling the salt concentration, temperature and agitation are often 
manipulated in fibril growth experiments. Specific stages of Aβ fibril formation are 
highly temperature dependent. Raised temperatures shorten the lag phase and 
accelerate nucleation, but do not affect the elongation stage of fibril formation (Lin, 
et al. 2008). Agitation is performed widely in the literature to aid formation of 
fibrils. Lee et al found an increase in fibril formation in the presence of agitation by 
a factor of 2-4 (Lee, et al. 2007). Additionally agitation can affect fibril structure 
(Petkova, et al. 2005), possibly because agitation accelerates nucleation, preventing 
intramolecular structural rearrangement and instead favouring rearrangement on an 
intermolecular scale. In contrast quiescent conditions allow longer time for 
intramolecular rearrangements, resulting in increased stability and more 
energetically favourable structures to form (Lee, et al. 2007).  
 
DuBay et al found that the rate of fibril formation increased with peptide 
concentration (DuBay, et al. 2004). A higher protein concentration increases the 
likelihood of protein association. This could effect nucleus formation, if the nucleus 
                                                                          Chapter 5. Cu
2+
 ions Accelerate Fibril Growth 
 
157 
is of a certain number of protein molecules (see Chapter 1), and also elongation. 
However a high protein concentration may favour aggregation over fibril formation. 
The concentration dependent nature of fibril formation can be likened to the 
crystallization of proteins, in which overly precipative conditions for self-association 
will cause amorphous aggregates rather than ordered crystals to form. This fine line 
between fibril formation and aggregation may explain why some studies found no 
effect on fibril formation with increased protein concentration (Johansson, et al. 
2006). 
 
Disagreements over which factors are more important in aiding or hindering fibril 
formation are common; this is especially true for metal ions. Studies showed more 
than a decade ago that Zn
2+
 and Cu
2+ 
ions cause marked aggregation of Aβ (Atwood, 
et al. 1998, Bush, et al. 1994). However, further investigations suggested that Zn
2+
 
and Cu
2+
 promote amorphous aggregation of Aβ and actually inhibit fibre formation 
and cell toxicity (Raman, et al. 2005, Yoshiike, et al. 2001). In this study, 
temperature, agitation, salt concentration, pH, metal and peptide concentration are 
all optimised and manipulated to promote fibril formation and minimise aggregation.  
 
5.2. Aims 
• Optimise the fibril growth assay to promote fibril formation and minimise 
amorphous aggregation. 
• Determine if there is a role for Cu2+ ions in promoting fibre formation. 
• Extract rate constants from fibril growth curves to allow comparison between 
lag times and elongation rate. 
• Ascertain any differences between Aβ(1-40) and Aβ(1-42) fibril formation. 
• Determine the effect of peptide and metal concentrations and pH on fibril 
formation rates.  
 
5.3. Experimental 
For peptide solubilisation, the theoretical background of the use of Thioflavin T, and 
the specifics of transmission electron microscopy experiments please refer to 
Chapter 2.   
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5.3.1. Fibril Growth 
Fibre growth kinetics are very sensitive to a number of factors that must be carefully 
controlled. They include the pH, concentration, agitation, temperature and ionic 
strength. Solubilisation of Aβ into a seed-free form is also important; the method for 
peptide solubilisation, and evidence to suggest it is seed-free, is discussed in Chapter 
2. Fibre growth experiments were typically with 5 µM Aβ(1-40) or 3 µM Aβ(1-42) 
and the peptide was incubated at 30 
o
C in 160 mM NaCl, 50 mM HEPES buffer. 
This temperature and salt concentration allowed reproducible fibril formation 
growth curves, with a lag phase and a high concentration of fibrils at the end of 
incubation (as determined by ThT fluorescence). Additionally 160 mM NaCl is 
physiologically relevant (Lazarus-Barlow 1896). HEPES was used for its low 
affinity for Cu
2+
 and Zn
2+
 ions (see Table 2.1 in Chapter 2). Agitation was optimised 
to 30 seconds orbital shaking every 30 minutes. 
 
Fibril formation was monitored by a BMG Fluostar Galaxy fluorometer. This 
fluorometer allowed 96 well plates to be used and temperature and agitation to be 
controlled. An excitation filter wavelength of 440 nm and an emission filter 
wavelength of 490 nm were used. 50-100 flashes (readings) were taken, and shaking 
was orbital and over a shaking width of 3 mm. 96 well plates used were sterile, flat 
bottomed and from Becton Dickinson. To minimise evaporation in the experiments 
the plates were sealed with Starseal polyolefin film sealing tape (Starlabs) and the 
wells were filled to 300 µL to reduce the volume of air in the plate. 
 
Small adjustments were made with 10 mM NaOH or HCl to the stock Aβ solutions. 
The pH, a critical parameter in fibre growth rates, was measured before and after 
each fibre growth experiment; variations were ±0.05 pH units or less over the course 
of the experiment. Metal stock solutions were CuCl2 25 mM and ZnCl2 20 mM or as 
a Cu(Gly)2 chelate. The Thioflavin T (ThT) stock was dissolved in water to 2 mM, 
and kept foil wrapped and at 5 °C, then a small volume added to the experimental 
sample to give a final concentration of 10 µM. UHQ water (10
-18
 Ω
-1
cm
-1 
resistivity) 
was used at all times. 
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5.3.2. Growth Curve Analysis  
Conversion of essentially monomeric Aβ to fibrillar Aβ follows a characteristic 
sigmoidal growth curve, Figure 5.1a. This is characterised by an initial lag phase 
followed by a rapid growth phase in which ThT fluorescence markedly increases, 
and a final equilibrium phase where ThT fluorescence reaches a plateau. 
 
A number of empirical parameters can be obtained from a fibre growth curve. To aid 
comparison of fibril growth rates under different conditions Origin 7 was used to fit 
the experimental data to two different equations. These equations are widely used in 
the literature and were found to give the best fit to the experimental data. Figure 5.1b 
and 5.1c show the parameters used in both equations. 
  
Equation 1 includes the time needed to reach half maximal ThT intensity (t50) and 
the lag-time. The t50 is influenced by both the nucleation and elongation phase. 
These values can readily be extracted from the data by fitting the growth curve to the 
following equation (Uversky, et al. 2001). 
 
)/xox(
ff
ii
e1
xm
)xmy(Y
τ−−+
+υ
++=     (eq 1) 
 
Where Y is the fluorescence intensity, x is the time, Xo is the time at half height of 
fluorescence (t50). The apparent fibre growth rate is kapp=1/τ and the lag time (tlag) is 
Xo-2τ.  Equation 1 allows for a slope in the initial and final parts of the growth 
curve, (yi +mix), (υf+mfx), rather than forcing these to be horizontal. Table 5.1 
shows the t50, Xo; t(lag), (Xo - 2dx) and kapp(1/dx) derived from three data sets. 
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Figure 5.1. Fibril growth curves. (a) A typical fibril growth curve, monitored by ThT 
fluorescence, with a lag phase and elongation phase. (b) Key parameters used in 
equation 1 (Uversky et al. 2001), Y is the fluorescence intensity, x is the time, Xo is the 
time at half height of fluorescence (t50). (c) shows parameters from equation 2 (Morris et 
al. 2008), where [B]t is the fibrillar concentration as measured by the ThT signal and k1
(units of hrs-1) is proportional to the lag time and k2 is proportional to the slope during 
elongation.
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Equation 2 describes two rate constants for the initial nucleation and elongation 
process (Morris, et al. 2008). Firstly k1 describes the monomer converting into a 
nucleating species. The second rate constant (k2) describes monomer addition on to 
the nucleating species (elongation), see Table 5.2. It should be noted that k2 is 
simply an average rate of multiple additions and assumes that the rate constant is 
independent of fibre size.  
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Where [B]t is the fibrillar concentration as measured by the ThT signal and [A]0 is 
the total concentration of Aβ in monomeric and fibrillar form: [A]0=[B]t+[A]t (where 
[A]t is the amount of monomer at time t. k1 (units of hrs
-1
) is proportional to 1/lag 
time and k2[A]0 is proportional to the slope during elongation. These parameters are 
shown in Figure 5.1c. Thus k1 describes the lag-phase (nucleation) and k2 describes 
the growth phase (elongation).  
 
Kinetic parameters have been extracted from between 6 and 9 raw traces. Mean 
values with 1 standard error (SE) are given in Tables 5.1 and 5.2. A paired t-test was 
used to confirm the significance of the difference between the kinetics with and 
without Cu
2+
 ions. 
 
5.3.3. 1H NMR  
The pH dependent protonation state of the three histidine side-chains of Aβ were 
determined from 
1
H NMR chemical shifts of the εH and δH protons, recorded at 0.5 
pH unit intervals between pH 5 and 9. The singlet chemical-shift of the εC and δC 
protons were readily identified from the 1D 
1
H NMR spectra, His CεH and CδH 
assignments were confirmed using 2D 
1
H Total Correlation Spectroscopy (TOCSY) 
spectra, using standard acquisition parameters and a spin-lock of 60 ms. Assignment 
of the His6, His13 and His14 residues was based on previous 
1
H NMR studies with 
H6A H13A and H14A analogs (Syme, et al. 2006). The Aβ(1-28) fragment was 
used rather than full-length Aβ(1-40) to improve solubility. 10 µM DSS (sodium 2,2 
dimethyl-2-silapentane -5-sulphonate) was used as a reference. 0.1 mM Aβ(1-28) in 
50 mM phosphate buffer, in 90 % H2O, 10 % D2O, at 25 
o
C. The pH dependent 
shifts for ε and δ protons were fitted to a modified Hill equation to determine pKa 
for His6, His13 and His14.  
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5.4. Results and Discussion 
5.4.1. Copper Accelerates Fibril Growth Rates  
Using the well-established amyloid binding Thioflavin T (ThT) fluorescence assay, 
fibre formation was investigated over a range of Aβ(1-40) concentrations, with and 
without the presence of Cu
2+
 ions. Aβ(1-40) concentrations of greater than 10 µM, 
pH 7.4, showed no detectable amyloid fibrils in the presence of 1 mole equivalent 
Cu
2+
 ions, as previously reported (Raman, et al. 2005, Yoshiike, et al. 2001). 
However, when more dilute conditions of Aβ(1-40) were investigated, of between 5 
and 2 µM, rapid fibre formation was detected in the presence of Cu
2+
 ions. Figure 
5.2 shows that Cu
2+
 ions significantly increase the rate of Aβ(1-40) fibre formation 
at pH 7.4. In Figure 5.2a multiple ThT fluorescence traces are shown, with and 
without Cu
2+
 ions present, the ThT readings are absolute (not normalised). Figure 
5.2b shows normalised data from the mean of nine measurements repeated on two 
separate occasions (individual fluorescence traces are shown in Figure 5.3b and c). 
Metal-free Aβ(1-40) preparations typically take more than 70 +/- 2 hours to reach 
half maximal fluorescence (t50), while the same Aβ(1-40) preparations with 0.5 or 1 
mole equivalent of Cu
2+
 ions cause fibres to form in nearly half the time; 38 +/- 2 
hours, (Figure 5.2c). A paired t-test confirms that Cu
2+
 ions significantly increase 
fibre growth rates with 99.9 % confidence. Kinetic parameters taken from the fibre 
growth curves are given in Tables 5.1 and 5.2. 
                                                                          Chapter 5. Cu
2+
 ions Accelerate Fibril Growth 
 
163 
 
Figure 5.2. Cu2+ accelerates fibre growth. (a) Fibre growth curves with 0.5 
mole equivalent Cu2+ (blue traces) and without Cu2+ (red traces) at pH 7.4. Six 
traces are shown for each condition and the ThT fluorescence values are 
absolute. Aβ(1-40) 5 µM, HEPES buffer 50 mM, 160 mM NaCl at 30 ºC.  (b) 
Average of 9 growth curves recorded on two separate occasions, apo in red, 1 
mole equivalent Cu2+ in blue. The fluorescence signal is normalised at maximal 
intensity. (c) Time to reach half-maximal fluorescence (t50) in two experiments 
with 0 (red), 1 (mid-blue) or 0.5 (dark blue) mole equivalents of Cu2+ ions. The 
presence of Cu2+ typically halves the time taken to form fibres. Error bars are for 
standard error from nine traces. 
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Figure 5.3. Cu2+ accelerates Aβ fibril growth. Comparison of Cu2+ loaded (blue 
traces) and Cu2+-free (red traces). Aβ(1-40) at 5 µM, pH 7.4 in the presence of (a) 2.5 
µM Cu2+, or 5 µM Cu2+ in (b) and (c). Figures (b) and (c) are from two separate 
experiments. All carried out in 50 mM HEPES, 160mM NaCl, 30º C, with agitation 
for 30 seconds every 30 minutes. The ThT fluorescence intensities have been 
normalized. Averages of the nine traces are shown in Fig. 4.2(b). 
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Table 5.1.  Kinetic Data from fibril growth curves using equation 1. Data 
obtained from fitting equation 1 to the graphs shown in Figure 5.2 and 5.3, with 
the standard error shown in parentheses. (a) is taken from the data shown in Figure 
5.2a, (b) is taken from the data shown in Figure 5.3a and b and (c) obtained from 
fitting to Figure 5.3c. Equation 1 determines the kinetics parameters: t50 (Xo), tlag
(Xo - 2dx) and kapp (1/dx) with the number of traces shown in n. 
80.12 (0.02)16 (4)36 (2)1.0 
Cu2+
90.091 (0.006)49 (2)72 (1)Apo(c)
90.17 (0.03)28 (3)41 (3)1.0 
Cu2+
80.20 (0.06)14 (3)20 (3)0.5 
Cu2+
90.09 (0.03)53 (8)68 (2)Apo(b)
60.20 (0.01)32.2 (0.8)42.6 (0.6)0.5  
Cu2+
60.120 (0.007)55 (3)72 (2)Apo(a)
nk
app 
(hrs-1)t
lag
(hrs)t
50
(hrs)
 
 
Inspection of the growth curves indicates that both the nucleation and elongation 
rate are accelerated by Cu
2+
 ions for Aβ(1-40). The average t50 time, based on the 
data sets shown in Figure 5.2 and 5.3, is 71 hours for apo-Aβ, 31 hours for Aβ-0.5 
mol eq Cu
2+
, and 39 hours for Aβ-1 mol eq Cu
2+
. The average tlag time is 52 hours 
for apo-Aβ, and 23 hours for Aβ-0.5 eq Cu
2+
 and 22 hours for Aβ- 1 eq Cu
2+ 
(Table 
5.1). The lag-time is particularly reduced by Cu
2+
 ions. 
 
Using the second equation, where the nucleating rates and elongation rates are 
obtained. The average apo nucleating rate is 0.21 * 10
-3 
h
-1
, whereas in the presence 
of 1 mol eq Cu
2+
 it is three times faster, at 0.63 * 10
-3 
h
-1
. The elongation rate is 
twice as fast in the presence of 1 mol equivalent Cu
2+
. The results of these equations 
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suggest that the effect of Cu
2+
 ion on Aβ(1-40) fibril formation is to accelerate both 
the nucleation and elongation stages of fibril growth. 
 
 
  Nucleating Rate (x 10
-3
) Elongation Rate (x10
-3
) 
(a) Apo 0.037 (0.017) 0.117 (0.007) 
 50% Cu
2+ 
0.16 (0.03) 0.147 (0.004) 
 
(b) Apo 0.19 (0.07) 0.098 (0.008) 
 100% Cu
2+
 0.15 (0.06) 0.19 (0.00) 
 
(c) Apo 0.41 (0.08) 0.073 (0.005) 
 100% Cu
2+
 1.1 (0.4) 0.14 (0.02) 
 
 
 
 
Table 5.2. Nucleating and elongation rate obtained from equation 2. Data 
obtained from fitting to the data shown in (a) Figure 5.2a,(b) Figure 5.3b and (c) 
Figure 5.3c. The standard error is shown in parentheses.
 
 
Interestingly, in studies with Aβ(1-42), at 1, 3 and 5 µM, the growth curves in 
Figure 5.4 show that the lag phase is of a similar length both in the presence and 
absence of Cu
2+
, however the elongation rate is faster when Cu
2+
 is present. A 
possible reason for the nucleation rate of Aβ(1-42) being unaffected by the presence 
of Cu
2+
, whereas in Aβ(1-40) it is notably reduced, is the formation of a different 
nucleating species. Different fibril forming nuclei for Aβ(1-40) and Aβ(1-42) have 
been suggested (Bitan, et al. 2003) and are discussed further in Chapter 1 Section 
1.6.3.  
 
The second interesting aspect of Cu
2+
 induced fibril formation of Aβ(1-42) is that 
total Aβ fibre content is significantly enhanced by the presence of Cu
2+
 ions at 3 and 
5 µM in contrast to Aβ(1-40), where, as seen in Figure 5.2a, fibrils formed faster but 
the end ThT signal was lower in the presence of Cu
2
. It is possible that this is a result 
of Cu
2+
 not accelerating the nucleating stage of Aβ(1-42) fibril growth. This allows 
more time for intramolecular organisation of the fibril and subsequently more stable 
fibre formation, whereas in Aβ(1-40) Cu
2+
 accelerates nucleation to the point where 
there is some aggregate formation, even at low Cu
2+
 concentrations.  
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Figure 5.4. Cu2+ accelerates Aβ(1-42) fibril growth. Aβ(1-42) at (a) 
1 µM, (b) 3 µM  and (c) 5 µM  with and without 0.5 mole equivalents 
Cu2+ ions. Growth curves are a sum of 6 traces. Absolute ThT 
fluorescence intensity is shown. All carried out in 50 mM HEPES,
160mM NaCl, 30º C, with agitation for 30 seconds every 30 minutes. 
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Copper was also added bound to a chelate to mimic in vivo conditions where there is 
very little free Cu
2+
. In the experiments shown in Figure 5.5 Cu
2+
 was added as a 
Cu(Glycine)2 chelate. However this produced identical results to adding Cu
2+
 alone.  
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Figure 5.5.  Fibril growth with Cu2+ as a Cu(Gly)2 chelate. Comparison of 
5 µM Aβ(1-40) with no Cu2+ (red spectra), 2.5 µM Cu2+ (blue spectra partly 
hidden) and 2.5 µM Cu2+(glycine)2 chelate (green spectra). The ThT 
fluorescence intensities of the data have been normalized, however the 
addition of glycine made no difference to either the rate or intensity of the 
fibril growth curve compared to adding Cu2+ alone, and the sets of traces (2 x 
5 traces) overlap. 5 µM Aβ(1-40) in 50 mM HEPES, 160 mM NaCl, pH 7.4, 
30º C, with agitation for 30 seconds every 30 minutes. 
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5.4.2. Morphology of the Cu2+ Induced Fibrils 
The nature of the Cu
2+
 promoted amyloids was then characterized. Transmission 
electron microscopy (TEM) images indicate the presence of fibres (Figure 5.6). 
Based on TEM images, under these conditions, the morphology of the fibres 
generated appears quite similar for fibres formed with and without the presence of 
Cu
2+
 ions. It is noted that previous studies by other groups using TEM did not reveal 
fibres in the presence of Cu
2+
 because the high Aβ and Cu
2+ 
concentrations used 
caused amorphous precipitation (Raman, et al. 2005, Yoshiike, et al. 2001).  
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Figure 5.6. TEM images of Aβ(1-42) fibrils formed in the absence (a) 
and presence (b) of Cu2+ ions. The morphology of fibres formed with and 
without Cu2+ ions present are similar, typically long, straight, unbranched
fibres are observed often stacked together. The scale bar is 50 nm. The 
negatively stained fibres are generated from 3 µM Aβ(1-42) with and 
without 0.5 mole equivalent Cu2+ ions, over 200 hours with agitation every 
30 minutes, at 30 ºC in 50 mM HEPES, 160 mM NaCl. The fibrils were 
then freeze-dried to approximately 0.5 mg/mL. 
 
 
A further test to ensure that fibrils had been made in the presence of Cu
2+
 was to see 
if the Cu
2+
 generated fibres were capable of seeding fibre formation of fresh, metal-
free Aβ(1-40).  Figure 5.7 shows that seeding did occur, indicated by a reduction in 
the lag-time.  
 
5.4.3. pI and Fibril Growth 
How does the presence of Cu
2+
 ions accelerate the rate of fibre formation? At µM 
concentrations of Aβ Cu
2+
 does not form crossed-linked species (Drew, et al. 2009, 
Syme, et al. 2004) and the Cu
2+
 coordination geometry is identical in the monomer 
and fibre (Karr, et al. 2008, Sarell, et al. 2009). This rules out copper bridging to 
form cross-linked Aβ as a possible mechanism of accelerated fibre formation. It is 
also possible that Cu
2+
 coordination may trigger the Aβ misfolding that nucleates 
fibre assembly, however the conformational changes in Aβ upon Cu
2+
 binding are 
small and outside of the fibre core (Sarell, et al. 2009, Syme, et al. 2004). Instead, 
the pH dependency of fibril formation, and Cu
2+
’s effect on the net charge of the 
protein was investigated.  
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Figure 5.7. Cu2+ induced fibrils will seed fibril formation. Comparison 
of 5.5 µM apo Aβ(1-40) (red traces) and 5 µM apo-Aβ with 10 % 
preformed (Cu2+ promoted) Aβ-fibrils (green traces). All carried out in 50 
mM HEPES, 160mM NaCl, pH 7.4, 30º C, with agitation for 30 seconds 
every 30 minutes. The fluorescence intensities are absolute values.
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Fibre growth experiments were performed at a number of pH values (8.0, 8.5, and 
9.0) to see if Cu
2+
 enhanced fibril growth at higher pHs. In each case Cu
2+
 increases 
the rate of fibre formation compared to fibril growth of apo-Aβ (Figure 5.8). Overall 
fibril growth rates become slower as the pH was increased away form the pI of Aβ. 
At pHs below 7.4, amorphous aggregation was favoured over fibril formation and 
subsequently in the presence of Cu
2+
 no fibril growth was observed.  
 
The effect of the net charge of Aβ(1-40) on the rate of fibre formation was 
investigated further and in more detail by monitoring fibre growth of apo-Aβ over a 
wider range of pHs (Figure 5.9). It is clear that as the pH drops from 8.3 to 5.9 the 
rate at which fibres form significantly increases. Figure 5.9b is a plot of lag-times 
versus pH, lag times (tlag) reduce from 170 (+/- 8) hours at pH 8.3 to 23 (+/- 4) hours 
at pH 5.9.  
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Figure 5.8. Cu2+ accelerates Aβ fibril growth over a range of pH’s. 
(a) pH 8 (b) pH 8.5 and (c) pH 9. Blue traces are for Aβ(1-40) with 1 
mole equivalent Cu2+, red traces are for apo Aβ(1-40). (a) and (c) are 
means of the fluorescence from six growth curves. Aβ(1-40) at 5 µM in 
50 mM HEPES, 160 mM NaCl.
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The reason for the pH-mediated increase in fibril growth shown in Figure 5.9 is well 
documented. Intermolecular self-association of peptides and proteins is strongly 
influenced by the net charge of the protein. As Aβ approaches its isoelectric point, a 
pI of 5.3, and an overall neutral charge, its solubility decreases (Hortschansky, et al. 
2005). Histidine is the only amino acid with an ionisable side-chain in the 
physiological pH range, and is also involved in the Cu
2+
 binding complex. To 
determine if the pKa of histidine residues were related to fibre growth, the 
protonation states of histidines within Aβ were investigated and compared to fibril 
formation rates.  
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Figure 5.9. pH dependence of Aβ fibre formation. (a) Fibre growth 
curves (average from 6 traces) between pH 5.5 and 8.7, for Aβ(1-40) 
at 5 µM with 160 mM NaCl. The maximal ThT fluorescence signal 
has been normalized. (b) The lag-times for fibril growth (tlag) versus
pH. The insert indicates the protonation state of the three histidine 
residues of Aβ versus pH, data is based on 1H NMR chemical shift. 
The rate fibres form increases as Aβ approaches its isoelectric point 
and this is dependent on histidine protonation.  Error bars are 
standard error based on 6 traces.
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The protonation state of the three His residues within Aβ(1-40) (His6, His13 and 
His14) was determined over a range of pH values using 
1
H NMR chemical shift 
measurements (Figure 5.9b insert and Figure 5.10).  
 
Figure 5.10.  pKa measurements of Aβ histidine residues. (a) A selection of 1D 
1H NMR spectra from a pH titration, 100 µM Aβ(1-28) in 20 mM phosphate 
buffer at 25 ºC. CδH and CεH singlets from H6 (blue), H13 (red) and H14 
(purple) are highlighted. (b) 2D TOCSY spectrum of histidine region of Aβ(1-
28), pH 7, 60 ms spin-lock mixing time. (c) pH dependence of CδH and CεH 1H 
chemical shift. pKa are: 6.67, 6.67 and 6.64 at 25 °C in 90% H2O 10% D2O. 
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The pKa of the His residues at 25 
o
C are 6.7. A 2D 
1
H TOCSY was also performed 
(Figure 5.10b) to confirm the His CεH and CδH assignments. It is noted that the pH 
dependence of the fibre growth rates bears a strong resemblance to the protonation 
state of the histidine residues within Aβ. From this data it appears that the 
protonation state of the three imidazole rings and consequently the net charge of Aβ 
is crucial to its amyloidogenicity.  
 
In addition to pH, the binding of metal ions will also perturb the net charge of Aβ. It 
is known that Cu
2+
 (and Zn
2+
) ions bind to the three histidine residues within Aβ 
(Dong, et al. 2003, Drew, et al. 2009, Faller, et al. 2008, Faller, et al. 2009, Karr and 
Szalai 2008, Sarell, et al. 2009, Syme, et al. 2004, Syme and Viles 2006). At pH 7.4 
Aβ’s histidine residues are predominately (80 %) deprotonated and neutrally 
charged, thus coordination of a divalent Cu
2+
 (or Zn
2+
) ion to Aβ's histidines adds 
two positive charges. Adding two positive charges to Aβ at pH 7.4 makes the Aβ 
peptide complex more neutral in overall net charge. These results suggest that the 
coordination of Cu
2+
 to the histidine residues of Aβ results in faster fibril formation. 
 
5.4.4. The Balancing Act of Fibril Formation: Effect of Cu2+ Stoichiometry 
on Fibril Growth 
Having established a mechanism for Cu
2+
 accelerated fibril formation, the 
stoichiometric effect of Cu
2+
 on fibre growth was investigated in more detail. All 
concentrations of Cu
2+
 up to 1 mole equivalent caused the rate of fibrillisation to 
increase. Interestingly, sub-stoichiometric amounts of Cu
2+
 between 0.2-0.4 mole 
equivalents, display the greatest increase in fibre growth rates (Figure 5.11).  
 
This supports the observation that Cu
2+
 accelerates nucleation (as well as elongation) 
as this suggests sub-stoichiometric amounts of Cu
2+
 can “seed” fibre formation. 
Further addition of Cu
2+
 beyond one mole equivalent caused precipitation of Aβ(1-
40) and markedly reduces the amount of fibres generated, as previously noted (Jun, 
et al. 2009). The total amount of fibres generated in the presence (or absence) of 
Cu
2+
 ions can be quite variable, presumably reflecting competition between fibril 
formation and amorphous aggregation.  
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Figure 5.11. Effect of Cu2+ concentration on fibril growth rates. Normalised fibril 
growth curves with different mole equivalents of Cu2+ ions. The insert shows that fibre
growth times (t50) all decrease in the presence of Cu
2+ ions, from 150 hours for the apo 
(red) to 50 hours with 0.4 mole equivalents of Cu2+ ions (cyan).  The maximal effect is 
between 0.2 and 0.4 mole equivalent Cu2+. With excess, 2 and 4 mole equivalents, of 
Cu2+ ions the fibril growth is completely inhibited. Growth curves represent the mean 
of 6 traces, standard error is shown. Aβ(1-40) at 5 µM in 50 mM HEPES, 160 mM 
NaCl, at pH 7.4, 30 °C, with intermittent agitation. 
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Figure 5.12a illustrates that the effect of Cu
2+
 ions on Aβ(1-40) does not only 
accelerate fibril formation, but as Cu
2+
 concentration increases, the balance between 
fibril formation and amorphous aggregation increasingly favours the latter. Likewise 
in Figure 5.12b, as the pH increases from pH 8.3 total fibre formation decreases 
despite the increase in fibril formation rate. Presumably as the rate of fibril 
formation increases there is less time available for stable contacts to form between 
sidechains and the structure of the fibrils is less stable, resulting in increased 
amorphous aggregation. This effect is reduced with dilution but 2-5 µM levels of 
Aβ(1-40) are required for reliable timely detection. A limitation in previous 
experiments that showed only amorphous aggregates was the high concentration of 
Aβ(1-40) and Cu
2+
 ions used (Raman, et al. 2005, Yoshiike, et al. 2001) (typically 
50 µM, 100 µM respectively), much higher than that found in vivo. As can be seen 
from these experiments, the effect of Cu
2+ 
on Aβ fibril formation favours rapid fibril 
formation, and if conditions such as pH or concentration are also too “favourable,” 
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fibril formation becomes too fast to result in stable fibrils and this may explain why 
the predominant view in the literature is that Cu
2+
 ions only result in amorphous 
aggregates.  
Figure 5.12. Effect of Cu2+ concentration and pH on total fibril levels. (a) Effect 
of Cu2+ on the maximal ThT fluorescence signal of Aβ fibres. At 2 and 4 mole 
equivalent Cu2+ the fibril growth is inhibited. b) The effect of pH on the maximum 
fluorescence. 5 µM Aβ(1-40) in 50 mM HEPES, 160 mM NaCl, at pH 7.4, 30 °C, 
with intermittent agitation. . 
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5.4.5. Effect of Zn2+ on Fibril Growth 
Interestingly accelerated fibril formation appears to be quite specific for Cu
2+
 ions, 
Zn
2+
 ions completely inhibit fibre formation even at 3 µM of Aβ(1-40) (Figure 
5.13). This may be due to the very different coordination geometry (at µM 
concentration) between the two metal ions. Cu
2+
 ions form an intra-molecular 
complex with Aβ, (Drew, et al. 2009, Karr and Szalai 2008, Sarell, et al. 2009, 
Syme, et al. 2004) while at µM levels current data suggests zinc ions will form an 
inter-molecular complex, cross-linking between histidine residues on multiple Aβ 
molecules (Faller and Hureau 2008, Syme and Viles 2006). These cross-linked Zn
2+
-
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Aβ species will inhibit amyloids forming by interfering with the regular cross-beta 
assembly.  
 
Figure 5.13. Zn2+ inhibits fibril growth. Fibril growth curves with 1 mole 
equivalent of Zn2+ ions (green traces) and metal free (red traces) (a) 3 µM Aβ(1-
40), pH 7.4 (b) 4 µM Aβ(1-40), pH 7.4 (c) 5 µM Aβ(1-40), pH 7.4 (d) 5 µM 
Aβ(1-40), pH 8.0 . All carried out in 50 mM HEPES, 160mM NaCl, 30º C, with 
agitation, 3-6 traces for each experiment are shown. 
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5.4.6. Conclusions  
This chapter suggests that Cu
2+
 ions increase the rate of fibre formation, at pH 7.4, 
by causing Aβ to approach its isoelectric point. To put these observations in context, 
the increase in fibre growth rates measured here due to Cu
2+
 ions are comparable to 
those observed for (metal free) Aβ (1-40) mutants associated with familial early 
onset AD (E22K/G/Q), where a halving of the growth times (t50) of fibre formation 
is also reported (Murakami, et al. 2003).  
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Currently the vast majority of studies examining the effect of Cu
2+
 on Aβ suggest 
Cu
2+
 either inhibits fibril formation or causes amorphous aggregates to form 
(Chauhan, et al. 1997, Ha, et al. 2007, Yoshiike, et al. 2001). One of the only studies 
to date that supports the findings in this chapter is Huang et al, who studied the 
effects of Cu
2+
, Zn
2+
 and Fe
3+
 on seeding experiments of Aβ(1-40) with Aβ(1-42) 
and found that trace levels of zinc, copper, and iron initiated Aβ oligomerisation 
(Huang, et al. 2004). However, in their experiments with ThT they do not show data 
for Aβ(1-40), only a seeded mixture of Aβ(1-40)/Aβ(1-42), which makes 
comparisons with the results in this chapter difficult. Additionally with their ThT 
data they show only one time point, at 10 days, which suggests highest fluorescence 
for Aβ(1-40)/Aβ(1-42) in the presence of Cu
2+, 
and surprisingly Zn
2+
, in contrast 
with the results in Figure 5.13. The data shows total fibres generated rather than the 
kinetics of fibre formation. The effect of metal ions on Aβ(1-40) alone was studied 
using turbidometric analysis only, which would also be affected by amorphous 
aggregation and thus is not reflective of only fibril formation. Additionally they 
suggest trace metals accelerate fibril formation through acting as a seed. The 
findings in this chapter partly support this hypothesis, as sub-stoichiometric Cu
2+
 
levels were most effective at accelerating fibril formation, but the additional effect 
of metal ions on the pI of Aβ is not investigated by Huang et al. 
 
Metals have also been proposed as triggers for other misfolding and assembly 
diseases such as dialysis-related amyloidosis (Calabrese, et al. 2008), Parkinson’s 
disease (Uversky, et al. 2001) and prion diseases, although it remains to be 
established if the mechanisms by which metals induce fibrillisation are shared. The 
observations in this chapter provide a rationale for the in vivo findings in 
Drosophilia and mammals which link the AD phenotype with impaired Cu
2+
 
homeostasis (Sanokawa-Akakura, et al., Sparks, et al. 2003). It is known that Cu
2+
 
levels in the brain increase with age (Barnham, et al. 2008), thus the observations in 
this chapter should refocus attention on loss of Cu
2+
 homeostasis as a possible risk 
factor in AD. Cu
2+
 chelators are now being investigated in clinical trials as a 
potential therapy for Alzheimer’s disease (Barnham and Bush 2008, Cherny, et al. 
2001). 
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In the next chapter, the toxicity of Aβ fibres, with and without Cu
2+
, is investigated, 
to determine if the concentration-dependence of Cu
2+
 accelerated fibril formation 
shown in this chapter, is mirrored in the toxic effects exerted by Aβ fibrils. 
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Abstract
Recent in vivo studies using animal models of Alzheimer’s disease (AD) have
shown that impaired copper homeostasis enhances the toxic effects of amyloid beta-
peptide (A. In the experiments described here, a clonal neuronal cell line was used
as a model to assess Aβ toxicity. Fibrillar and monomeric Aβ were added to the cell
culture and cell viability monitored with a fluorescent dye (alamar blue). The results
show that Cu2+ ions bound to A are consistently more toxic to neuronal cells than
A in the absence of Cu2+ ions, while the same levels of Cu2+ in the absence of A
are not toxic to the cells. Additionally Cu2+ binding to the non-amyloidogenic Aβ(1-
16) fragment is not toxic.
The degree of Cu-A cyto-toxicity correlates with the levels of Cu2+ ions that
accelerate fibre formation as described in Chapter 5, with the greatest toxicity
observed at sub-stoichiometric levels of Cu2+. Additionally monomeric Aβ requires
longer incubation with the cells to exert toxicity than fibrillar Aβ, suggesting self-
association may be necessary for Aβ toxicity. An active role for Cu2+ ions in
promoting cell death suggests impaired copper homeostasis may be a risk factor for
Alzheimer’s disease.
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6.1. Introduction
In vitro and in vivo studies performed since the early 1990s have supported the
hypothesis that A has a direct role in the neurodegeneration that occurs in AD.
However a clear idea of the molecular events and mechanisms for A toxicity has
yet to be established. In this introduction some of the different models that can be
used to study toxicity and different measures of toxicity are discussed.
6.1.1. In Vitro Toxicity Models
In vitro models and tests have been developed in response to the complexity of the
in vivo cellular environment, and the difficulties and expense with conducting tests
in vivo.  Commonly used models in Alzheimer’s disease include primary neuronal
cultures (Opazo, et al. 2002, Pike, et al. 1993, White, et al. 1999, Whitson, et al.
1989) and immortal cell lines, including human neuroblastomas (SH-SY5Y)
(Hughes, et al. 2010), mouse albino neuroblastomas (Neuro-2A) (Dahlgren, et al.
2002) and pheochromocytoma (PC12) (Poduslo, et al. 2010) cells.
Cell lines will differ in their sensitivity to Aβ. A(25-35) was over 200 fold more
toxic to PC12 cells than Neuro-2A cells (Calderon, et al. 1999). PC12 cells have 4-5
fold lower concentrations of glutathione than Neuro-2A cells, which makes PC12
cells more sensitive to A-induced oxidative stress. Additionally A showed a
higher propensity to bind to PC12 cell membranes than a range of other models,
including a neuronal cell line, cortical primary neurons and hippocampal primary
neurons (Simakova, et al. 2007). Thus the PC12 cell line was chosen to be the model
for A toxicity in this thesis.
6.1.2. Toxicity Assays In Vitro
There are numerous methods to evaluate the toxicity of a compound to cells.
Although none of these assays can reliably predict toxicity in vivo they are useful
tools to compare different treatments and are widely used to indicate toxicity at a
basic level. An overview is given below:
Cell Counting
The number of surviving cells are quantitated as a percentage of the number of live
cells counted after plating (Whitson, et al. 1989). Counting cells stained with trypan
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blue can also be used as a measure of cell viability (Pike, et al. 1993). Here, the
exclusion of trypan blue (trypan negative) indicates cells with an intact cell
membrane.
Lactate Dehydrogenase Release Assay
The lactate dehydrogenase (LDH) assay measures the number of viable cells, either
by measuring the number of cells via total cytoplasmic LDH or membrane integrity
as a function of the concentration of cytoplasmic LDH that leaks into the
extracellular medium (Koh, et al. 1987). LDH in the extracellular medium will
reduce nicotinamide adenine dinucleotide (NAD) to NADH. NADH then reacts
stoichiometrically with a yellow tetrazolium salt to produce a red, formazan-class
dye which is measured by absorbance at 492 nm. The amount of formazan is directly
proportional to the amount of LDH in the culture, which is in turn directly
proportional to the number of dead or damaged cells. Formazan dyes are commonly
used in cell viability assays as they are formed by the reduction of tetrazolium salts
by dehydrogenases and reductases, and thus are a good indicator of cell viability.
They vary in colour depending on the original tetrazolium salt.
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is traditionally
the most widely used measure of cell viability since it was developed by Mosmann
in 1983 (Mosmann 1983). MTT is a tetrazolium salt that produces a yellow solution
when dissolved in water. Active mitochondrial dehydrogenases in metabolically
active cells will convert MTT to insoluble purple formazan crystals. This change
will not occur in dead cells. The insoluble formazan is solubilised by the addition of
cell lysis buffer, and the absorbance at 570 nm measured.
Alamar Blue
Alamar blue is used to measure cell viability in this chapter, so it will be discussed
in more detail. The alamar blue assay uses the reactions of the electron transport
chain as a measure of cell proliferation and cyto-toxicity. Alamar blue is an
oxidation-reduction indicator. The active ingredient of alamar blue (resazurin) is a
blue, nontoxic, cell permeable compound that is nonfluorescent. Upon entering cells,
resazurin is reduced by mitochondrial enzymes to resorufin, which produces very
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bright red fluorescence (Figure 6.1). Viable cells continuously convert resazurin to
resorufin, thereby generating a quantitative measure of cell viability. Excitation of
the dye occurs at ~560 nm with the subsequent emission at ~ 590 nm.
Figure 6.1. Structure and metabolism of the cell viability dye alamar blue
(Invitrogen). Resazurin is reduced by mitochondrial enzymes to the strongly
fluorescent resorufin.
N
OO
O
O
N
OO O
Metabolic
reduction
The redox potential of alamar blue illustrates why it is a good indicator for detecting
oxidation of the electron transport chain (Table 6.1). The redox potential is a
measure of the tendency of a chemical species to acquire electrons and be reduced.
Each species has its own intrinsic reduction potential; the more positive the
potential, the greater the species' affinity for electrons and tendency to be reduced.
Table 6.1 shows that alamar blue has a midpoint potential greater than the midpoint
potential of the cytochromes. This allows alamar blue to detect oxidation by all the
components of the electron transport chain. MTT, also shown in Table 6.1, has a
lower midpoint potential than alamar blue. MTT’s midpoint potential is higher than
the electron donors FMNH2, FADH2, NADH and NADPH, but lower than the
cytochromes. Because of this MTT will interrupt the respiratory chain, whereas
alamar blue does not interfere with any of the redox reactions and thus allows the
cells to remain functional and healthy.
Alamar blue also performs with equal or better sensitivity than MTT. Human
hepatoma cells (HepG2) were exposed to 117 compounds and the effects measured
with MTT and alamar blue (Hamid, et al. 2004). The majority of the compounds
performed consistently in both assays, regardless of the underlying mechanism of
the compounds toxicity. However for a minority of compounds alamar blue
outperformed MTT in sensitivity.
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8202H2O↔O2+4H++4e-
380Alamar blueRED↔Alamar blueox+2H + 2e-
+80 to +290CytochromesRED↔Cytochromesox + 1e-
-110MTTRED↔MTTOX+ 2H++2e-
-210FMNH2↔FMN+2H++2e-
-220FADH2↔FAD+2H++2e-
-320NADPH+H+↔NADP+2H++2e-
-320NADH+H+↔NAD+2H++2e-
Eo’ (mV) pH
7.0 25 ºC
Half-reaction
Table 6.1. Redox potentials of components of the electron transport
system and alamar blue and MTT. The midpoint redox potentials (Eo’)
values were determined at pH 7.0 at 25 ºC. The midpoint potential (Eo’) for
any half reaction is defined as the voltage at which equilibrium is achieved
between the concentration of oxidized and reduced products (AbD Serotec
2010).
Alamar blue is frequently used in cell toxicity assays of PC12 cells, (Blum, et al.
2000, Magliaro, et al. 2009, Seyfried, et al. 2007) with no confounding effects
reported. Although MTT is commonly used to observe the effects of Aβ on cells in
the AD field, the difficulties in solubilising the formazan which forms during the
assay has resulted in other tests becoming more popular, and alamar blue has been
used recently to study A antimicrobial activity in Alzheimer’s disease (Soscia, et
al. 2010) and Aβ toxicity to neuronal cultures (Chung, et al. 2010). Further details
on the specific use of alamar blue are given in the experimental section of this
chapter.
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6.2. Aims
 Develop a suitable system for monitoring A(1-40) and Aβ(1-42) and Cu2+
toxicity in PC12 cells.
 Determine what concentrations of Cu2+ alone are toxic.
 Determine how Cu2+ influences the toxicity of both monomeric and fibrillar
A(1-40) and Aβ(1-42).
 Ascertain if there is a relationship between fibril growth and toxicity.
6.3. Experimental
6.3.1. Cell Culture Protocol
PC12 cells were obtained from the Health Protection Agency (HPA) Culture
Collections, lot number 08F011. The predominant culture medium used was as
recommended by the HPA: RPMI 1640 + 2 mM Glutamine + 10 % Horse Serum
(HS) + 5 % Fetal Bovine Serum (FBS). Cultures were maintained at approximately
6 x 106 cells/mL and incubated at 5 % CO2, 37 °C in 25 cm2 cell culture flasks
(Iwaki). Cells were loosely adherent and gentle pipetting was sufficient to dislodge
them. Cells were centrifuged at 1000 RPM (95 x g) for 5 minutes and resuspended
in fresh medium every 3-4 days to an approximate cell concentration of 2 x 105
cells/mL.
To determine the stock cell concentration, a 10 L aliquot was added to 10 L of 3
mg/mL trypan blue. 10 L from this solution was added to a haemocytometer and
the cells counted. The cells were diluted in Opti-MEM and added to the wells of a
96 well plate, see individual experiments in the results section for exact
concentrations. The cells were typically incubated with the test samples for 24
hours, prior to alamar blue addition.
20 µL alamar blue (Invitrogen) was added to each 200 µL well volume. The wells
were incubated at 37 C for 4-6 hours to allow colour development. The
fluorescence was measured in a Molecular Devices SpectraMax Gemini XPS
spectrofluorometer, excitation 530 nm, emission 585 nm with a cut off at 550 nm.
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6.4. Results
Optimisation of Cell Toxicity Assay
6.4.1. Morphology and Behaviour of PC12 Cells
The PC12 cell line was established from rat adrenal pheochromocytoma cells
(Greene, et al. 1976). In the growth medium used in this thesis the PC12 cells have a
round shape and tend to grow in small clumps. The doubling time of the cells is 92
hours. The cells synthesise and store sizeable quantities of the neurotransmitters
dopamine and norepinephrine. Consequently PC12 cells resemble chromaffin cells
and sympathetic neurons making them a useful model for studying the toxic effect of
Aβ preparations in vitro.
6.4.2. Choice of Cell Media
The media used for normal cell growth (RPMI 1640 + 2 mM Glutamine + 10 % HS
+ 5 % FBS) contains high levels of competing copper ligands, such as serum
albumin. The levels of albumin in blood plasma, e.g. in FBS and HS, is much higher
than found in the CSF and brain interstitium, where Aβ-Cu2+ interactions are thought
to take place. For example in humans albumin is present at 600 µM in blood plasma,
but only at ~3 μM in the CSF (Carter, et al. 1994, Licastro 1993). Consequently,
Opti-MEM media (Invitrogen) with no added serum was used as an alternative.
Opti-MEM is a modification of Eagle’s minimal essential medium, buffered with
HEPES and sodium bicarbonate, and supplemented with hypoxanthine (purine
derivative), sodium pyruvate (source of energy) and L-glutamine (amino acid). The
protein level of Opti-MEM is 15 g/mL, with insulin and transferrin as the only
protein supplements. More information on the exact protein and trace metal
concentrations was requested from Invitrogen but was refused due to the
confidential nature of this information. In most of the experiments described in this
thesis, 50 L of Opti-MEM was used in each 200 L well, thus the protein
concentration contributed from the Opti-MEM was 0.75 g/200 L compared to a
typical concentration of 8.66 g/200 l of A. Thus competing ligands for Cu2+
outside the cell are minimised.
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6.4.3. Alamar Blue Experimental Specifics and Definitions
Alamar blue is a quantitative dye, the greater the fluorescence, the greater the
number of viable cells. In the majority of experiments in this chapter, the effect of
treatments on the cells is described by percentage cell growth, i.e. the ability of the
cells to metabolise alamar blue. Alamar blue was added at different time points and
the cell growth, or lack of it determined. Cell viability is used to describe the effect
of treatments when a single alamar blue addition was carried out. The effect of
treatments on PC12 cells are described as “toxic” occasionally in this chapter, but
this refers to the effect of the treatments in impairing cell viability and cell growth,
rather than necessarily resulting in cell death. Alamar blue only acts as a measure of
cell metabolism, and thus is not a direct measure of cell toxicity
It is also important to note that alamar blue metabolism is unidirectional, i.e. once it
is metabolised by living cells, it can not then indicate if the cells begin to die. Thus
when the alamar blue readings plateau, it may be that the cells are dying. Because of
this the data shown in this chapter is the first point where the alamar blue
fluorescence began to plateau. Where the data is presented as percentage cell
viability (or percentage cell growth), the values were calculated using:
Percentage cell viability = (F- Fbuff) / (Fcells - Fbuff)*100
Where F is the alamar blue fluorescence, Fbuff is the buffer fluorescence only and
Fcells is the fluorescence of cells with no treatments.
6.4.4. Using Opti-MEM Media
Opti-MEM was used as an alternative media to RPMI + HS + FBS, RPMI alone was
tried but cell viability was poor. Firstly the optimum cell concentration for A
toxicity experiments was investigated. PC12 cells were serially diluted in Opti-
MEM, and alamar blue added at either day 0 or day 4. The bargraph in Figure 6.2a
shows the alamar blue fluorescence of cells seeded at 3 x 106 cells/mL after 4 hours
incubation with alamar blue. These wells have the highest alamar blue fluorescence
compared to starting cell concentrations of (b) 3 x 105, (c) 3 x 104 and (d) 3 x 103
cells/mL. After 4 days incubation, Figure 6.2a shows alamar blue fluorescence at
this seeding concentration has reduced to ~ 50 % of the cell growth at 0 days.
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In contrast, cells seeded at 3 x 105 cells/mL in (b) and 3 x 104 cells/mL in (c) show
an increase in alamar blue fluorescence over the same period. The most dilute
starting concentration of 3 x 103 cells/mL (Figure 6.2d) shows only a small increase
in cell growth, suggesting this concentration of PC12 cells is too dilute.
Figure 6.2. Effect of cell concentration on cell growth. Alamar blue was added at 0
days or 4 days to PC12 cells in Opti-MEM cell medium, pH 7.4. PC12 cells starting
concentrations were (a) 3 x 106 cells/mL (b) 3 x 105 cells/mL (c) 3 x 104 cells/mL and
(d) 3 x 103 cells/mL. Average data shown calculated from three wells for day 0 and
two wells for day 4. Error bars are standard error.
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3 x 104 cells/mL 3 x 103 cells/mL(d)(c)
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From this data it was found that cells at concentrations of 105 and 104 grew well in
Opt-MEM media. Additionally cells seeded at 104 cells/mL were monitored for
longer and it was found that up to 7 days incubation in Opti-MEM media did not
shown a decrease in cell viability. Thus further experiments were performed using
starting cell concentrations of 104 cells/mL to allow maximum growth over the time
course of the experiment
6.4.5. Effect of Diluting Opti-MEM with HEPES/NaCl
The degree of dilution of Opti-MEM by the addition of A preparations was
investigated next. Ideally, minimal dilution of the peptide preparations would be
necessary. However A fibres are grown in 50 mM HEPES + 160 mM NaCl (see
Chapter 5 Section 5.3.1) and it was not known what effect dilution of Opti-MEM
with this buffer would have on PC12 survival. Thus PC12 cells were grown for 4
days in different ratios of the two media (Opti-MEM and HEPES/NaCl) and their
viability examined (Figure 6.3).
0
10000
20000
30000
40000
50000
Flu
ore
sc
en
ce
 (A
FU
)
10
0 75 50 25 10 0
Opti-MEM (%)
Figure 6.3. Cell viability at 4 days in Opti-MEM dilutions. 2.5 x 104 cells/mL
PC12 cells were incubated in different concentrations of Opti-MEM diluted with 50
mM HEPES + 160 mM NaCl, both at pH 7.4. Metabolism of alamar blue by PC12
cells is greatest in the presence of 50 % or above Opti-MEM. 0 % and 10 % Opti-
MEM show low cell viability. Averages of 3 wells and error bars are standard error.
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Figure 6.3 shows that alamar blue fluorescence was highest in 100 % and 75 %
Opti-MEM. Cell viability was greatly reduced when the media contained more
HEPES than Opti-MEM. This decrease was even more pronounced at 10 % and 0 %
Opti-MEM. From this experiment it was concluded that the cells would optimally be
grown in 100 %, 75 % or 50 % Opti-MEM. However to maintain an A
concentration that was toxic, a media combination of 25 % Opti-MEM, 75 %
HEPES/NaCl was typically used. Control cells not incubated with Aβ had the media
diluted to the same extent as Aβ-treated cells.
6.4.6. Free Cu2+ and A(1-16) bound Cu2+ Toxicity
To determine whether Cu2+ alone is toxic, PC12 cells were incubated with a range of
Cu2+ concentrations.
Figure 6.4. Free Cu2+ ions are not cyto-toxic. Cu2+ ions were added as CuCl2
and incubated with 5.9 x 104 cells/mL in Opti-MEM cell medium, pH 7.4. (a)
Alamar blue was added after 1 day incubation and cell viability monitored. Data
is shown after 70 hours total incubation. (b) At 6 days alamar blue was added
again and additional readings taken. Cell viability in the presence of Cu2+ was
comparable to the viability of cells without Cu2+ ions in (a) and Cu2+ increased
cell growth in (b). Averages calculated from 3 wells. Error bars are standard error.
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Figure 6.4 shows that all Cu2+ concentrations up to 2.5 M Cu2+ had no detectable
effect on cell growth. Surprisingly the presence of additional Cu2+ appears to
enhance cell viability.
The effect of Cu2+ bound to the non-amyloidogenic Cu2+ binding fragment, A(1-
16), was also studied (Figure 6.5).
Figure 6.5. Cu2+ bound to A(1-16) is not toxic. Cu2+-A(1-16) was added to
5.9 x 104 cells/mL immediately (t0) or incubated for 200 hours (t200) under fibril
forming conditions before addition to PC12 cells. Alamar blue was added after 1
day A incubation with the cells. Data is shown after 3 days total incubation,
averages calculated from 3 wells, error bars are standard error.
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The use of A(1-16) is a particularly good control as Cu2+ binds to this shorter
fragment of A with the same affinity and coordination geometry (Drew, et al. 2009,
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Karr, et al. 2008, Sarell, et al. 2009, Syme, et al. 2004) as full-length Aβ, but A(1-
16) lacks the amyloidogenic region and does not form fibrils. Figure 6.5 shows that
Cu2+ ions when bound to A(1-16) do not affect cell viability. The interaction of
A(1-16) with and without Cu2+ was studied for both freshly solubilised A(1-16)
(t0 in Figure 6.5) and also A(1-16) which had undergone the standard fibril growth
procedure (t200 in Figure 6.5). This data shows that addition of Cu2+ bound protein
is not generically toxic to cells, and that any detrimental effects of Cu2+ are specific
to their interaction with A(1-42) and A(1-40).
Cu2+ and A(1-40) and (1-42) Toxicity
6.4.7. Cu2+ and A(1-42) Fibre Toxicity
The effect of A(1-42) fibrils formed in the presence or absence of Cu2+ on the cell
viability of PC12 cells was investigated. Figure 6.6 shows PC12 cell viability after 3
days incubation with A(1-42) fibrils. Two findings are evident from this data.
Firstly, it can clearly be seen that cells incubated with A(1-42) fibres, in both the
presence or absence of Cu2+, show a decrease in cell viability. This is especially
evident at lower concentrations, i.e. 0.9 M A(1-42) decreases cell viability more
than 4.5 M. This may be because at low concentrations of Aβ(1-42), fibres formed
may be smaller than fibres formed at higher Aβ(1-42) concentrations. The smaller
fibres could diffuse to the PC12 cell membrane more easily and rapidly than the
larger fibres, resulting in greater cell toxicity.
The second finding from Figure 6.6 is that the presence of Cu2+ consistently results
in a larger decrease in cell viability at all concentrations than apo-A(1-42). For
example, 2.7 M apo-A(1-42) fibres decreased cell viability to 40 % viability.
However the same concentration of A fibres in the presence of half a mole
equivalent Cu2+ ions results in only 4 % viability. This experiment was repeated on a
number of occasions and each time the presence of Cu2+ ions consistently enhanced
A’s negative effect on PC12 cell viability. This suggests that in PC12 cells,
Cu2+ ions bound to A impair cell viability more than A in the
absence of Cu2+ ions, while the same levels of Cu2+ in the absence of A are
not toxic to the cells.
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Figure 6.6. Cu2+-A(1-42) fibrils are more cyto-toxic than A(1-42) fibrils. 1, 3
and 5 µM A(1-42) fibrils were formed with and without 0.5 mol eq Cu2+ ions. After
fibril formation (monitored by ThT) the fibrils were added to 10 % (v/v) PC12 cells.
Cell concentration was 5.9 x 104 cells/mL. 2.5 M Cu2+ was added to the cells to
check for free Cu2+ toxicity. All preparations were incubated with the cells for 24 hrs
then alamar blue added. The data shown here is after a total incubation time of 3
days. Error bars are standard error.
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6.4.8. Effect of Cu2+:A Ratio on Cell Toxicity
Next the ratios of Cu2+ to A(1-40) that cause toxicity were investigated. This was
examined in light of the results from the fibril formation studies described in
Chapter 5, which showed that fibril formation was accelerated by the presence of
Cu2+ ions, but only at stoichiometric and substoichiometric Cu2+ concentrations.
Thus cell assays were carried out to see if the same concentration-dependence of
Cu2+-A(1-40) affected PC12 cell viability.
Figure 6.7 shows that 10 M A(1-40) bound to as little as 0.01 mole equivalent
Cu2+ (100 nM) is significantly more effective at impairing cell growth than the same
concentration of A(1-40) in the absence of Cu2+ ions (Figure 6.7). 0.1 mole
equivalent Cu2+ bound A(1-40) had an even more pronounced affect on cell
viability, and 0.5 mole equivalents of Cu2+ ions were also more toxic than A(1-40)
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in the absence of Cu2+ ions. However at the Cu2+ ratio of 1:1 mole equivalents (10
M Cu2+), cell growth is no longer impaired. Indeed at 5 mole equivalents of Cu2+,
relative to A(1-40), Cu2+ is actually protective.
These observations complement the optimum ratio of Cu2+-A(1-40) that generates
amyloid fibres, as shown in Chapter 5. Sub-stoichiometric amounts of Cu2+ (0.2-0.4
mole equivalents) were shown in the previous chapter to be more effective at
generating amyloid fibres, while Cu2+ levels above 1 mole equivalent will actually
inhibit fibre formations. These results show that the influence of Cu-A(1-40) ratios
on toxicity in PC12 cells must relate closely to the ability of Cu2+ to accelerate (or
inhibit) fibre formation, this is discussed further in the discussion section of this
chapter.
Figure 6.7. Cu2+-A and A added as monomers inhibit growth after 6 days
incubation. 10 µM monomeric A(1-40) with a range of Cu2+ concentrations were
incubated with 5.4 x 104 cells/mL in Opti-MEM cell medium, pH 7.4. Alamar blue
was added after 6 days incubation. Averages calculated from 3 wells and error bars
are standard error.
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6.4.9. Monomer vs. Fibrillar Toxicity
The results described in Figure 6.7 show A(1-40) added as a monomer to PC12
cells and alamar blue added after 6 days incubation. To observe if A(1-40) also
affected cell viability after a shorter incubation, in the same experiment alamar blue
was added after only 2 days incubation and cell viability monitored for a further 2
days (Figure 6.8). However addition of monomeric A(1-40) shows no impairment
of cell viability within 4 days of addition (Figure 6.8).
Figure 6.8. Cu2+-Aβ and Aβ added as monomers do not inhibit growth after 4
days incubation. Monomeric Apo and Cu- Aβ(1-40) were incubated with 5.4 x 104
cells/mL PC12 cells in Opti-MEM at pH 7.4. Alamar Blue added after 48 hr Aβ
incubation with cells, data shown is after 4 days total incubation. Error bars are
standard error based on 3 wells.
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This suggests that it takes longer than 4 days incubation for monomeric A(1-40) to
cause toxicity to PC12 cells. This is in contrast with the toxicity seen with Aβ(1-42)
fibrils in Figure 6.6 where toxicity was observed within 3 days. When Aβ(1-42) is
added to PC12 cells as a monomer it may remain monomeric during incubation, and
in this form take longer to have a negative effect on cell growth than when applied
as fibrils. Alternatively the longer incubation time before toxicity is observed may
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be due to the time taken for A to form a toxic species. This is supported by fibre
growth trials in the cell media using a ThT assay (Figure 6.9) which shows that both
apo-A(1-42) and Cu2+-A(1-42) will form fibrils in Opti-MEM. Although the
experimental conditions are slightly different to those in the cell viability assays, the
fibre formation curves suggest that the time taken to form fibrils in Opti-MEM may
be an influencing factor on Atoxicity.
Figure 6.9. Aβ and Cu2+-Aβ added as monomers to Opti-MEM form fibrils.
4 µM apo-Aβ(1-42) (red trace) and 0.5 mol eq Cu2+ (blue trace)  in 25 % (v/v)
Opti-MEM, 75 % (v/v) 50 mM HEPES/160 mM NaCl in standard fibril growth
conditions (see Chapter 5 Section 5.3.1).  Fibril growth is monitored by ThT and
shows that both Apo and Cu-Aβ(1-42) form fibrils under these conditions.
Average of 6 traces shown and the data is zeroed.
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6.5. Discussion
The results in this chapter show that both pre-formed fibrils and monomeric A(1-
40) or Aβ(1-42) have detrimental effects on PC12 cells. There are a few studies
already published investigating the relationship between Cu2+ and A cell-toxicity,
but these studies appear to show conflicting results. Opazo et al agreed with the
studies in this chapter and found that copper promoted toxicity however the toxicity
experiments were carried out with excess EDTA present (Opazo, et al. 2002). This
metal chelator has a 1018 affinity for Cu2+ ions compared to the 1010 affinity of
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A(1-42) for Cu2+ (Sarell, et al. 2009), thus it seems unlikely the Cu2+ ions were
bound to A. Yoshiike et al found that Cu2+ appeared to protect against toxicity
(Yoshiike, et al. 2001). But in both Yoshiike and Opazo’s studies the nature of the
A preparation was not well defined (i.e. amorphous aggregate, monomer or fibre)
and this may be the source of the discrepancies. In contrast the nature of the A
preparation in this chapter was known, as evident by the toxicity of fibrillar full
length A(1-40) or Aβ(1-42) with Cu2+ bound compared to the lack of toxicity
observed with non-fibrillar A(1-16). Additionally monomeric A-Cu2+ was only
toxic after 6 days incubation, suggesting that some degree of oligomerisation may be
necessary for toxicity. A third study by Meloni et al did not show conclusively
whether the observed cell toxicity of A-Cu2+ was simply due to the presence of
Cu2+ ions or specifically Cu2+ bound to A in a oligomeric/fibrillar form (Meloni, et
al. 2008). The results in this chapter suggest that at the experimental Cu2+
concentrations used free-Cu2+ has no toxic effects on the PC12 cells.
The toxic effect of Cu2+-A warrants further discussion. Cu2+-A detrimentally
affects cell viability more than apo-A. There are potentially two reasons for the
enhanced toxicity of A in the presence of Cu2+ ions:
Hypothesis 1: Increased oxidative stress at the membrane. A has been shown to
bind to PC12 cell membranes with high affinity (Simakova and Arispe 2007). If A
is also bound to Cu2+ this would result in an accumulation of Cu2+ ions at the
neuronal cell surface, where Cu2+ could generate toxic hydrogen peroxide and
hydroxyl radicals. Lipid peroxidation of the membrane will compromise membrane
integrity and result in cell death.
Hypothesis 2 Formation of toxic species. The results in this chapter and those in
Chapter 5 suggest that Cu2+’s role in promoting not only fibril formation, but also
smaller species that form along the fibril formation pathway could promote the
formation of A species that are toxic to cells. The rate, quantity or morphology of
the Cu2+ promoted fibres or prefibrillar oligomers may cause the heightened cyto-
toxicity.
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If it was simply a matter of reactive oxygen species (ROS) generation by Cu2+ ions
bound to A (hypothesis 1) then one might expect the more Cu2+ bound to A, the
greater the toxicity due to increased levels of ROS from cycling of the Cu2+.
However, in Figure 6.7 small concentrations of Cu2+ ions (0.1 M) are more toxic
than much higher concentrations (5 M) of Cu2+ ions. In light of this, the ability of
Cu2+ to promote fibres (described in Chapter 5), appears to be the significant factor
in Cu2+ promoted A cell toxicity, supporting hypothesis 2. This is supported by a
study with human islet amyloid polypeptide (IAPP), the fibril forming protein in
type-2 diabetes mellitus, which showed that the kinetic profile of IAPP-induced
membrane damage is characterized by a lag phase and a sigmoidal transition, which
matches the kinetic profile of IAPP fibril growth. Thus the process of fibril
formation on the cell membrane was directly responsible for damage to the
membrane (Engel, et al. 2008). It is possible that a similar mechanism occurs with
A fibrils. However hypothesis 1 and 2 could both be valid, as it is possible that the
fibrillar species formed with Cu2+ present, not only form faster, but also result in A
species with a different underlying structural form to species formed by apo-A. The
alternative structure of A species could bind Cu2+ in a redox active form, thus
facilitating Cu2+ redox cycling.
To investigate these hypotheses further tests could be performed. To see if more
lipid peroxidation occurs in PC12 cells incubated with Cu2+ bound fibrils
(hypothesis 1) there is a large range of tests that could be conducted (Halliwell
2007). The thiobarbituric acid (TBA) assay is one of the oldest and most frequently
used methods for measuring peroxidation. It measures the concentration of
malondialdehyde (MDA). MDA arises from peroxidation of polyunsaturated fatty
acids in membrane lipids. The TBA in the assay reacts with any MDA present to
form a red complex with an absorbance maximum at 532 nm, and thus allows
comparisons of the degree of lipid peroxidation under different conditions. However
the TBA assay has a number of flaws associated with it and is vulnerable to
misinterpretation, so it is instead now recommended that MDA concentrations are
measured directly by HPLC or GC-MS (Halliwell 2007).
To study the Cu2+ induced fibrils more closely (hypothesis 2) a variety of different
structural techniques could by used. Morphology of the fibers could be examined by
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transmission electron microscopy more closely and in further detail than has been
performed in this thesis, atomic force microscopy could also be used for this
purpose. Additionally antibodies could be used to identify if there were any specific
morphological differences, such as Kayed et al’s antibody which differentiates
between fibrils and oligomers (Kayed, et al. 2003). Alternatively a more detailed
atomic level model could be developed from solid state NMR.
In conclusion, the results presented here show Cu2+ decreases cell viability in PC12
cells through the affect of Cu2+ on A fibril formation. It will be of interest to see if
the precise mechanism is identified, and if there are differences between Cu2+ loaded
fibrils and apo-fibrils. The results described here are used to help build a hypothesis
for Aβ-Cu2+ toxicity in AD in the next, and final, chapter of this thesis.
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7. Conclusion
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In this chapter three models of potential modes of Aβ-Cu2+ toxicity are outlined. These
models are based on changes in copper homeostasis both within the cell and
extracellularly. The three main sources of metal ions in the brain are 1) a vesicular pool
located in synaptic vesicles of nerve terminals,  2) an ionic pool of free or loosely bound
ions and 3) a protein-metal complex pool (Frederickson 1989). The three models focus
predominantly on the first two sources of copper. Disruption to protein-metal
complexes will not be discussed in detail as a potential mechanism for AD onset, as this
pool of protein-metal complexes has extremely high affinities, for example superoxide
dismutase has a dissociation constant of 6 fM (Rae, et al. 1999) and it is thus unlikely
that Aβ would reach levels high enough within the cell to compete with this pool of
copper. However protein-metal complexes will be touched upon in all three hypotheses.
Model 1. The Synaptic Hypothesis.
Model one examines the vesicular pool of copper at the synapse, and a possible mode of
interaction with Aβ in the synaptic cleft due to Cu2+ dyshomeostasis. This model is
based on the work of Schlief et al, who found a role for copper in preventing NMDA
receptor-mediated neuronal toxicity (Schlief, et al. 2006) and Snyder et al who found
that NMDA receptor trafficking is regulated by Aβ (Snyder, et al. 2005). These two
findings provide evidence for an interaction between Aβ and Cu2+ at the synapse.
The synapse is a good place to hypothesise a model for the trigger for AD for several
reasons: Aβ fibrils first appear at the synapse, and synaptic damage and loss is a good
correlation to the severity of AD symptoms (Terry, et al. 1991). This model suggests a
cascade of events arising from intracellular Cu2+ deficiency at the synapse which results
in AD onset and progression.
Copper is essential for nervous system development and continuing function, with a
range of roles including acting as an enzyme cofactor, peptide amidation and
neurotransmitter synthesis (Culotta 2001). Nowhere is this more evident than in the
fatal neurodegenerative Menkes disease, which occurs due to a loss-of-function
mutation in the gene encoding a copper-transporting ATPase, Atp7a. (Vulpe, et al.
1993).
Strikingly, recent research has shown that Atp7a has a critical role in the release of a
pool of copper in neurons (Schlief, et al. 2006). Synaptic NMDAR activation results in
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the rapid trafficking of Atp7a to the somato-dendritic and axonal compartments of
neurons followed by rapid release of a vesicular pool of copper from the neuronal
membrane. Once released,  endogenous copper catalyses the S-nitrosylation of NMDA
receptors, resulting in a down-regulation of their activity (Schlief, et al. 2006). Thus
copper acts as a neuroprotectant,  preventing NMDA-mediated excitoxicity (Schlief, et
al. 2006). Excitoxicity can occur if NMDAR and other receptors are over-stimulated in
response to neurotransmitter (glutamate) release. Over-activation of NMDAR results in
high levels of calcium entering the cell which go on to activate a range of enzymes that
damage the cell, resulting in cell death (Choi 1992).
Strikingly another important neuroprotectant that prevents NMDAR over-stimulation is
Aβ. Aβ promotes down-regulation of NMDA receptors through endocytosis of the
receptors (Snyder, et al. 2005). This is further supported by a study showing that
activation of NMDA receptors results in increased levels of Aβ, through a favouring of
the amyloidogenic pathway over the non-amyloidogenic pathway (Lesne, et al. 2005),
thus suggesting a feedback mechanism between NMDA stimulation, Aβ production and
NMDA down-regulation. Thus balanced Aβ and copper homeostasis are both essential
in preventing excitoxicity at the synapse. A possible model for Aβ and Cu2+ at the
synapse is shown in Figure 7.1.
So what might be the trigger for the formation of Aβ-Cu2+ complexes at the synapse and
the development of AD pathology? This model hypothesises that large changes in Cu2+
homeostasis in AD are responsible. In AD Cu2+ is present in extracellular plaques and in
the serum in AD at high concentrations (Lovell, et al. 1998, Squitti, et al. 2002),
conversely intracellular copper levels decrease (Deibel, et al. 1996). The effects that
copper dyshomeostasis at the synapse could have in regards to promoting Aβ-Cu2+
complex formation are discussed below:
1. Intracellular copper deficiency has been shown to alter the structure of lipid rafts
(Hung, et al. 2009) which may favour γ-secretase cleavage at the Aβ(1-42)
cleavage site instead of the Aβ(1-40) site.
2. Intracellular copper deficiency would lead to Cu+-free APP molecules, which
may have a different structure to the Cu+-loaded APP that is present in non-AD
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brains. This change in APP structure could also lead to an increased propensity
for γ-secretase cleavage at the Aβ(1-42) cleavage site.
3. In addition to increasing the ratio of Aβ(1-42) to Aβ(1-40) through effects 1 and
2, a decrease in intracellular Cu2+ may result in a small decrease in Cu2+ release
at the synapse. This would result in a slight loss of Cu2+-mediated
downregulation of NMDA receptors. The subsequent overstimulation of the
NMDAR would result in sustained Aβ release and thus an increase in Aβ
concentrations at the synapse. Regulatory mechanisms for degradation of Aβ
would become overwhelmed, especially as neprilysin levels decrease as we age
(Iwata, et al. 2005) and Aβ clearance has been shown to be impaired in AD
(Mawuenyega, et al. 2010). This would result in Aβ accumulation at the synapse
and an increased propensity for copper binding.
4. Once Aβ concentrations reached a critical level at the synapse, Aβ could begin
to out compete other copper binding proteins to bind copper at the synapse,
especially as a major one, metallothionein, is down regulated in AD (Meloni, et
al. 2008). Copper-seeded fibril formation could then occur, which would have
two toxic effects. One is the physical damage caused by fibrils at the synapse.
The fibrils could pierce the neuronal membrane (Engel, et al. 2008), or allow the
cycling of copper resulting in production of free radicals (Butterfield, et al.
2001).  The second is that newly released Aβ and copper would be rapidly
recruited into fibrils at the synapse, and thus they would no longer function in
their neuroprotectant roles against NMDAR over-activation. NMDAR activation
would not be prevented and thus the signal for the neuroprotectants copper and
Aβ to be released would continue. A positive feedback loop would be initiated
with more and more copper and Aβ being released to try and prevent NMDAR
excitotoxicity resulting in further fibril formation. These two effects of physical
damage by fibrils and excitotoxicity due to the loss of function of copper and Aβ
as neuroprotectants, would produce the synaptic damage and loss that is
characteristic of early signs of AD.
Thus in conclusion, the disrupted copper homeostasis that occurs in the AD brain is
hypothesised to effect copper’s role as an important neuroprotectant at the
glutamatergic synapse. Downstream effects of copper dyshomeostasis include an
Chapter 7. Conclusions
205
increase in Aβ(1-42) levels, an increase in Aβ concentrations in the synaptic cleft, and
an increase in the likelihood of an Aβ:Cu2+ complex formation, resulting in an AD
pathology.
Figure 7.1. Model of hypothetical interaction of A and copper at the
glutamergic synapse. A is secreted into the synaptic cleft from APP and acts
to down regulate NMDA receptors. Additionally NMDA receptor activation
by glutamate results in calcium release into the cell, which results in the
release of copper which blocks NMDA receptors from glutamate limiting
further calcium entry into the cell, preventing excitotoxicity. Neprilysin
normally degrades A, and metallothionein normally binds copper. But both
are downgraded in AD. Adapted from Tanzi 2005 and Schlief 2006 and Bush
2008.
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Model 2. The Ligand Hypothesis
Model two focuses on the ionic/loosely-bound pool of copper, and emphasises the
importance of non-protein Cu2+ ligands, specifically carnosine in the olfactory bulb. A
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decrease in the carnosine concentration in the brain is hypothesised here to result in an
increase in free Cu2+ in the olfactory bulb and result in amyloid formation.
Carnosine (β-alanyl-histidine) is one of a group of ω-aminoacylamino acids and is
highly expressed in the olfactory bulb at 2-5 mM concentrations (Ferriero, et al. 1975).
Figure 7.2. Structure of Carnosine (Baran 2000)
Carnosine is of interest in relation to this thesis for three major reasons:
Firstly, carnosine will chelate copper and the copper-carnosine complex has been
studied in some detail. There are three groups within carnosine that undergo acid base
reactions between pH 1 and 10, the carboxylic acid group, an ammonium group, and the
protonated N3 imidazole group (Figure 7.2). Interestingly EPR data shows that there is a
concentration dependence to the stoichiometry of the Cu2+:carnosine complex (Brown,
et al. 1979). When carnosine is present in excess a monomeric complex forms. However
as the carnosine concentration reduces the monomeric complex begins to be in
equilibrium with a dimeric complex, until at equimolar concentrations formation of a
dimeric complex is favored (Brown and Antholine 1979). Another group found that at
equimolar concentrations of copper and carnosine the dimeric complex (Cu2L2H-2)0 is
the only species (Sovago, et al. 1982).
The dissociation constant of the carnosine-copper complex has not been definitively
characterised, one suggestion is that the binding constant is surprisingly low, at only 1.1
M-1 for a 1:1 complex (determined at pH 7.8) (Velez, et al. 2008). However it is
possible that complexes formed at different stoichiometries of carnosine and copper
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may have very different stability constants as shown in Table 7.1 (Baran 2000).
Importantly the very high concentrations of carnosine in the olfactory bulb (2-5 mM) in
non-AD cases (Ferriero and Marogolis 1975) means carnosine may have an important
role in forming copper-carnosine complexes in the olfactory bulb and skeletal muscle.
The predominant role suggested for carnosine is as a biologically significant antioxidant
due to the imidazole ring- carnosine was shown to prevent the oxidative damage of
deoxyguanosine induced by copper ions (Kohen, et al. 1988) and the copper-carnosine
complex has been shown to possess SOD-like activity (Kohen, et al. 1991). Carnosine
can scavenge peroxyl radicals and singlet oxygen and significantly protects olfactory
bulb neurons from copper-mediated toxicity, although only at relatively high levels of
carnosine (1 mM or above) (Horning, et al. 2000). This suggests that it is no
coincidence that carnosine is at its highest levels in two of the tissues with the highest
active oxidative metabolism – the brain and skeletal muscle (Boldyrev 2000).
Equilibrium Log k
Cu2+ + L-+ H+ = [CuLH]2+ 13.30 ± 0.03
Cu2+ + L-= [CuL]+ 8.47 ± 0.01
Cu2+ + L-= [CuLH-1]0 + H+ 2.44 ± 0.07
2Cu2+ + 2L-= [Cu2L2H-2]0 + 2H+ 8.35 ± 0.02
2Cu2+ + L-= [Cu2LH-1]2++ H+ 5.37 ± 0.02
Table 7.1 Stability constants in the Cu(II)/Carnosine system (at 25 ºC) (Baran
2000)
Secondly, olfactory dysfunction is a significant aspect of AD pathology. Loss of smell
is one of the first symptoms of AD, and plaques and neurofibrillary tangles occur in the
olfactory bulb (Murphy 1999). Immunostaining of Aβ in transgenic rats shows amyloid
plaques form early on in the olfactory bulb, Figure 7.3 (Badea, et al. 2010).  In fact, a
potential method for early diagnosis of AD is the use of olfactory sensory dysfunction
experiments with studies using a transgenic AD mouse model showed that progressive
olfactory impairment corresponded with an increasing Aβ burden in the olfactory region
(Wesson, et al. 2010).
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Figure 7.3. Immunostaining for Aβ reveals progressive accumulation of amyloid
plaques (brown) throughout the forebrain of transgenic APP mice. Initial
amyloid deposits can be clearly seen in the cortex, hippocampus, and olfactory bulb
by 4 months in this highly overexpressing transgenic model; pathology worsens
significantly with time Badea et al 2009.
Olfactory
Bulb
Carnosine may have an important role in copper homeostasis in the brain: neurological
damage observed in Wilson’s disease, which is a disease involving incorrect copper
transport, is highly similar neurological injury produced by improper metabolism of
carnosine (Bessman, et al. 1962). This suggests that carnosine has an important role in
preventing copper- related toxicity, via being a major chelator of “free” copper within
the olfactory bulb and skeletal muscle. Interestingly carnosine is currently being studied
as a potential therapeutic for pathologies related to increased oxidative stress and metal
dyshomeostasis (Lanza, et al. 2011).
Significantly in respect to model one, carnosine has also been shown to act
antagonistically towards copper’s effects on NMDA receptors – voltage clamp
experiments showed that whereas copper blocked most of the current evoked by
NMDA, carnosine was found to completely prevent this effect (Trombley, et al. 2000).
Thus there appears to be a role for carnosine as a neuromodulator of copper at the
synaptic cleft.
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Another reason for including carnosine in a model for AD onset is the effect of
carnosine on Aβ fibrillisation and toxicity. Carnosine has been shown to inhibit
advanced glycation end-product (AGE) formation. AGEs significantly accelerate fibril
formation through cross linking Aβ. Inhibitors of AGE have been shown to result in a
marked improvement in cognition and memory in AD patients after treatment (Munch,
et al. 1997), thus suggesting that carnosine has an effect on inhibiting Aβ fibril
formation. Additionally 5 µM Aβ(1-42) addition to PC12 cells caused a concentration-
dependent reduction of viability. However pre-treatment with 5 mM carnosine
ameliorated this impairment, suggesting that as well as inhibiting fibril formation,
carnosine also protects against Aβ toxicity (Fu, et al. 2008).
So how might carnosine have a role in AD? Interestingly in a study of changes in amino
acid and dipeptide levels in AD, carnosine was highlighted as undergoing one of the
biggest decreases in plasma levels, when the plasma of patients with probable AD was
compared to that in control subjects there was a decrease in carnosine levels by ~ 50 %
(Fonteh, et al. 2007). Thus this model suggests that decreases in carnosine levels in AD
result in a decreased ability for carnosine to form a complex with extracellular copper.
This would have two detrimental effects: 1) In the absence of being bound to carnosine,
Cu2+ would be free to undergo redox cycling and produce ROS, resulting in membrane
damage. 2) Low carnosine levels would result in an increased propensity for Aβ to
compete with carnosine for this loosely bound pool of copper, increasing the likelihood
for Aβ-Cu2+ formation. Figure 7.3 shows that once amyloid forms in the olfactory bulb,
it rapidly spreads throughout the brain, suggesting that once the critical stage of amyloid
formation in the olfactory bulb has occurred, AD pathology throughout the brain occurs.
Model 3. Hypothesis based on the data in this thesis
In this final model, the main findings outlined in Chapters 3, 4, 5 and 6 are briefly
summarised and then a model with these findings and parts of model one and two is
suggested.
In this thesis the interaction between A and Cu2+ was studied in detail. In Chapter 3 it
was found that A has an affinity for Cu2+ of approximately 50 pM. When this is
compared to other copper binding proteins in the brain, such as human serum albumin
(HSA), which has a high affinity for Cu2+ (a Kd of 1 pM) (Masuoka, et al. 1993) it can
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be clearly seen that the affinity of HSA is higher than the affinity of A. Additionally
concentration is important: although Aβ may have a higher affinity for Cu2+ than
carnosine, the level of carnosine is ~ 1000 000 (Ferriero and Marogolis 1975) higher
than Aβ (Vigo-Pelfrey, et al. 1993) under non-disease conditions. Thus Cu2+ in the
synaptic cleft is unlikely to ever be “free” but bound to either proteins with a high
affinity for Cu2+  such as metallothionein, or to ligands present at a high concentration,
such as carnosine.
Chapter 5 showed rapid Aβ fibrillisation in the presence of Cu2+, however as stated
above under non disease conditions as Aβ-Cu2+ complex is unlikely, and Aβ alone is
inhibited from forming fibrils under normal disease conditions by carnosine inhibiting
AGE formation (Munch, et al. 1997) and by the low Aβ concentrations (Vigo-Pelfrey,
et al. 1993) which are controlled by effective Aβ clearance from the synaptic cleft by
neprilysin (Iwata, et al. 2001).
So what could happen under AD conditions? This model is set in the olfactory bulb
glutamatergic synapse:
1. Copper dyshomeostasis begins, with a decrease in the intracellular Cu+ pool
(Deibel, et al. 1996) `
2. Decreased release of Cu+ into the synaptic cleft results in decreased inhibition of
NMDAR (Schlief, et al. 2005)
3. Decreased inhibition of NMDAR by Cu2+ results in increased Aβ release as
compensation to avoid excitotoxicity (Snyder, et al. 2005)
4. Decreased intracellular Cu2+ results in a favouring of amyloidogenic processing
of Aβ, with an increase in the Aβ(1-42):Aβ(1-40) ratio
5. Aβ clearance is impaired (Mawuenyega, et al. 2010), due to a decrease in
neprilysin, resulting in a further increase in Aβ concentration in the synaptic
cleft
6. Carnosine levels decrease (Fonteh, et al. 2007), increasing the potential for
Aβ:Cu2+ complex formation. The carnosine decrease also increases the
likelihood of AGE formation and an increase in oxidative stress at the synapse.
7. Aβ reaches a critical concentration at the synapse where it can begin to compete
with remaining carnosine ligands for Cu2+, due to Aβ’s high affinity for Cu2+, as
shown in Chapter 3.
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8. Sub-stoichiometric Cu2+ binding to Aβ results in rapid Cu2+-induced A fibril
formation, as shown in Chapter 5, where Cu2+- bound A formed fibrils twice as
fast as apo-A.
9. Once formed, these fibrils seed monomeric A to result in further fibril
formation. Additionally the results in Chapter 4 show that once formed, fibrils
can continue to bind Cu2+, as Cu2+ can diffuse through the fibril structure to
form a 1:1 stoichiometry with the fibres. Importantly, once Cu2+-bound A
aggregates are formed, metallothionein is unable to aid deaggregation of, or
extract copper from, the aggregates (Chung, et al. 2010).
10. Newly released Cu+ or Aβ in response to NMDAR activation is ineffective as
instead of binding to the NMDAR they are sequestered into the fibrils, resulting
in prolonged NMDAR activation, and further release of Cu+ and Aβ in response.
11. In Chapter 6 it was shown that A-Cu2+ fibres were significantly more toxic to
PC12 cells than apo-A fibres or Cu2+ bound to the soluble fragment A(1-16).
These fibres result in physical damage to the neuronal cell membrane
12. . Redox cycling of Cu2+ bound to Aβ and the low levels of carnosine result in
increased oxidative stress at the synapse
13. Inefficient inhibition of NMDAR by Cu+ and Aβ results in excitoxicity
14. Neuronal cell death and synapse loss begin to occur, resulting in olfactory
dysfunction. Amyloid plaques spread from the olfactory bulb through the brain,
eventually resulting in widespread memory loss and loss of brain function and
severe AD pathology.
This hypothesis aims to combine the results found in this thesis and current literature
into a hypothetical model that may explain parts of the bigger picture of AD. If
Cu2+dyshomeostasis is responsible for the onset of AD, it will be interesting to see the
results of the phase III clinical trial of the metal chelator PTB2 (Lannfelt, et al. 2008).
This chelator is derived from 8-hydroxyquinoline, which will bind Cu2+ at pH 7.4 with
stepwise apparent Kd’s of Kd1 = 0.2 nM and Kd1 =2 nM, giving an overall Kd of 4 x 10-19
M (Dawson 1986). This is a much higher affinity than the 5 x 10-11 M dissociation
constant determined for A in Chapter 3, and suggests that this compound would
remove Cu2+ from A, thus suggesting it could be an effective therapeutic.
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In summary, the data in this thesis suggests that A has the potential to bind Cu2+ with a
high affinity, accelerate fibril formation, continue to bind Cu2+ once in the fibrillar
form, and cause toxicity in vitro. The literature also seems to support a role for Cu2+ in
AD pathology. However a great deal of scepticism remains in the AD field as to
whether there is a role for metal ions in AD, thus whether the results of the trial will be
compelling enough to change the current “Amyloid cascade hypothesis” to the
“Amyloid and metal cascade hypothesis” remains to be seen.
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